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Introduction
 
Pertussis (whooping cough) is a highly contagious acute bacterial disease involving the 
respiratory tract and is caused mainly by Bordetella (B.) pertussis and to a lesser extent by 
B.parapertussis. It is most severe in young infants. It has a worldwide prevalence and occurs 
in all age groups.
History
The history of whooping cough starts, according to the literature, with the description by 
Guillaume de Baillou (1538-1616) 1 of an epidemic in 1578 in France, published for the first 
time only in 1640 by his nephew. 
Was the disease not known before, or known maybe by other names and in different countries 
by different names?
Kohn 2 suggests that the description of the Perinthus cough by Hippocrates (around 400 B.C.) 
might possibly be whooping cough or a mix with other diseases such as viral respiratory 
infections. In the Oxford English Dictionary 3 kinkehost is mentioned in Reginald’s Vita Godrici 
from around 1190. In the “Middelnederlandsch woordenboek” 4 (dictionary of medieval Dutch) 
it is suggested that gisschen might be an early eastern Dutch word for whooping cough, used in 
the first half of the 14th century. In his History of Pediatrics in the Netherlands 5 van Lieburg 
refers to the Miracle book of the St Jan’s cathedral in ‘s Hertogenbosch, in the southern part of 
the Netherlands, in which a pilgrimage is described to the statue of the holy Mary because of 
the recovery of a boy from kychoest, in 1383. Nils Rosen von Rosenstein 6 from Sweden states, 
not knowing when the disease came to his country, that in France it first appeared in 1414, 
without giving a source. In Schiller-Lübben’s “Mittelniederdeutsches Wörterbuch” 7(dictionary 
of medieval German) kinkhoste is found in a source from 1464. Dodonaeus (1517-1585) in his 
“Cruijde boeck” 8 (book of herbs) already in 1554 describes cures for the kieckhoest!
De Baillou called it quinta, referring to Hippocrates 1. Coqueluche, the present name in 
French for whooping cough, was then the common name for influenza 9. Holmes 10 reports 
that pertussis was called chyne-cough in England as early as 1519. Cherry and Heininger 11 
say it was called the kink (in Scottish synonymous with fit or paroxysm) and kindhoest (a 
Teutonic word meaning child’s cough) in the Middle Ages. Nils Rosen von Rosenstein 6 calls 
it in his book about pediatric diseases from 1798 Keichhussten. In a JAMA editorial 12 names 
as tosse canina (dog’s bark, Italy), Wolfshusten (howling of wolves) and Eselshusten (braying of 
donkeys)(both from Germany) and chincough (boisterous laughter, Old English) are given. In 
Chinese it is called “cough of 100 days” 13. 
In Dutch it is called kinkhoest, coming from old names as kinkhôste, kichhoest, keichhusten, 
Chapter 1

Chapter 1
as van Esso describes 14. In the Dictionary of the Dutch Language (Woordenboek der 
Nederlandsche Taal) 15 the same names are given and others as kie(c)khoest, kijkhoest, kikhoest. 
Also it refers to Dodonaeus (1517-1585) who called the disease kich, or kinchoest in a latter 
edition of his “Cruydt-Boeck” from 1608 16. 
Since in these old days there were no possibilities to prove the diagnosis we will never know 
whether all these diseases then were the same as our whooping cough that, as we know today, 
is caused by B.pertussis, or that they were pertussis-like syndromes, caused by one or more 
other pathogens 17-23. 
Clinical Manifestations
Clinical manifestations of whooping cough may show substantial variation depending on 
previous vaccination, earlier infection with B.pertussis, age or the clinical condition of the 
patient. The clinical course is divided into three stages. After an incubation period of 5 to 
10 days, with an upper limit of 21 days, illness begins with the catarrhal phase. This phase 
lasts 1 to 2 weeks and is usually characterized by low-grade fever, rhinorrhea and progressive 
cough.
In the subsequent paroxysmal phase, lasting several weeks, B.pertussis causes severe and 
spasmodic cough episodes with a characteristic whoop, often with cyanosis and vomiting. The 
patient usually appears normal between attacks. Paroxysmal attacks occur more frequently at 
night with an average of 15 attacks per 24 hours. During the first 1 or 2 weeks of this stage 
the attacks increase in frequency, then remain at the same level for 2 to 3 weeks and then 
gradually decrease. The paroxysmal stage usually lasts 1 to 6 weeks but may persist for up to 
10 weeks. 
Young infants (under 6 months of age) may not have the strength to have a whoop but they do 
have paroxysms of coughing. The cough though may be absent and disease may then manifest 
itself with spells of apnoea 24. 
Although pertussis may occur at any age, most cases of serious disease and the majority of 
fatalities are observed in early infancy. The most important complications in the USA are 
hospitalization (72.2% in children younger than 6 months, 3.9% for those over 20 years of age), 
bronchopneumonia (17.3% vs. 3.4%), seizures (2.1% vs. 0.5%), acute encephalopathy (0.5% 
vs. 0.1%), the latter frequently resulting in death or lifelong brain damage and death (0.5% vs. 
0) 25. Heininger reported in proven pertussis patients in Germany an overall complication rate 
of 5.8%, pneumonia (29%) being the most frequent complication. In infants <6 months of age, 
the rate of complications was 23.8% 26. 
At the end of the catarrhal phase, a leukocytosis with an absolute and relative lymphocytosis 
frequently begins reaching its peak at the height of the paroxysmal stage. At this time, the 
total blood leukocyte levels may resemble those of leukemia (> 100,000/mm3), with 60 to 80 % 

lymphocytes. 
The convalescent phase, the last stage, lasting 1 to 3 weeks, is characterized by a gradual, 
continuous decline of the cough before the patient returns to normal. However, paroxysms 
often recur with subsequent respiratory infections for many months after the onset of pertussis. 
Fever is generally minimal throughout the course of pertussis. 
Microbiology
The genus Bordetella contains species of related bacteria with similar morphology, size 
and staining reactions. To date there are 8 species known of Bordetella: B.pertussis 27, 
B.parapertussis 28,29, B.bronchiseptica 30, B.avium 31 (formerly designated Alcaligenes faecalis), 
B.hinzii 32,33 (formerly designated A.faecalis type II), B.holmesii 34, B.trematum 35 and B.petrii 36. 
B.pertussis, B.parapertussis and B.bronchiseptica are genomically closely related. The first four 
are respiratory pathogens. B.pertussis is an obligate human pathogen. B.pertussis was long 
considered the sole agent of whooping cough. A mild, pertussis-like disease in humans may 
be caused by B.parapertussis and occasionally by B.bronchiseptica. B.parapertussis appears 
both in humans and animals. The natural habitat of B.bronchiseptica is the respiratory tract 
of smaller animals such as rabbits, cats and dogs. Human infections with B.bronchiseptica are 
rare and occur only after close contact with carrier animals, no human to human transmission 
occurs. Most patients with severe disease by B.bronchiseptica have an (immuno-) compromised 
clinical status 37. B.avium and B.hinzii are important in birds. B.hinzii and B.holmesii are 
found in blood cultures from immune compromised patients. B.trematum and B.petrii have 
been recently discovered, B.trematum in wounds in humans, B.petrii (an anaerobic species) 
in a bioreactor.
B.pertussis is a small (approximately 0.8 µm by 0.4 µm), rod-shaped, or coccoid, or ovoid Gram-
negative bacterium that is encapsulated and does not produce spores. It is a strict aerobe. It is 
arranged singly or in small groups and is not easily distinguished from Haemophilus species. 
B.pertussis and B.parapertussis are nonmotile. 
Bacteriological confirmation of suspected whooping cough is often missed, as culturable 
B.pertussis does not seem to persist far beyond the catarrhal stage and in addition requires 
special growth factors to grow on artificial media.
B.pertussis, the causative agent of pertussis with affinity to the mucosal layers of the human 
respiratory tract, has different antigenic or biologically active components (see table 1), 
although their exact chemical structure and location in the bacterial cell are known only in 
part.
Chapter 1

Pathogenesis
Infection results in colonization and rapid multiplication of the bacteria on the mucous 
membranes of the respiratory tract 38. It produces a number of virulence factors, which 
comprise pertussis toxin, adenylate cyclase toxin, filamentous haemagglutinin, fimbriae, 
tracheal cytotoxin, pertactin and dermonecrotic toxin. The expression of these factors is 
regulated by the bvg locus 39,40. This system assures that the organism synthesizes components 
only in response to certain environmental stimuli. Bacteremia does not occur. Studies of the 
different B.pertussis adhesion molecules and toxins and their corresponding biologic activities 
have yielded plausible explanations for many of the symptoms of whooping cough (table 1). In 
humans, an initial local peribronchial lymphoid hyperplasia occurs accompanied or followed 
by necrotizing inflammation and leukocyte infiltration in parts of the larynx, trachea and 
bronchi. Usually, peribronchiolitis and variable patterns of atelectasis and emphysema also 
develop. To date, there is no possible explanation for the development of the characteristic 
paroxysmal coughing in pertussis. 
Table 1: Biologically active and antigenic components of Bordetella pertussis  and possible roles in pathogenesis and 
immunity. 11,13, 39
                                                                                                                                                                                            
Adenylate cyclase toxin (ACT): An extracytoplasmic enzyme that impairs host immune cell function 
by elevating the levels of intracellular cAMP; by virtue of its hemolysin function it may contribute to 
local tissue damage in the respiratory tract.
Bordetella resistance to killing factor (Brk): A 32-kd outer-membrane protein. An adhesin that also 
provides resistance to killing by the host’s complement system.
Filamentous hemagglutinin (FHA): A cell surface protein. Promotes attachment to respiratory 
epithelium. Agglutinates erythrocytes in vivo. Antibodies to FHA protect against respiratory tract 
challenge but not against intracerebral challenge in mice
Fimbriae: Two serologic types (types 2 and 3). Antibody to specific types causes agglutination of the 
organism. Organisms may contain fimbriae 2, fimbriae 3, fimbriae 2 and 3, or neither fimbriae 2 nor 
fimbriae 3. Fimbriae may play a critical role as adhesins.
Heat-labile toxin (also called dermonecrotic toxin): Cytoplasmic protein that causes ischemic necrosis 
at dermal injection site in laboratory animals. It may contribute to local tissue damage in the respiratory 
tract.
Lipopolysaccharide (LPS) (endotoxin): An envelope toxin with activities similar to endotoxins of 
other gram-negative bacteria. A significant cause of reactions to whole-cell pertussis vaccines. Antibody 
to LPS causes agglutination of the organism. Associated with fever and local reactions in mice.
Pertactin (PRN): A 69-kd outer-membrane protein that is an important adhesin. Adenylate cyclase-
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associated. Antibody to pertactin causes agglutination of the organism and protects against respiratory 
tract challenge in mice.
Pertussis toxin (PT) (also called lymphocytosis-promoting factor): A classic bacterial toxin with 
an enzymatically active A subunit and a B oligomer-binding protein. PT promotes attachment to 
respiratory epithelium, sensitization to histamine, elicits lymphocytosis, enhances insulin secretion and 
stimulates adjuvant and mitogenic activity. It is an extracellular envelope protein. It causes T lymphocyte 
mitogenesis, stimulates interleukin-4 & IgE production, inhibits phagocytic function of leukocytes and 
it causes cytopathic effect on Chinese hamster ovary cells. Antibodies to PT protect against respiratory 
tract and intracerebral challenge in mice
Tracheal colonization factor (TCF): A proline-rich protein that functions predominantly as an adhesin 
in the trachea.
Tracheal cytotoxin (TCT): A disaccharide-tetrapeptide derived from peptidoglycan. Causes local tissue 
damage in the respiratory tract and ciliary stasis
Type III secretion system (bscN): Several not yet specified proteins that secrete effector proteins into 
host cells.
Host Defenses
B.pertussis infection and vaccination induce substantial immunity which usually lasts for 
several years, although in varying degree. Second infections of adults, usually with atypical 
symptoms and thus not regularly diagnosed as pertussis, may be more frequent than 
previously assumed 41,42. Immunity acquired after infection with B.pertussis does not protect 
against other Bordetella species 43.
Pertussis toxin is assumed to be one essential protective immunogen but numerous findings 
indicate that other components, such as filamentous hemagglutinin, heat-labile toxin, 
agglutinogens, outer membrane proteins and adenylate cyclase toxin, may also contribute to 
immunity after infection or vaccination 44-46. In addition, it was recently shown that antibodies 
to pertactin but not to pertussis toxin, fimbriae, or filamentous hemagglutinin, are crucial for 
phagocytosis of B.pertussis 46a. The immunogenicity of these substances may be significantly 
increased by the presence of pertussis toxin 47. This synergism indicates that pertussis toxin 
could function as an adjuvant to a variety of protective antigens of B.pertussis. The defense 
mechanisms are both nonspecific (local inflammation, increase in macrophage activity and 
production of interferon) and specific (proliferation of specific B and T cells) 48. 
The nature of immunity in whooping cough is, however, incompletely understood. A role of 
circulating antibody in immunity is indicated by the correlation between protection of human 
vaccinees and their antibody titers 44-46. However, effective immunity does not necessarily 
depend on the presence of protective antibodies and immunity to whooping cough may 
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therefore be mediated essentially by cellular mechanisms 48,49. This cell-mediated immunity 
may be considered the crucial carrier of long-term immunity and titers of specific humoral 
antibodies may diminish over the years.
Epidemiology 
World-wide, B.pertussis causes some 20-40 million cases of pertussis per year, 90% of which 
occur in developing countries and an estimated 200 000-400 000 fatalities each year 11,13,50. 
Since the last decade many developed countries experience a re-emergence of pertussis, even 
countries that have had high vaccination coverage for many years. Because of waning natural-
derived and vaccine induced immunity older children and adults are susceptible to infection 
again. Therefore it is assumed that infection-frequency is probably highest in adolescents and 
adults and consequently those age groups are the main source of infection for infants 51.
In the Netherlands in 1989-1994 the mean incidence on the basis of notification and serology 
was 2.4 and 2.3 per 100,000 per year. In 1996 there was a steep increase in notifications 
(27.3/100,000), positive serology, hospital admissions and even deaths 52-54. Since then the 
incidence remained higher than before 1996 (Fig 1).
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Fig1: Pertussis in the Netherlands from 1989 to 2004: Notifications, positive two point serology, positive one point 
serology; hospital admissions from 1996 to 2004, based on first day of illness 51
note: Before 1996 all serological tests for pertussis were performed at the LIS-RIVM. However, since 1998 at least 
three of the 16 regional Public Health Laboratories and also some other(hospital) laboratories have started to perform 
serology with commercial available assays. Consequently, the population coverage of serological surveillance based 
on serological data of LIS-RIVM is now estimated to have decreased from 100% in 1996 to less than 50% in 2002. 
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Fig 2: Bordetella pertussis notifications in the Netherlands per city/town from 1-1-2000 to 30-9-2004. Number of 
notifications per 100.000 inhabitants 94.
Notifications per 100.000 inhabitants vary per city/town from 1-1-2000 to 31-5-2004 from 0 
to 610 (Fig 2). Not only there is a strong regional variation in number of notifications but also 
a discrepancy between notifications and number of positive serology (table 2).
According to the Central Statistics of the Netherlands in 1989-1995 2 deaths due to pertussis
were reported. In the period 1996-2002 8 deaths due to pertussis were reported: two in 1996,
two in 1997, one in 1998 and three in 1999. For the years 2000, 2001 and 2002 no deaths due
to pertussis were reported 51. 
Although in older literature there are reports of reinfection with whooping cough, there are 
no reports on proven reinfection 41,55-59.
Changes in vaccination coverage, vaccine quality or accuracy in reporting have been excluded 
as possible causes for the increase in incidence. However, there have been adaptations of 
B.pertussis to the vaccine. Notable changes in the variety of B.pertussis strains were found 
between the populations from the prevaccination era and the subsequent period. The 
reduction in genotypic diversity in the 1960s and 1980s was associated with the expansion 
of antigenically distinct strains, different from the vaccine strains, showing polymorphism in 
pertussis toxin and pertactin 60. This might have contributed to the re-emergence of pertussis 
in the Netherlands. 
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Table 2: Incidence and absolute number of pertussis (in table) per year and per source, in the period 1989-2002 51.
year 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Noti-
fications 523 397 145 160 346 519 341 4231 2671 2508 6980 4229 8030 4504
Positive 
two point 
serology 350 278 110 238 482 498 272 1885 924 468 855 458 701 344
Positive one
point 
serology 1760 1204 411 861 1489 1867 1070 7854 4107 3247 5377 2990 4914 2473
Estimated 
coverage of
serologic 
data*
100% 100% 100% 100% 100% 100% 100% 100% 94% 77% 72% 60% 55% 51%
Hospital 
admissions 221 157 82 101 288 276 162 513 436 282 509 247 397 261
*: Before 1996 all serological tests for pertussis were performed at the LIS-RIVM. However, since 1998 at least three 
of the 16 regional Public Health Laboratories and also some other (hospital) laboratories have started to perform 
serology with commercial available assays. Consequently, the population coverage of serological surveillance based 
on serological data of LIS-RIVM is now estimated to have decreased from 100% in 1996 to less than 50% in 2002.
Transmission
In most countries B.pertussis is endemic with superimposed epidemic cycles. These cycles 
occur approximately every 4 years in vaccinated populations and approximately every 2 to 3 
years in non vaccinated populations, although in the Netherlands the incidence is higher now 
(every 2-3 years) compared to the period prior to the epidemic in 1996-1997 (every 4 years) 
51,61. Most infections occur from July to October. Pertussis is very contagious. It is transmitted 
obligatory from human to human by direct contact with discharges from respiratory 
mucous membranes of infected persons primarily via droplets by the airborne route. The 
mucous membranes of the human respiratory tract are the natural habitat for B.pertussis 
and B.parapertussis. Most infections occur after direct contact with diseased persons, 
specifically by inhalation of bacteria-bearing droplets expelled in cough spray. The patient 
is most infectious during the early catarrhal phase, when clinical symptoms are relatively 
mild and noncharacteristic. Subclinical cases may have similar epidemiologic significance. 
Healthy transient carriers of B.pertussis or B.parapertussis are assumed to play no significant 
epidemiologic role. Chronic carriage by humans is not documented. 
Immunity
Pertussis infection or vaccination results in a long-lasting but not necessarily lifelong protection 
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against the typical clinical manifestations of the disease, or reinfection. The protection may 
not be complete, as atypical or unrecognized infection in presumably immune persons, 
particularly adults, may be easily overlooked. Also, newborn babies of mothers who have 
had pertussis are not necessarily protected. Hence, following previous infection, occasional 
exposure to B.pertussis strains circulating in the community may be required to sustain high-
level immunity. Although the level of antibodies to pertussis toxin, pertactin or filamentous 
hemagglutinin are sometimes used as serological indicators of protection 44,45, lack of generally 
accepted correlates of immunity and animal models are impediments to the evaluation of new 
pertussis vaccine candidates and the monitoring of the consistency of production.
Although vaccination has caused a firm decrease in incidence and mortality over the years, 
occasional local epidemics do occur. The disease is especially dangerous in the first 6 months 
of life. There seems no distinct influence of the season or climate on the morbidity rate but 
there may be an increase in the summer and fall. Older persons (i.e., adolescents and adults) 
and those partially protected by the vaccine may become infected with B.pertussis but usually 
have milder or asymptomatic disease 62. Pertussis in these persons may present as a persistent 
(>7 days) cough and may be indistinguishable from other upper respiratory infections. 
Inspiratory whoop is uncommon. In some studies, evidence for a B.pertussis infection was 
found in 25% or more of adults with cough illness lasting >7 days 63,64. Even though the disease 
may be milder in older persons, these infected persons may transmit the disease to other 
susceptible persons, including unimmunized or under immunized infants. Adults are often 
found to be the first case in a household with multiple pertussis cases 65,66.
Diagnosis
Whooping cough is a clinical diagnosis according to WHO criteria 67 as established in 2000: 
a case diagnosed by a physician, or a person with a cough lasting at least 2 weeks with at least 
one of the following symptoms: paroxysms (i.e. fits) of coughing, inspiratory “whooping” 
or post-tussive vomiting (i.e. vomiting immediately after coughing) without other apparent 
cause. Criteria for laboratory confirmation are: isolation of B.pertussis or detection of genomic 
sequences by polymerase chain reaction (PCR) or positive paired serology (i.e. fourfold 
increase) 68.
Only since Bordet and Gengou 27 in 1906 cultured B.pertussis we could be sure about the 
diagnosis. Recovery of B.pertussis is the golden standard but culturing B.pertussis is not very 
easy. Bordetellae can be cultured from nasopharyngeal swabs or nasopharyngeal secretions. 
The sensitivity of the culture depends mainly on the technique of taking the nasopharyngeal 
swabs (calcium alginate or Dacron) or secretions, direct inoculation of nasopharyngeal swab 
material onto special freshly prepared media (Bordet-Gengou or Regan-Lowe) for primary 
isolation and immediate aerobic incubation in a stove. B.pertussis grows slowly, thus it is 
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recommended to extent incubation time from 7 to 14 days. 
The newest test for detection of B.pertussis and B.parapertussis is by polymerase chain 
reaction (PCR), a very specific test and more sensitive than culture. Nasopharyngeal swabs 
are suspended, then incubated and amplificated. The final PCR product is analyzed by gel 
electrophoresis and hybridization. In later stages of the disease PCR testing is more often 
positive than culture, as in patients treated with antibiotics or in vaccinated patients 69. The 
PCR yield is about 2.4 fold higher than culture. The poor performance of culture may be 
due the fastidious nature of B.pertussis but it is also possible that by PCR B.pertussis DNA is 
detected in samples in which the organisms have become nonviable. In patients with clinical 
symptoms of B.pertussis infection and positive serology sensitivity of PCR and culture is low 
(21% and 7% respectively) but specificity of both is 98% 69.
In adolescents and adults culture or PCR is not useful when disease duration is longer than 
3-4 weeks 69. In contrast, in non vaccinated or partially vaccinated young children culture 
or PCR is useful in any stage of the disease since they have an immature mucosal immune 
response and therefore a slower eradication of the bacteria.
Where with increasing disease duration the usefulness of PCR and culture declines thus 
serology becomes more important. Already in 1911 Bordet and Gengou published the first 
serological methods, detecting agglutinating antibodies to whole B.pertussis cells 70. This 
remained the hallmark of pertussis serology for more than 70 years 71. In the eighties of the 20th 
century various enzyme immunoassays have been developed and presently immunoglobulin 
G against pertussis toxin (IgG-PT) is the most used and validated test to prove B.pertussis 
infection 68,71. IgG-PT is only produced after infection with B.pertussis, not by other Bordetella 
species, nor are any cross reactions described. Although, van der Zee et al showed in 2 PCR-
proven cases of B.parapertussis infection an significant increase of IgG-PT, suggesting that yet 
in some strains of B.parapertussis the transcriptionally silent IgG-PT genes may have come to 
expression but a co-infection with B.pertussis could not be excluded 69. 
In newborns and after vaccination against B.pertussis, IgG-PT should be looked at with caution 
because of transplacental transfer or induction by vaccination 68. After the fourth vaccination 
with the Dutch vaccine there is only a temporary and small increase and in both instances 
there is a fast decrease 72. However, other whole-cell vaccines and acellular vaccines might 
induce higher IgG-PT levels 45,73. Antibodies against other antigens as pertactin, fimbriae and 
filamentous hemagglutinin (FHA) are also available but less validated and are also produced 
in reaction to infections with other Bordetella species and perhaps other related bacteria. 
IgG-PT, appearing as late as week 3 of illness, reaches its peak approximately 4.5 weeks after 
infection but is retarded in very young children (<1 year). Serology for B.pertussis is considered 
positive by the finding of a significant, ≥ 4-fold increase of IgG antibodies to pertussis toxin 
(IgG-PT) in paired sera to a level of at least 20 U/ml. This hampers the diagnosis of B.pertussis 
infection, since many patients present themselves later in their disease having already high 
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levels of IgG-PT without showing a significant increase.
Differential diagnosis
Especially in immunized people or in those who suffered earlier from pertussis infection 
the atypical complaints may be difficult to distinguish from infection by other pathogens, 
like adenovirus, influenzavirus, parainfluenza viruses, respiratory syncytial virus, Chlamydia 
pneumoniae or Mycoplasma pneumoniae, which may cause a pertussis like syndrome 17-20,23. 
Also mixed infections may complicate the diagnosis 21,22.
Treatment and Prevention
Although immunization against B.pertussis infection has caused a great reduction in the 
incidence of pertussis, outbreaks still occur, even in countries with high vaccination coverage. 
Erythromycin, 40-50 mg/kg/day for 10-14 days, usually considered the treatment of choice, 
will eliminate viable B.pertussis organisms from the respiratory tract within a few days11,74-77. A 
7 day course of erythromycin has proven to be as efficacious as 14 days 78. Newer macrolides as 
azithromycin, 10 mg/kg/day for 3 or 5 days 75,79, or 10 mg/kg the first day and 5 mg/kg/day for 
4 days 77,79, or clarithromycin, 10-15 mg/kg/day for 7 days 75,76 have also shown to be effective 
in the treatment of pertussis with fewer side effects than erythromycin. Erythromycin-
resistant strains of B.pertussis have been isolated but this seems to be very uncommon 80,81. 
Although rare, the use of erythromycin in young infants is associated with hypertrophic 
pyloric stenosis 82,83. An alternative to erythromycin is trimethoprim-sulfamethoxazole, 6-
10 mg trimethoprim/kg/day for 14 days 84. Fluoroquinolones have good in vitro activity 
against both B.pertussis and B.parapertussis and may be useful in the treatment of B.pertussis 
infection, although there are no supporting clinical data at present 85.
Human hyperimmune pertussis globulin is still used occasionally 86,87. Further treatment is 
symptomatic. High altitude or flying has been suggested as an effective treatment for the 
coughing complaints 88,89.
During the paroxysmal phase of the disease, eradication of the bacteria by antimicrobial 
drugs, such as erythromycin, will not significantly change the clinical course, although there 
is some clinical evidence that some macrolides might reduce coughing complaints 90. 
Although it is better for susceptible children (unimmunized children without a history of 
whooping cough) to avoid contact with pertussis patients during the first 4 weeks of their 
illness, this is often difficult to achieve. Exposed unimmunized children are given a macrolide 
for 10 days after contact is discontinued or after the patient ceases to be contagious. Exposed 
immunized children younger than 4 years are most probably protected but protection may be 
enhanced by macrolides or by a booster dose of acellular pertussis vaccine 91.
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Vaccination
Currently, approximately 80% of the world’s children are vaccinated against pertussis, most of 
whom have received the diphtheria-tetanus-whole cell pertussis combination 50.
Pertussis vaccine is produced from smooth forms (phase I) of the bacteria as a killed whole-
cell vaccine. General vaccination was introduced in the Netherlands in 1952. Furthermore, 
since 1 January 1999 the primary vaccination for pertussis has been advanced. From that time 
children are vaccinated at the age of 2, 3, 4 and 11 months, instead of 3, 4, 5 and 11 months. 
Finally, in November 2001 a booster vaccination with an acellular vaccine, comprised of 
pertussis toxin, pertactin and filamentous hemagglutinin, was introduced in the National 
Immunisation Programme at the age of 4 years 51.
Owing to a relatively mild course of disease and to occasional complications after vaccination, 
it has been argued that general vaccination with the whole-cell vaccine is no longer justified. 
Therefore acellular pertussis vaccines have been developed. These vaccines are composed 
very differently and contain various amounts of structural components from the bacteria. 
Components available for vaccine production include pertussis toxin (which is detoxified), 
filamentous hemagglutinin, pertactin and fimbrial antigens 2 and 3. Since 2000 4 year 
old children in the Netherlands are given a booster with acellular vaccine. Recent data 
suggest that after primary vaccinations of infants these vaccines can convey similar levels 
of protection as the whole-cell vaccine. Thus, acellular vaccines have also been licensed for 
primary vaccination. In the Netherlands this acellular vaccine will be introduced for regular 
vaccination in 2005 51,91,92.
Aim and outline of this thesis:
In 1996 there was an outbreak of pertussis in the Netherlands, both in vaccinated and in non 
vaccinated people of all ages. Many questions arose what the cause or causes for this sudden 
increase in B.pertussis infection were. Among others the question arose whether vaccination 
or previous natural infection with B.pertussis guaranteed lifelong protection. As stated before 
criteria for laboratory confirmation of B.pertussis infection are: isolation of B.pertussis or 
detection of genomic sequences by PCR or significant, ≥ 4-fold increase of IgG-PT in paired 
sera to a level of at least 20 U/ml. Because many patients visit their physician after weeks of 
coughing, culture or PCR are less sensitive and serology may already show high levels of IgG-
PT without significant increase anymore. Thus we wondered if one point serology could be a 
useful tool in the diagnosis of B.pertussis infection. Since there are no cutoff values in one point 
serology as proof of actual or recent B.pertussis infection it would be opportune to develop 
such cutoff values. Therefore it is important to establish what level of IgG-PT is proof of a 
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recent B.pertussis infection. Consequently we wondered what the natural course of IgG-PT is 
after infection. Accordingly it is necessary to gain insight in the rise, peak and decline of IgG-
PT after natural infection with B.pertussis. Since B.pertussis infection is especially dangerous 
in young children not or partially vaccinated and since the main source of infection for these 
children are adults with often atypical clinical manifestations, it is important to gain insight in 
the incidence of B.pertussis infection 93. Is it possible, once knowing the natural course of IgG-
PT, to calculate the incidence of B.pertussis infection in the Netherlands in different age groups 
from available surveillance data on IgG-PT levels in the general population? 
For these reasons we investigated the level of IgG-PT in patients who suffered from B.pertussis 
infection, in the years after their infection, every time a blood sample was taken for other 
reasons. Following these patients through the years we looked out for patients with renewed 
clinical symptoms of B.pertussis infection and a renewed increase of IgG-PT. From other studies 
17-22,24 it is known that in some patients there may be evidence of other pathogens involved in 
the pertussis syndrome besides B.pertussis and in others of pertussis-like complaints without 
proof of B.pertussis infection. We questioned therefore whether there are many mixed infections 
in patients with pertussis like complaints and which pathogens are involved. 
The aim of this thesis is to find an answer to the following questions:
1: Which titer of IgG-PT in one point serology is proof for recent infection?
2: May a patient suffer from B.pertussis infection more than once in a lifetime?
3: What is the natural course of antibodies against B.pertussis after infection?
4: What is the yearly incidence of B.pertussis infection?
5: What is the best way to protect newborns and not yet (fully) vaccinated babies against 
    B.pertussis infection?
6: How often mixed infections occur in B.pertussis infection? 
7: What is the role of other respiratory pathogens in the pertussis like syndrome?
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Abstract
Laboratory confirmation of pertussis by culture, PCR, or detection of antibody increase in 
paired sera is hampered by low sensitivity in the later stages of the disease. Therefore, we 
investigated whether and at which level concentrations of immunoglobulin G (IgG) antibodies 
against pertussis toxin (PT), IgG-PT, in a single se rum sample, are indicative of active or 
recent pertussis. IgG-PT, as measured by enzyme-linked immunosorbent as say in units per 
milliliter, was analyzed in 7,756 sera collected in a population-based study in The Netherlands, 
in the sera of 3,491 patients with at least a fourfold increase of IgG-PT, in paired sera of 89 
patients with pos itive cultures and/or PCR results and in the sera of 57 patients with clinically 
documented pertussis with a median follow-up of 1.4 years. We conclude that, independent 
of age, IgG-PT levels of at least 100 U/ml are diag nostic of recent or active infection with 
Bordetella pertussis. Such levels are present in less than 1% of the popu lation and are reached 
in most pertussis patients within 4 weeks after disease onset and persist only temporarily. 
Introduction
Whooping cough is a highly contagious bacterial infection of the respiratory tract, caused 
by Bordetella pertussis. It is most severe in unvaccinated infants. Evidence is increasing that 
B. pertussis infections occur more frequently in older children and adults in vaccinated 
populations than has been commonly rec ognized (1, 4, 6, 8, 18, 23, 27). These individuals 
may play an important role in the transmission to infants too young to be vaccinated (4, 7, 20, 
26). Adequate laboratory diagnosis is important for the control and prevention of pertussis. 
In The Netherlands, the case definition for notification of pertussis includes defined typical 
clinical symptoms and labo ratory confirmation. Laboratory confirmation is defined as ei ther 
a positive culture or a positive PCR for B. pertussis or B. parapertussis, or positive two-point 
serology, i.e., a signifi cant increase (at least fourfold) of antibodies against (antigens of) B. 
pertussis. This case definition for notification is highly specific but it results in low sensitivity, 
especially when labo ratory diagnosis is initiated at a late stage of the disease. Other countries 
also report that pertussis diagnosis is hampered by low sensitivity (17, 21, 28, 31, 32). Culture 
of B. pertussis is laborious and insensitive; the ability to isolate B. pertussis by culture decreases 
progressively during the disease (13, 14). The sensitivity of PCR is superior to that of culture; 
however, this sensitivity, like that of culture, rapidly decreases by the time the paroxysmal 
phase has developed and with increasing age (16, 35). In The Netherlands, confirmation of 
suspected per tussis is attempted often by serology. However, in our sero diagnostic practice, 
for more than 50% of the suspected cases, only one serum sample is submitted or else high 
titers are found in paired sera without a significant increase. Similar problems have also been 
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reported by others (10, 24, 29).
Because pertussis toxin (PT) is expressed only by B. pertussis and cross-reacting antigens have 
not been described (15, 24) and because immunoglobulin G (IgG) responses occur in most 
patients with B. pertussis infection, we investigated whether and at which level, titers of IgG 
antibodies against PT (IgG-PT) in a single serum sample are indicative for active or recent 
pertussis.  
We analyzed IgG-PT in the sera of a large cross-section of the population (n = 7,756), in the 
paired sera of patients of all ages in whom clinical suspicion of pertussis was confirmed by 
at least a fourfold increase of IgG-PT (n = 3,491) and in the paired sera of patients in whom 
pertussis had been confirmed by culture of B. pertussis or by positive pertussis PCR (n = 89). 
The course of IgG-PT after natural infection, i.e., the duration of high levels, was assessed in 
long-term follow-up sera of 57 patients after pertussis had been clinically documented. 
Materials and Methods
Collection of sera and data from the general population and patients. (i) Cross-section 
of the general population (n = 7,756). The study design and data collection have been 
published elsewhere (22). Briefly, eight municipalities with probabilities proportional to their 
population sizes were sampled within each of five geographical Dutch regions with similar 
population sizes. An age-stratified sample (classes 0, 1 to 4, 5 to 9,..., 75 to 79 years) of 380 
individuals was randomly selected from each municipality. These individuals were requested 
to give a blood sample and to fill out a questionnaire in which the participants were asked 
whether they had had a period with coughing attacks that had lasted for more than 2 weeks. 
They were also asked whether a physician had diagnosed pertussis, either during the past year 
or for more than 1 year previously. No information was available as to whether the physician 
had diagnosed pertussis by symptomatology, serology, culture, or PCR. The participation 
rate was 55%. Sufficient serum for pertussis serology was available from 7,756 of the 8,359 
participants. Sera were collected in 1995 and 1996 and stored at -70°C until use. 
(ii) Patients with serologically confirmed pertussis. Until 1997, the National Institute 
of Public Health and the Environment was the only laboratory in The Netherlands that 
performed pertussis serology examinations for patients with a suspected pertussis infection. 
Routinely, the submitted sera were assayed for both IgG-PT and IgA against B. pertussis. In 
all cases, if the date of onset of symptoms and/or date of sampling of serum was missing upon 
submission of serum, a standard questionnaire was sent to collect the data. From January 
1989 onwards, all data and results were registered in an electronic database.
For the purpose of this study, patient data and serologic results were obtained in the period 
from 1989 to 1996 from 3,491 patients in whom the clinical suspicion of pertussis had been 
confirmed by the detection, in paired sera, of a ≥4-fold increase of IgG-PT to ≥20 U/ml.
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Likewise, data were analyzed for 15,319 patients whose first submitted serum sample contained 
≥100 U of IgG-PT per ml without (in the case of paired sera) a fourfold IgG-PT increase. 
(iii) Patients with typically symptomatic infection with B. pertussis and their longitudinal 
sera. During the period from 1989 to 1998, we obtained follow-up serum samples from 57 
patients with a clinical diagnosis of typical pertussis (paroxysmal cough lasting more than 
2 weeks) so that we could study the longitudinal course of IgG-PT after infection. Twenty-
three patients showed at least a fourfold increase in IgG-PT in paired sera and 34 patients 
had an IgG-PT level in a first serum sample of at least 75 U/ml. The IgG-PT level was at 
least 100 U/ml for 31 of these 34 patients. The follow-up period varied from 6.5 months to 
6.7 years after the acute phase of infection (mean, 1.8 years; median, 1.4 years). The number 
of serum samples collected in the follow-up periods varied from two to seven (mean and 
median of three). All patients were from a single pediatric practice. The patients were treated 
with macrolides for their pertussis. Only those patients participated who continued to be 
treated by the pediatrician after the episode of pertussis because of other medical conditions 
(mostly allergic conditions and/or asthma) or who consulted the pediatrician again at a later 
stage because of new medical problems. In addition, sera from parents with clinical pertussis 
were selected. The median age of the patients in which the longitudinal course of IgG-PT was 
studied was 3.5 years (range, 0 to 35 years). A total of 10 patients were less than 6 months old; 
7 patients were 6 to 11 months old; 19 patients were between 1 and 4 years old, 16 patients 
were between 5 and 9 years old; 2 patients were 11 or 12 years old; and 3 patients were 30 to 
35 years old. Thirty-nine of the patients were vaccinated, six patients were unvaccinated and 
for twelve patients the vaccination status was unknown. In all cases the follow-up sera used 
for the study were “left over” from samples obtained for some other diagnostic procedure. 
Informed consent for the study was obtained from the patients or their parents. 
(iv) Patients with PCR and/or culture-proven pertussis. In the period from 1993 to 1998, 
the diagnosis of pertussis for 89 patients had been confirmed by culture of B. pertussis and/or a 
positive pertussis-specific PCR, while paired sera from these patients had also been submitted 
for serology. Of the 89 patients, 58 had participated in a clinical study to assess the sensitivity 
of the pertussis or parapertussis PCR in comparison with culture and serology (35). For each 
of the remaining patients, a pertussis PCR test was performed in the regional public health 
laboratory in Tilburg, The Netherlands. In all cases, the first serum of the pair was obtained 
on the same day that material for culture and/or PCR had been obtained: the second sample 
was obtained 2 to 4 weeks later. Of the 89 patients, 37.1% were 0 to 5 months old, 7.9% were 
6 to 11 months old, 21.3% were 1 to 4 years old, 25.2% were 5 to 9 years old, 2.2% were 10 to 
14 years old and 5.6% were ≥15 years old. 
In-house IgG-PT ELISA. The patient sera had been submitted immediately after sampling 
and were assayed in the routine setting of the serology laboratory of our institute within 4 days 
after receipt. The population sera, which had been collected in 1995 and 1996, were assayed 
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in 1997 and 1998 in the same routine setting at a rate of approximately 200 sera per week. 
The IgG-PT was measured by enzyme-linked immunosorbent assay (ELISA) as previously 
described (35). In short, the procedure was as follows. Purified PT (National Institute of Public 
Health and the Environment) was used to coat 96-well ELISA plates after precoating with 
fetuin (50 mg/liter in phosphate-buffered saline). Peroxidase-labeled rabbit anti-human IgG 
was used as a conjugate and 3,3’,5,5’-tetrameth-ylbenzidine (TMB) was used as the substrate. 
Negative, low-positive and medium-positive control sera with defined IgG-PT contents were 
run on each plate. The sera were tested in duplicate in 1:100 and 1:400 dilutions against serial 
dilutions of a positive reference serum with a range of 1.6 to 100 “local” U/ml. The optical 
density (OD) of the 1:100 dilution was used to calculate the IgG-PT concentration. When the 
OD of the 1:100 dilution of a serum was above the range that constituted the steep part of the 
dose-response curve, the OD of the 1:400 dilution was used. 
Due to the use of only two dilutions for the sera, the IgG-PT assay has an upper limit (500 
U/ml) above which the values are not further differentiated. The lower detection limit of the 
assay is 5 U/ml. 
Results are expressed in “local” units per milliliter. The reference serum was also calibrated 
against the FDA preparation lot 3 (Food and Drug Administra tion Laboratory of Pertussis, 
Rockville, Md.). The formula for conversion of local to FDA units per milliliter appeared to 
be as follows: local U/ml x 1.25 = FDA U/ml within this assay (9). 
Data analysis. For the cross-sectional population-based study, frequencies of IgG-PT levels 
from <5 U/ml (lower detection limit) to ≥500 U/ml (upper differentiation limit) within each 
municipality were weighted by the proportion of the age group in the population. To produce 
national estimates for percentiles 1, 2.5, 10, 25, 50, 75, 97.5 and 99, these weighted and age-
specific frequencies were averaged over the 40 municipalities (5). The following age groups 
were separately analyzed: 0 to 5 months, 6 to 11 months, 12 to 17 months, 18 to 23 months, 2 
years, 3 years, 4 years, 5 to 9 years, 10 to 14 years and ≥15 years. 
The proportions with IgG-PT levels of <5U/ml, 5 to 9 U/ml, 10 to 49 U/ml, 50 to 99 U/ml, 100 
to 499 U/ml and ≥500 U/ml were also assessed. The proportion of these groups that reported 
a pertussis diagnosis or a period with coughing attacks during the past year was calculated. 
The proportion of those who had a pertussis diagnosis and/or coughing attacks more than 
one year ago and the proportion without any pertussis diagnosis or coughing attacks were 
also calcu lated. 
Likewise, for the patients with serologically proven pertussis (i.e., a ≥4-fold increase of IgG-
PT in paired sera), the total and (similar) age-specific percentiles 1, 2.5, 10, 25, 50, 75, 97.5 
and 99 for IgG-PT levels were calculated for the second sera of the serum pairs. The median 
duration of disease at the time of initiation of laboratory diagnosis, i.e., the time of sampling 
of first sera, was assessed for these patients in the following age groups: 0 to 5 months, 6 to 11 
months, 1 year, 2 years, 3 years, 4 years, 5 to 9 years, 10 to 14 years and ≥15 years. 
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The median duration of the disease was also assessed for the same age groups for the selection 
of patients from the serological database with ≥100 U/ml at the time of the first serum 
sampling without a fourfold IgG-PT increase. 
The Wilcoxon signed ranked test was used to test differences between age groups in the IgG-
PT distributions in the patients with positive cultures and/or PCR with a P value of 0.05, 
which was considered statistically significant. 
To study the longitudinal course of IgG-PT levels after pertussis infection for patients in the 
follow-up study, the association between the IgG-PT level and time in 2log days after the first 
day of illness (and the effect of age) was analyzed with a mixed linear model (PROC MIXED 
in SAS version 6.12) (30). A 2log transformation of both the IgG-PT level in units per milliliter 
and of time in days since the first day of illness was performed. This way, linear regression 
yielded the best fit. 
For those patients with follow-up data at 0 to 5 months, 6 to 11 months, 12 to 23 months, 2 to 
3 years and 4 to 7 years after onset of the disease, the propor tions with IgG-PT levels of <20, 
20 to 49, 50 to 99 and ≥100 U/ml were calculated. If multiple serum samples were available 
for one patient within one follow-up period, the serum sample with the highest IgG-PT level 
was used.
Results
The IgG-PT distribution in the population compared to the IgG-PT distribution in second 
sera of serum pairs of patients with serologically confirmed pertussis: choice of cut-offs 
to be validated. The IgG-PT levels in individuals of the population-based study were low in 
comparison to those in second sera (i.e., reconvalescence sera) of patients with serologically 
con firmed pertussis; these distributions showed little overlap (Fig. 1). In the population-based 
study, the median IgG-PT was 6 U/ml and for percentiles 97.5 and 99 the values were 69 and 
97 U/ml, respectively. In the second sera of patients with serolog ically confirmed pertussis, 
the median IgG-PT was ≥500 U/ml; the 10th percentile was 66 U/ml (Fig. 1).
In the population-based study, the median IgG-PT level was <5 U/ml in the age group <10 
years old, rose to 5 U/ml for 10  to 14-year-olds and was 7 U/ml for patients 15 years old or 
older (Fig. 1). For those 0 to 5 months old, 6 to 11 months old and 18 to 23 months old, the 
percentile 97.5 value was less than 20 U/ml, while in the other age groups the values given by 
percentile 97.5 ranged from 26 U/ml (4-year-olds) to 98 U/ml (10-to 14-year-olds). Further 
differentiation in 5-year age classes from 15 to 19 years to 75 to 79 years showed a stable 
IgG-PT distribution for those who were ≥15 years old (data not shown separately). With the 
exception of the 10-to 14-year-olds, the age-specific percentile 99 value was below 100 U/ml.
The percentages with undetectable IgG-PT (i.e., <5 U/ml) decreased from 85.5% for infants 
aged 6 to 11 months to 67.4% for infants 12 to 17 months and increased again to 79.4% at the 
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age of 4 years (Fig. 1). The proportion with undetectable IgG-PT decreased to 31.7% in those 
≥15 years of age. From this age onwards, this percentage remained stable (data not shown 
separately). 
The median and the 10th percentile of the distributions of IgG-PT in the second sera of 
patients with serologically proven pertussis showed little variation in the different age groups; 
the median IgG-PT values ranged from 316 to ≥500 U/ml and the 10th percentile values 
ranged from 40 to 87 U/ml (Fig. 1). The percentage of patients with an IgG-PT level of ≥500 
U/ml ranged from 40.7 to 57.0% within the various age groups (Fig. 1). Thus, the IgG-PT 
distributions in the population differed for the various age categories but the IgG-PT immune 
re sponses in pertussis patients did not. Therefore, for further assessment of specificity and 
sensitivity of certain IgG-PT lev els for recent and/or active infection with B. pertussis, we 
chose cutoffs of IgG-PT levels which were age independent, i.e., which were based on the 
comparison of the IgG-PT distribu tion in the total population and the IgG-PT distribution 
in second sera of the total group of serologically confirmed per tussis patients. Cutoffs of 50 
and 100 U/ml were chosen be cause IgG-PT levels of ≥50 and ≥100 U/ml were detected in, 
respectively, 92.7 and 81.0% of patients (second sera) with serologically confirmed pertussis. 
Such levels were rare, i.e., respectively, 3.6 and 0.8% in the general population. That is to say, 
they gave specificities of such values as 96.4 and 99.2%, respectively. The specificity of the 
proposed cutoff of ≥100 U/ml was maximally 100% for the ages of 0 to 5 months, 12 to 17 
months, 18 to 23 months and 2 years; minimally 97.9% for 10-to 14-year-olds; and for the 
cutoff value, ≥50 U/ml, max imally 100% for the ages of 0 to 5 months and 18 to 23 months 
and minimally 96.2% for 10-to 14-year-olds and ≥15-year-olds.
 
 
Fig 1: IgG-PT distribution in the population-based study and in pertussis patients (second sera) with at least a 
fourfold increase in IgG-PT level in paired sera. Results for the population-based study are given in shaded bars and 
results for second sera of pertussis patients are given in open bars; the total numbers of individuals/patients are given 
beside the bars. 
Chapter 2

Validation of the proposed IgG-PT cutoffs as markers for recent or active infection with 
B. pertussis. (i) Relationship between high IgG-PT levels in the population and recall of 
pertussis diagnosis and/or paroxysmal coughing. In the population-based study, while 
9.6% of those with an IgG-PT level of <5 U/ml reported coughing attacks or pertussis during 
the last year, this percentage was statistically significantly greater, being 19.9% for those with 
an IgG-PT level between 50 and 99 U/ml and 25.5% for those with an IgG-PT level of ≥100 
U/ml (Table 1). 
The percentage of individuals who reported that pertussis was diagnosed or who reported to 
have had coughing attacks more than 1 year ago showed a smaller increase with increasing 
IgG-PT. The differences in the percentage were not statistically significant (Table 1). 
TABLE 1. Percentages of individuals with a history of pertussis or coughing attacks during the last year, of individuals with pertussis or
coughing attacks more than 1 year ago, and of individuals without pertussis or coughing attacks according to
IgG antibody levels in the population-based studya
Occurrence pertussis or
coughing attack status n
% Individuals with IgG concn of:
5 U/ml 5–9 U/ml 10–49 U/ml 50–99 U/ml 100 U/ml
% 95% CIa % 95% CI % 95% CI % 95% CI % 95% CI
Yes, during last yearb 886 9.6 8.0–11.3 11.6 9.4–13.8 11.3 9.7–12.9 19.9 13.0–26.9 25.5 12.2–38.8
Yes, more than 1 year agoc 463 5.5 4.3–6.7 6.1 4.6–7.6 6.7 5.2–8.5 7.3 3.5–11.0 14.1 2.7–25.5
Nod 6,407 84.9 82.8–87.0 82.3 79.9–84.6 81.8 80.1–83.5 72.8 65.2–80.5 60.4 45.3–75.5
Total 7,756 100 100 100 100 100
a CI, conﬁdence interval.
b Participants who reported that a physician diagnosed pertussis during the last year or participants who reported coughing attacks that had lasted for more than
2 weeks during the last year. Among the 886 individuals, 15 individuals reported pertussis, and 12 of these 15 individuals reported coughing attacks.
c Participants who reported that a physician diagnosed pertussis more than 1 year ago or participants who reported coughing attacks that had lasted for more than
2 weeks more than 1 year ago. No pertussis was diagnosed and no coughing attacks were reported during the last year. Among the 473 individuals, 126 individuals
reported pertussis, and 45 of these individuals reported coughing attacks.
d Participants who did not report pertussis or coughing attacks during the last year or more than one year ago.
(ii) Longitudinal course of IgG-PT levels after infection. In each of the 57 patients with 
clinical pertussis for whom there were follow-up serum samples, the IgG-PT decreased with 
time after the onset of the disease (Fig. 2). In the mixed linear model with the IgG-PT in 
2
log U/ml and time from the onset of the disease in 
2
log days, the intercept amounted to 
14.61 and the slope was -1.128. Thus, this model predicts that the mean time of persistence 
of an IgG-PT level of ≥100 U/ml amounts to 134 days (4.4 months) and that after 365 
days a level of 32 U/ml is reached. Although IgG-PT levels of ≥500 U/ml were not further 
differentiated, the slopes did not change statisti cally significantly assuming that the levels 
of ≥500 U/ml were 1,000 U/ml or restricting the analysis to those samples with IgG-PT 
levels of ≥500 U/ml. No effect of age or vaccination status was shown in the mixed linear 
model. The data points for each individual patient were connected linearly. The result ing 
lines show that the IgG-PT level was below 100 U/ml within 1 year for 47 of the 57 patients. 
For 7 of the remaining 10 patients, the IgG-PT levels decreased below 100 U/ml during the 
subsequent follow-up period, which ranged from 1.4 to 4 years. For two of the remaining 
three patients, the follow-up period was less than 1 year. For these two patients, the IgG-PT 
levels amounted to 160 and 304 U/ml after 0.84 and 0.92 year of follow-up, respectively. The 
remaining patient had an IgG-PT level of 252 U/ml at 1.1 years after the first day of illness. 
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Fig 2: IgG-PT levels (in 
2
log U/ml) versus time elapsed (in 
2
log days) since date of onset for 57 patients with clinical 
pertussis.
As shown in Table 2, the highest IgG-PT level detected between 0 and 5 months after onset of 
the disease was ≥100 U/ml in 90% of the patients, while the highest IgG-PT level detected in the 
remaining patients was between 50 and 100 U/ml. At 6 to 11 months after the onset of the disease, 
the level had declined to <50 U/ml in 40% of the patients. A decrease to <50 U/ml had occurred 
in 72% after 12 to 23 months, in 86% after 2 to 3 years and in 100% after 4 to 7 years (Table 2). 
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TABLE 2. IgG-PT levels in patients with clinical pertussis
versus time elapsed since disease onset
IgG-PT level
(U/ml)
% of patients with indicated IgG-PT level at time of serum
collection after onset of diseasea
0–5 mo
(n  57)
6–11 mo
(n  30)
12–23 mo
(n  25)
2–3 yr
(n  14)
4–7 yr
(n  8)
100 90 20 16 7 0
50–99 11 40 12 7 0
20–49 0 13 28 36 13
20 0 27 44 50 88
a n, number of patients.
(iii) Time between onset of the disease and development of high IgG-PT levels. Sera from 
patients for all age groups with an IgG-PT level of ≥100 U/ml in the first serum sample without 
a fourfold increase in IgG-PT level had been sampled at a later stage of the disease (median 
30 days) than the first sera of patients showing a fourfold increase in IgG-PT level 
(median 17 days) (Table 3). The first samples from patients younger than 3 years of age 
were collected a few days earlier than the samples from older age groups, particularly
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for patients with at least a fourfold increase in IgG-PT.  
The results given in Table 3 also show the number of pa tients with an IgG-PT level of ≥100 U/ml 
in a first serum that in our serodiagnostic database of 1989 to 1996 is considerably larger (4.5-
fold) than the number of patients with at least a 4-fold increase in IgG-PT. This discrepancy 
increases with age from 1-fold for the 0-to 5-month-old ages to 13.6-fold for those of ≥15 years. 
(iv) Sensitivity of the proposed cutoffs for IgG-PT in PCR and/or culture-confirmed 
pertussis cases. Among the 89 pa tients for whom pertussis was confirmed by a positive 
culture and/or a PCR both in the IgG-PT distributions in the first and second serum samples, 
no statistically significant differences were found between age groups. The distributions of 
IgG-PT in the first and second sera of the serum pairs of these patients are shown in Fig. 3. 
In 3 of the 89 patients, IgG-PT was undetectable (<5 U/ml) in both the first and the second 
serum samples. In two other patients the IgG-PT rose from <5to7 and 8 U/ml. In 69 patients 
a ≥4-fold increase of IgG-PT was detected, in 11 patients the IgG-PT in the first serum sample 
was ≥100 U/ml and no fourfold rise was detected and in 4 patients the rise in IgG-PT was 
<4-fold and the IgG-PT level in the first serum sample was <100 U/ml. Thus, if detection of 
a ≥4-fold increase of IgG-PT in paired sera and detection of ≥100 U of IgG-PT per ml in a 
single serum sample are used as the criteria for the serodiagnosis of active or recent infection 
with B. pertussis, the sensitivity of IgG-PT serology in this “gold standard” group of patients is 
enhanced from 77.5% (69 of 89) to 89.9% (80 of 89). Overall, the sensitivity of IgG-PT levels 
of ≥50 and ≥100 U/ml amounted to 88.8 and 76.4%, respectively; i.e., 79 and 68 of the 89 
patients had IgG-PT levels of ≥50 and ≥100 U/ml in the first and/or second serum samples 
respectively.
Discussion
Our results show that an IgG-PT level of at least 100 U/ml is a specific tool in laboratory 
confirmation of patients with a suspected pertussis infection in The Netherlands. The levels 
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TABLE 3. Time between onset of the disease and ﬁrst blood sampling for patients with at least a fourfold IgG-PT increase and
for patients with at least 100 U/ml in the ﬁrst serum sample without a fourfold IgG-PT increase
Age
Patients with at least a fourfold IgG-PT increase Patients with at least 100 U/ml in ﬁrst serum samplewithout a fourfold IgG-PT increase
No. of patients Median (days) Percentiles 2.5–97.5 Mean (days) No. of patients Median (days) Percentiles 2.5–97.5 Mean (days)
0–5 mo 517 14 2–53 17.0 497 30 4–108 36.8
6–11 mo 144 14 2–61 16.8 305 29 2–105 35.4
1 yr 174 15 2–62 19.2 426 28 4–122 36.3
2 yr 195 15 4–88 19.6 763 30 6–109 38.1
3 yr 262 18 3–60 19.7 966 30 7–119 38.5
4 yr 362 21 5–55 21.9 1,499 31 7–112 39.0
5–9 yr 1,191 18 3–58 20.6 5,655 31 7–103 37.6
10–14 yr 327 18 4–61 21.3 2,180 31 7–111 40.0
15 yr 222 16 3–67 19.3 3,028 30 6–108 37.2
Total 3,394a 17 3–59 19.8 15,319 30 6–109 38.0
a n  3,491 due to missing values for time of disease onset.

       
Fig 3: IgG-PT distribution in the first and second serum samples of patients with a positive culture and/or PCR for 
B. pertussis. White circles indicate sera with at least a fourfold increase in IgG-PT to a level of at least 20 U/ml. Black 
circles indicate sera without a fourfold increase in IgG-PT; pairs of sera are connected with a dotted line. Half-black, 
half-white circles indicate sera in which the degree of increase of IgG-PT could not be determined due to the upper 
limit of differentiation of the IgG-PT assay of ≥500 U/ml; pairs of sera are connected with a dotted line. 
of IgG-PT in the Dutch population are lower than and overlap only slightly, IgG-PT levels 
that are reached in patients with clinical symptoms of pertussis and a significant immune 
re sponse to B. pertussis. IgG-PT levels of at least 100 U/ml were observed in <1% of the overall 
general population, varying between maximally 2.5% for 10-to 14-year-olds and <0.5% 
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for those 2 years of age or younger. Furthermore, such levels were present in the second 
serum sample of 80% of those patients who had at least a fourfold increase in IgG-PT. 
Our longitudinal study of pertussis patients shows that the levels decreased within less than 1 
year to a level below 100 U/ ml after natural infection with B. pertussis for almost all pa tients 
who had had high IgG-PT levels. The regression model predicts that a level of 100 U/ml is 
reached in 4.5 months and a level of <40 U/ml is reached within 1 year after onset of the 
disease. For seven of eight patients with a longer follow-up time, the IgG-PT levels were below 
20 U/ml by 4 to 7 years after the disease onset. Thus, IgG-PT levels of at least 100 U/ml for 
patients with suspected whooping cough are indica tive of recent or active infection with B. 
pertussis.   
In our population-based study, the percentage of individuals who reported pertussis or 
coughing attacks in the last year increased from 10% for those with IgG-PT levels of <5 U/ml 
to 26% for those with levels of at least 100 U/ml. This finding offers further support for our 
conclusion that a high IgG-PT level is indicative of recent or active infection with B. pertussis. 
Ten percent of the individuals in the population study with an IgG-PT level of <5 U/ml 
reported pertussis or coughing attacks in the last year. On the one hand, this may be explained 
by other respiratory tract infections that cause “pertussis-like” symptoms (36), rapid decline 
of a previously high IgG-PT level, or absence of an IgG-PT response after B. pertussis infection. 
It is also possible that not all subjects answered the question properly. On the other hand, the 
large percentage (60%) of individuals with high antibody titers who did not report per tussis 
or long-lasting coughing attacks might be due to very mild, atypical or even asymptomatic 
infection with B. pertussis. In a household exposure study, a B. pertussis infection was shown 
to exist in 46% of the exposed subjects who remained well (7). In another study, only 26% of 
the adults with labora tory evidence of a B. pertussis infection reported recent symp toms 
compatible with pertussis (31).  
Although IgG-PT is induced after whole-cell vaccination only in children aged 12 to 17 months 
and thus after the fourth dose given at the age of 11 months, a temporary and small increase 
was observed. These results are consistent with obser vations in a vaccine trial showing very 
low levels of IgG-PT after the first to third vaccinations and a small increase just after the 
fourth vaccination as Nagel and others have observed (19, 25). Thus, it is very unlikely that 
high levels of IgG-PT are induced by previous vaccination with Dutch whole-cell vaccine. 
However, other vaccines might induce higher IgG-PT levels since the response to PT varies 
between different whole-cell vaccines and acellular vaccines (2, 12, 33, 34). However, even 
when a level of at least 100 U/ml is reached, it is likely to decline shortly afterwards (12, 
33, 34). Giuliano et al. (12) reported that mean titers were close to the limit of detection 15 
months after the primary immunization with acellular vaccine. High IgG-PT levels must be 
interpreted more cautiously in children recently vaccinated with a vaccine known to induce 
relatively high levels of such antibodies. 
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In addition to specificity, both sensitivity and positive pre dictive value are important as 
diagnostic tools. Using paired sera of patients with positive PCRs and/or positive cultures 
(gold standard group), a sensitivity of IgG-PT of at least 100 U/ml was 76%. At least a fourfold 
increase was found in most of the remaining patients in whose paired sera the IgG-PT level 
remained lower than 100 U/ml. One might speculate that a level of at least 100 U/ml may have 
been reached at a later point. Only 6% of all patients had very low IgG-PT levels in both sera 
without significant dynamics. With the exception of those aged 10 to 14 years, a level of IgG-
PT of at least 100 U/ml exceeded the 99th percentile in the general population. Fur thermore, 
as described above, it was likely that individuals in the general population with IgG-PT levels 
above this value had had a recent or active B. pertussis infection. Based on this 99th percentile, 
the positive predictive values will still amount to 90 and 80%, assuming the proportions 
of true pertussis pa tients to be 9 and 4%, respectively, among those who sub mitted serum 
samples [i.e., 9/(9 + 1) and 4/(4 + 1)]. However, depending on the clinical presentation and the 
epidemiological situation, the a priori chance of true positivity in most cases will be higher. 
Using a more conservative estimate, i.e., percentile 97.5 in the general population, the positive 
predictive value will not be below 80%, assuming a percentage of true positives of 10%. 
Even an IgG-PT level of at least 50 U/ml has some predictive value, since it amounts to 
70%, assuming a percentage of true positives of 10%. This suggests that the diagnosis 
of pertussis is likely among patients with clinical symptoms of pertussis with such 
IgG-PT levels. However, we interpret such a result to be indicative of but not definite 
proof of, a recent B. pertussis infection and we advise submission of a second serum 
sample. If no further change of IgG-PT level has occurred as evidenced by a second 
serum sample, we conclude that “recent or active infection with B. pertussis is possible.”  
Serological data obtained at our laboratory show that using our cutoff value for the IgG-PT 
level of at least 100 U/ml would increase the number of patients with serologically proven 
per tussis by more than fourfold. The increase is smallest for in fants and greatest for adults, 
which is probably related to a longer delay in consulting a physician and/or initiating labora-
tory testing in older children and adults. This is supported by the similar median time (28 
to 30 days) between the first blood sampling and the onset of symptoms for the various 
age groups for those with an IgG-PT level of at least 100 U/ml. For pa tients with at least 
a fourfold increase in IgG-PT the median time (17 days) between the first blood sampling 
and the first symptoms is about 2 weeks shorter than that for those without a fourfold 
increase and IgG-PT levels above 100 U/ml. The most useful method for pertussis diagnosis 
depends on the time of initiation. PCRs and cultures are most useful early in the disease. 
However, if they are negative, the diagnosis is indeterminate and serology tests should be 
initiated. Late in the disease, PCRs and cultures are fairly insensitive (with an exception for 
infants less than 1 year old) and serology is then the method of choice (16, 21, 35).  
To diagnose pertussis, other investigators have also used single serum samples from a control 
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group for defining a cut off but most studies were limited to a specific study setting and were 
not meant for routine diagnosis (1, 6, 20, 21, 23, 27, 28, 32). Our control group consisted of 
a large number of participants from a population-based study so the representativeness is 
probably better guaranteed. 
Cattaneo et al. point out that it is unlikely that a single serology value can be used to define 
infected persons in a broad age range because age, geographic area, prevalence of infection 
and history of vaccination all have to be taken into account (3). Yet an IgG-PT level of at least 
100 U/ml in a single serum sample might be a specific diagnostic tool for pertussis in other 
countries too. After all, it is likely that such high IgG-PT levels will not or will be reached 
only temporarily no matter which vaccine is used. After the initial increase, the IgG-PT level 
decreases again after B. pertussis infection, high predictive values are calculated under different 
assumptions about prevalence of infection and, finally, a large proportion of individuals with 
a B. pertussis infection show high IgG-PT lev els later in the course of the disease. Thus, we 
believe that high IgG-PT levels could provide a useful laboratory tool for the diagnosis of 
pertussis in both the individual patient and in epidemiological studies (21, 29, 32). It might 
be worthwhile to validate our results in other countries.
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Abstract
Susceptibility to infection with Bordetella pertussis re -emerges several years after pertussis 
vaccination. However, the duration of immunity after natural infection with B. pertussis, 
postulated to be lifelong, is not known. In an ongoing study, the longitudinal course of pertussis 
antibodies in patients who have had laboratory  confirmed pertussis is being followed using sera 
obtained at irregular intervals. In 4 patients a re-infection with Bordetella pertussis is described 
respectively 7 (patient A), 12 (patients B and C) and 3.5 (patient D) y after the first infection. 
It seems that the longer the interval between the infections the more severe the complaints. 
Conclusion: To the authors’ knowledge, these are the first patients in whom symptomatic re-
infection with Bordetella pertussis has definitely been proven by laboratory confirmation of 
both episodes. Bordetella pertussis infection should be considered in patients with symptoms 
of typical or atypical whooping cough, irrespective of their vaccination status or previous 
whooping cough. 
Introduction
Bordetella pertussis causes a respiratory infection, which is most severe and potentially fatal 
in very young children. Most countries have implemented nation-wide vaccination against 
B. pertussis. However, owing to waning of vaccine -induced immunity (1, 2) infections with 
B. pertussis persist in vaccinated populations and these may remain unrecognized because of 
the atypical or mild nature of symptoms (3–6).      
In contrast, it has been commonly accepted that natural infection with B. pertussis confers 
lifelong protection (7, 8). However, this view has been chal lenged by several reports of 
occurrences of pertussis in patients who have previously had pertussis (8, 9). In these reports, 
definite laboratory confirmation that the first episode had indeed been pertussis was lacking. 
This report describes patients who suffered labora tory -confirmed typical pertussis and 
subsequently con tracted a second episode of coughing which was proven to be caused by B. 
pertussis. They took part in a study of the longitudinal course of pertussis antibodies after 
natural infection (12). 
Case reports
Patient A was born in 1989. For religious reasons her family refused vaccination. She 
visited our department for the fi rst time in 1991 because of asthma.  
In August 1992 she visited the outpatient clinic because of severe paroxysmal coughing. Because 
of the persisting coughing, pertussis serology was performed and demonstrated a greater than 
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48- fold rise in IgG antibodies titres to pertussis toxin (table 1) (10). In a later serum also 
IgA antibodies to B. pertussis (11) were detected and IgG antibodies to pertussis toxin had 
increased further to levels typical of recent infection (12) (table 1). After approximately 10 
weeks of severe paroxysmal coughing the patient eventually recovered completely. In serum 
obtained in 1995, three years after the first pertussis episode, the IgA and IgG antibody levels 
had decreased to low levels (table 1). 
                      
Table 1. Levels of IgA antibody to B. pertussis and IgG antibody to pertussis toxin in 
consecutive sera of patient A; the first symptomatic infection occurred in 1992, the 
second in 1999.
Date
(dd-mm-yy) Clinical status
IgA (11)
(U ml -1)
IgG (10, 12)
(U ml -1)
06-08-92
10-09-92
16-11-92
30-09-95
31-03-99
09-04-99
28-04-99
09-09-00
n.s.
Paroxysmal cough
Paroxysmal cough
n.s.
Mild coughing
Mild coughing
n.s.
n.s.
1
2
10
7
8
14
20
7
1
48
248
6
260a
344
492
44
n.s.: no symptoms
a Pertussis positive by polymerase chain reaction
In 31 March 1999 she visited the outpatient clinic because of a new episode of coughing, 
which had started 9 days before. Her pertussis serology showed a high level of IgG antibodies 
to pertussis toxin suggest ing recent infection. Subsequently, PCR (polymerase chain reaction) 
on material obtained from a nasophar yngeal swab demonstrated the presence of B. pertussis 
(13). She fully recovered in less than 3 weeks. The follow- up of pertussis serology showed that 
IgA and IgG antibody levels reached a peak at 5 weeks after onset of symptoms and that 9 and 
16 months later these levels had considerably decreased again. 
Patients B and C are female twins born in 1984. They were vaccinated against pertussis in 
the first year of life. From the age of one year they came under pediatric attention because of 
allergic rhinitis and severe bron chial asthma. In September 1989 they visited the outpatient 
clinic because of a change in cough pattern which reminded their grandmother of whooping 
cough. Two to three weeks before the visit they suffered for one or two days from severe 
coughing and high fever. In patient B this was accompanied by vomiting, in patient C by 
nasal discharge and diarrhea. In the weeks after they had cough paroxysms, especially during 
the night, often followed by vomiting and an inspiratory “whoop” at the end of a paroxysm. 
Paired serum analysis showed a significant rise of IgA and IgG titers against B. pertussis in 
patient B (table 2). In patient C titres did not rise significantly but they met the criteria for the 
diagnosis of B. pertussis infection with one point serology. 
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Table 2. Levels of IgA antibody to B. pertussis and IgG antibody to pertussis toxin in consecutive sera of patient B 
and C; the first symptomatic infection occurred in 1989, the second in 2001. 
Patient B Patient C
Date
(dd-mm-yy) Clinical status
IgA (11)
(U ml -1)
IgG (10, 12)
(U ml -1)
IgA (11)
(U ml -1)
IgG (10, 12)
(U ml -1)
20-09-89
10-10-89
27-10-89
11-06-01
01-07-01
Paroxysmal cough
Paroxysmal cough
Paroxysmal cough
Paroxysmal cough
Paroxysmal cough
1
8
68
1
88
368
1
6
9
38
72
144
112
168
The symptoms gradually faded during the next 4 months. In patient C a third titre was 
determined two weeks after the second, which showed a further increase in IgA and a 
decrease in IgG titre. Between 1989 and 2001 no blood samples came available for this study. 
In June 2001 both girls again visited the out patient clinic because of a cough, which lasted 
for four weeks and reminded their father of their first whooping cough episode. Patient B had 
experienced several nightly attacks with a whooping type of cough resulting in shortness of 
breath, which gave her the feeling of near suffocation. After several nights she learned to cope 
better with the attacks, which she thought to be caused by hyperventilation. In patient C the 
course was milder (cough attacks followed by a whooping inspiration). One point serology 
against B. pertussis was positive in both girls. Symptoms disappeared spontaneously in about 
two months. 
Table 3. Levels of IgA antibody to B. pertussis and IgG antibody to pertussis toxin in 
consecutive sera of patient D; the first symptomatic infection occurred in 1998, the 
second in 2001. In February 2001 she suffered from Influenza A.
Date
(dd-mm-yy) Clinical status
IgA (11)
(U ml -1)
IgG (10, 12)
(U ml -1)
13-05-98
26-05-98
02-09-99
01-02-01
16-02-01
07-11-01
Nocturnal coughing
and common cold
Nocturnal coughing
n.s.
Mild coughing
Mild coughing
Coughing now and then
11
39
25
11
14
27
228
500
71
10
10
492
n.s.: no symptoms
Patient D was born in 1994 and was regularly vaccinated. She was referred to the outpatient 
clinic because of persisting cough with common cold and tightness of the chest in May 1998. 
She was already treated for 2 weeks with clarithromycin and anti -asthmatic drugs without 
success. Serum analysis showed a significant rise of IgA and IgG titers against B. pertussis (table 
3). Continuation of therapy finally resulted in complete recovery within another month. She 
was then followed for her asthma. In February2001 she suffered again from coughing during 
an Influenza A (H1N1) infection. Titers against B. pertussis were low. She recovered within 2 
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weeks. In November 2001 she came for a routine visit. Her brother was diagnosed to have a B. 
pertussis infection in August 2001. She only suffered from a little coughing now and then, not 
worth mentioning, starting early September. Serology was again positive for B. pertussis. 
Discussion
Little is known about the persistence of immunity to B. pertussis after natural infection. The 
high levels of IgG antibodies to pertussis toxin (IgG -PT) that develop after natural infection 
decline to low levels within a few years (12), as typified in patients A and D. However, although 
high levels of IgG- PT are associated with protection (14), no evidence has been available 
that links low levels of these antibodies with susceptibility. In patients A and D, 4y after the 
first episode, the IgG- PT had declined to low levels (Tables 1 and 3) but at the time of the 
second infection (7 and 3.5 y after the first infection) partial immunity was still present, as 
sug gested by the short duration, mild nature of symptoms and the rapidity of the humoral 
immunoresponse compared with the first episode. Whether or not the relatively short interval 
in both patients between first and second symptomatic infection episodes is excep tional 
cannot be ascertained, since no other data on proven re-infection could be found. 
Others have concluded that natural infection does not provide lifelong protection against 
whooping cough as there are cases of re-infection based on clinical history but without 
laboratory confirmation (8, 9). Theoreti cally, other infectious agents could have been the 
cause for the recurrent pertussis syndrome (15). In most cases of possible re-infection the 
recalled pertussis syndrome had occurred at least 20 y earlier (9). 
To the authors’ knowledge, these cases are the first in which both the first and the second 
infection episodes were clinically documented and confirmed with labora tory tests. The fact 
that the patients participated in a long -term follow- up study of antibody levels after infection 
with B. pertussis (12) probably played an important role in detecting the second infection. It 
is very doubtful whether the second episode in patients A and D would have come to medical 
attention or would have been diagnosed as pertussis outside the confines of the study. 
The expected persistence of a reservoir of B. pertussis in the population underscores the need 
for the develop ment of alternative strategies specifically to protect unvaccinated neonates 
against potentially fatal pertus sis. For example, booster vaccinations repeated throughout life 
may be considered (16). 
The immediate implication of this observation is that patients who present with symptoms 
compatible with typical or atypical pertussis should be considered to have pertussis, not only 
if they have been previously vaccinated but also if they have had whooping cough before. 
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Summary
We aimed to provide a quantitative description of decay in pertussis antibody levels to aid in 
finding a serological estimate of the incidence of pertussis. The serum IgG response against 
pertussis toxin was studied in a group of clinically diagnosed patients. Individual records 
consisted of repeated serum IgG measurements at irregular intervals for up to 10 years post 
diagnosis. These data were analysed with a nonlinear regression model taking into account 
censoring at upper and lower threshold levels, measurement errors and individual variation 
in the shape and magnitude of the immune response. There was considerable variation 
between individual responses, both in strength (amplitude) and duration (shape). The inverse 
model relating IgG levels to time from infection (diagnosis) can be applied to cross-sectional 
IgG data to generate distributions of times from infection, which may be used to calculate 
infection rates and their variation, in populations sampled for cross-sectional IgG data. 
Introduction
Pertussis (whooping cough) is an infection of the res piratory tract caused by the highly 
contagious bac terium Bordetella (B.) pertussis. Despite high vaccination coverages, B. pertussis 
is still circulating in the Dutch population. Notification data show that most symp tomatic 
cases occur among vaccinated children aged 4–9 years [1]. However, symptoms are most 
severe among infants who are too young to be vaccinated. In order to protect this group at risk 
it is important to determine which people are most likely to transmit infection to newborns. 
We aimed to identify those age groups in the population in which most of the circulation of 
B. pertussis takes place. The age profile of notified cases may not reflect the age distribution of 
infection with B. pertussis because the case/infection ratio is probably higher in younger age 
groups [2]. It was necessary to determine the infection rates in each age category, rather than 
notification rates. 
In response to an infection, IgG titres typically show a rapid increase, followed by a steady, 
slow decline over a long period (several years) [1, 3–9]. Also IgG-PT induced after three or 
four doses of acellular or whole cell pertussis vaccine in the first year of life declines rapidly, 
mostly within one year, to low levels [10, 11]. Therefore, it is likely that in individuals in whom 
the last vaccination with pertussis vaccine has been administered more than one year ago, the 
finding of moderate or high levels of IgG-PT indicates infection with B. pertussis. Because the 
magnitude of the IgG-PT level is inversely related to time elapsed since infection, this suggests 
that in a patient with a given response, time from infection can be estimated from IgG levels. 
If this approach to estimating times from infection were feasible, cross-sectional studies 
of IgG-PT-levels could be used to estimate the incidence of infection independent of case 
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notification. This requires quan titative characterization of the IgG-PT-response to pertussis 
inclusive of its variation among individual patients. 
We used data from an ongoing long-term follow-up study in which blood samples were taken 
at irregular intervals from patients with clinically and serologically confirmed pertussis. At 
present, this study comprises 85 patients with follow-up times ranging from 6 months to 11 
years. Numbers of samples were unequally dis tributed among patients. In an earlier report 
on the first 57 patients in this longitudinal study it was shown that despite large variation in 
responses the general pattern appeared to be a rapid increase in antibody levels followed by 
a slow decrease. 
We tested several mathematical functions for their ability to fit these observed changes in 
IgG-PT levels with time. Here we present results of this analysis taking into account censoring 
at upper and lower threshold levels, measurement errors, as well as indi vidual variation in the 
shape and magnitude of the IgG-PT immune response. 
The selected model describes a functional relation ship between time since last infection and 
level of anti body titre. The model was applied to a cross-sectional population based study 
of IgG-pertussis antibody titres, permitting estimation of a distribution of in fection dates 
for individuals in this population. Such model-based age-specific distributions of times since 
infection assist in identifying those age groups in which circulation of B. pertussis is most 
prevalent. 
Methods
Data used 
During the period 1989–2000, a collection of follow-up serum samples was obtained from 85 
patients clinically diagnosed with pertussis (paroxysmal cough lasting more than 2 weeks) in 
whom the clinical diagnosis had been confirmed by the finding of an IgG-PT level of 75 U/ml 
in the first or the second serum obtained in the symptomatic stage. The specificity of IgG-
PT of 75 U/ml as an indicator of recent infection with B. pertussis has been estimated to be 
>97.5 % while the sensitivity was around 80 % [1]. For participation in this study a minimum 
follow-up period of 3 months was required. 
In one of the participating patients a second symp tomatic infection with B. pertussis occurred 
7 years after the first, confirmed by positive pertussis PCR and a strong rise of IgG-PT. For 
analysis in this study we considered this record to be two patients: the first one connected 
to the first episode of pertussis and its follow-up until the last sampling before the second 
epi sode and one connected to the second episode and the follow-up thereafter. Thus, in 85 
patients, 86 episodes of pertussis and the course of IgG-PT thereafter were analysed. Recently, 
an additional three patients ap peared to be re-infected [12]. These were not included in the 
present analysis. 
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The follow-up period ranged from 6 months to 11 years and the number of serial sera per 
patient ranged from 2 to 11. The age distribution of the patients is given in Figure 1. Most 
were children between 0.5 and 17 years of age (69/86). Eleven infants were less than 6 months 
old at the time they contracted pertussis. Also included were six adults with ages ranging 
from 30 to 41 years. Vaccination status as reported by the physician at the time of onset of 
pertussis was in 1 of 4 categories: negative, incomplete (1 or 2 vaccinations), complete (3 or 
4 vaccinations) or unknown. Four infants whose vaccination had not been completed at the 
time of pertussis were vaccinated shortly thereafter. We there fore decided to use five categories 
of patients: infants (0–0.5 years) vaccinated after infection (4); infants not vaccinated after 
infection (7); vaccinated juveniles (0.5–20 years) (62); unvaccinated juveniles (7) and adults 
(6). These subgroups were analysed separately. 
            
      
Only changes in the highly specific anti-pertussis IgG-titres were analysed. Titres were 
determined by enzyme-linked immunosorbent assay (ELISA) [11, 13] expressed in arbitrary 
units (‘ Dutch units per ml ’). In Figure 2 all measurements from all included patients are 
shown. Reproducibility of measure ments was checked according to Standard Operating 
Procedure (SOP: coefficient of variation in log-transformed readings from three control sera 
(low, medium and high titre) less than 20 %). For quantitat ive analysis, the scatter in these 
measurements there fore was considerable. 
Below 5 U/ml the ELISA test is considered insen sitive, therefore 5 U/ml was interpreted as 5 
U/ml or less. Serial dilutions were used to an upper limit cor responding to a concentration of 
500 U/ml: a value of 500 U/ml was therefore interpreted as 500 U/ml or higher. 
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Fig. 1. Age distribution of patients.
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Each patient record started with the time the first symptoms occurred. Strictly speaking, we 
did not estimate times from infection but times from first symptoms (or even first diagnosis). 
Since incubation periods may show variation among individual patients, individual responses 
could have been slightly offset relative to each other. 
Response model 
During the decreasing phase, the change in IgG titre with time appeared to be less steep 
than an exponential decay function. In a log–log graph, an exponential relation is a convex 
function with increasing negative slope with log-time. Our data did not seem to indicate such 
behaviour. Instead, in a log–log graph, decay appeared to be more or less linear (Fig. 2). This 
called for a power function as a model, which on a log–log scale would be a straight line with 
arbitrary slope. However, observations were taken at random points in time, usually starting 
somewhere during the rising phase of the response. Fitting a straight line to the log– log 
transformed data, as reported by de Melker [14], only accounted for the decaying phase of 
the response and required omission of these initial observations. Since there was no clearly 
defined criterion by which observations would be excluded, we chose to use a response model 
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Fig. 2. Data set of log-transformed IgG-values against log
time (in days) from all patients diagnosed at time 0 with
symptomatic infection by Bordetella pertussis. Individual
responses are connected, and log-transformed responses of
vaccinated juvenile patients against log-time, after appli-
cation of a smoothing kernel (moving average, bandwidth as
in inset), showing linear increase and decrease.
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that included the initial rising phase. 
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The parameter d can be interpreted as the amplitude of the response and the parameter a 
mainly determines the long-term decrease of the response. 
Figure 3 illustrates the shape of this function, in a non-transformed (lin–lin) graph to show 
the very slow decline with time. 
Model-fitting procedure 
The response model [equation (1)] can be used to cal culate expected values of the logarithm 
of the IgG titre. 
Fig. 3. Representative individual response curves generated
by the model in equation (1), ﬁtted to data from vaccinated
juvenile patients. These curves illustrate characteristics of
the responses : rapidly rising titres, followed by very slow
decrease, and variation in both levels and steepness of the
curves.
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Assuming normally distributed measurement errors, with standard deviation σ, the log-
likelihood function can be written as
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In our case the lower threshold in the ELISA test was 5 U/ml and the upper threshold was 500 
U/ml. Parameter values of the re sponse model (a, b, c, d) and the error of the detection method 
would be determined using this likelihood function. 
Initially, our response model was fitted to the pooled data neglecting individual variation. In 
this 1-level model measurement error was the only possible source of uncertainty. In order to 
assess variation in responses among individual subjects we would have fitted our model to the 
measurements of each individual re sponse, thereby generating sets of parameters




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for every individual i in the population. Since individual responses often consisted of only a 
few measurements, we decided to allow only one or two parameters to vary among individual 
subjects. Leaving aside the measurement error parameter 
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, fitting a model equation with 
four parameters to a population of n subjects thus generates n+3 parameter values (or 2n+2, 
where two parameters vary among individual responses), when 3 (2) parameters are equal 
for all subjects and n (2n) estimates for the (third and) fourth parameter to describe variation 
among subjects. 
In our response model in equation (1), the par ameters d describing the vertical offset on a 
log-scale (or the amplitude of the response) and a describing the shape of the response could 
be employed to model variation among individuals; the parameters b and c were shared by 
the whole population. The parameter 
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 (the measurement error) was assumed to be indepen-
dent of the individual whose serum was being analysed. 
Therefore, our final model included individual variation in both a and d, leaving us with a 
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In order to avoid cumbersome likelihood optimiz ation procedures this two-level model was 
analysed by a Markov chain Monte Carlo (MCMC) method, using the Metropolis–Hastings 
algorithm [15]. Par ameters were log-transformed, initial values were set at the values found for 
the one-level model (individual values for log(ai) and log(di) all equal) and prior dis tributions 
for the log-transformed parameters were uniform probability distributions with an interval of 
(-3, +3) log-units about the initial value (wider in tervals were checked and did not produce 
different results). For each iteration in the Markov chain the likelihood value was tabulated. 
The model was then allowed to run for about 10 000 iterations and a trend test was used to 
confirm stationarity of the series of likelihood values (equal means in successive bisections of 
the series). The iteration with the highest likelihood value was then chosen from this set of 
likelihood values 
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This was taken as an approximation of the true maxi mum likelihood parameter set. When 
the resulting response functions were plotted against separate individual observed responses, 
this seemed to be a reasonable assumption. The likelihood values also appeared to fall well 
below the values found for the one-level model and those of alternative two-level models with 
either a or d varying among individuals. Compared to a ‘likelihood supremum’ obtained by 
using the observed tires instead of the model function (using the measurement error from the 
fitted model) a significant improvement in goodness of fit was found (likelihood ratio tested 
against 
2
! deviate). This can be explained by the apparent lack of fit early in the re sponses 
(Fig. 5a). It should be noted that when indi vidual responses were fitted, each response curve 
was based mostly on only a few (sometimes as few as three) observations. Therefore, the 
 2
!
 
approximation of the deviance function should be treated with caution. 
For a sequence of log-times 5, 50 and 95% per centiles were determined for these maximum 
likeli hood fits. The median curve was used to describe the time–titre relation, while the 
5 and 95% percentiles indicated the magnitude of the variation among mem bers of this 
population. 
In addition to the maximum likelihood estimates, the Monte Carlo method provided 
information on parameter uncertainty, as the Markov chains for all parameters could be 
regarded as a sample from their joint posterior distribution. 
Patients were categorized according to age (adults older than 20 years, infants younger than 
6 months and juveniles older than 6 months and younger than 20 years) and vaccination 
status (unvaccinated and vaccinated). To test whether the two categories could be merged, 
given a certain regression model, a likeli hood ratio test was used as follows: first, calculate 
maximum likelihood values for each separate data category (say  and aL bL

). Then, pool 
the data and maxi mize the likelihood for the merged data (yielding a log-likelihood abL

). 
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 would now be tested against a 
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
variate with 
degrees of freedom equal to the number of parameters of the regression model [16]. Various 
combinations of cat egories were tested using this method. 
Results
Table 1 summarizes the results of application of the two-level model to the various patient 
categories (age, vaccination status). In Table 2 results of the likelihood ratio test for merging 
various combinations of cat egories are given. None of the response categories could be 
merged; differences were significant for all the tested combinations. Given the applied model, 
the IgG-PT response to infection with B. pertussis was seen to change with age and with 
vaccination status. 
Table 1. Maximum log-likelihoods for the two-level model applied to
separate patient categories
No.
patients
One-level Two-level
No. par* x2 log(L) No. par x2 log(L)
Juv, vacc 62 5 536.4 127 434.0
Juv, unvacc 7 5 48.9 17 33.6
Adults 6 5 25.0 15 6.6
Infants, vacc 4 5 10.5 11 0.5
Infants, unvacc 7 5 44.5 17 4.6
* No. par=number of parameters.
Table 2. Maximum log-likelihoods for joint categories, and diﬀerences D[x2 log(L)] with separately ﬁtted
model. The last column shows the signiﬁcance of the diﬀerence (likelihood ratio test, as explained in the text,
model ﬁtting procedure) at the 0.95 level. Therefore, responses from all categories must be considered diﬀerent,
given the proposed model
(log)likelihood (log)likelihood ratio
D.F. x2 log(L) DD.F. D[x2 log(L)] Signiﬁcance
Juv, vacc+unvacc 141 486.0 3 18.4 +
Juv, vacc+unvacc, adults 153 524.0 6 49.7 ++
Infants, vacc+unvacc 25 17.8 3 12.7 +
All 175 588.2 12 113.1 ++
Figure 5 shows two-level model fits to individual responses, illustrating large variations in 
shape and amplitude of responses in individual patients. 
Although statistically significant, the differences due to vaccination status within the two 
youngest age cat egories, infants and juveniles, were not large (Figs 5 a, b and 5 c, d, respectively). 
A small group of adult patients (Fig. 5e) appeared to have a response that differed from the 
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younger patients. The most prominent differ ence was the lack of early measurements: these 
adult patients apparently visited their physician later than the younger patients. This may 
have been associated with milder symptoms in adults (for instance causing a parent to infect 
a child who then developed severe enough symptoms for the infection to be detected in both 
the parent and the child). The decay of the re sponse in these adults did not differ greatly from 
that of the vaccinated juveniles. 
Fig. 4. (a) Maximum likelihood values of individual shape parameters (aˆi) and amplitude parameters (dˆ i) for the two-
level model ﬁtted to vaccinated juvenile patients. (b) Variation in shape (parameter ai) among patients (rank number i,
random order) expressed by plotting MCMC-based median values and 0.05 and 0.95 quantiles. (c) Variation in amplitude
(parameter di) among patients expressed by plotting MCMC-based median values and 0.05 and 0.95 quantiles.
Table 3 and Figure 4 show estimated parameter values for the largest category, vaccinated 
juvenile patients (comprising 62 patients, 72% of all patients). Maximum likelihood parameter 
values (with median; 5%, 95% percentiles) are shown in Table 3. For parameters ai (variation in 
shape of the response) and di (variation in amplitude of the response), fitted par ameter values 
for all patients in this category are shown in Figure 4. The uncertainty in these parameters is 
illustrated in Figure 4 b, c, which show median values with (MCMC-based) 95 % intervals. 
Measurement error
In the one-level model, all variation is interpreted as measurement error. Therefore, the 
value of the par ameter σ is larger than in the two-level model, where part of the variation is 
attributed to heterogeneity in patient responses. Despite the considerable individual variation, 
the estimated measurement error is very large. In the vaccinated juvenile patients, the logar-
ithm of this error factor decreased from 0.62 in the one-level model to 0.46 in the two-level 
model. This would mean that a 95 % confidence interval for the IgG-levels would extend over 
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approximately a factor five up or down, for the two-level model. 
Fig. 5. (a) Log–log graph of individual responses of the two-level model, ﬁtted to data from vaccinated juvenile patients. Also
shown data and (heavy line) median response. (b) Log–log graph of individual responses of the two-level model, ﬁtted to data
from unvaccinated juvenile patients. Also shown (c) infants, vaccinated after infection, (d ) infants, not vaccinated after
infection, and (e) adults.
Table 3. Parameter estimates for the one-level (1-l ) and the two-level (2-l ) model, applied to responses from
patients in all categories
aˆ bˆ cˆ dˆ sˆ
1-l 2-l 1-l 2-l 1-l 2-l 1-l 2-l 1-l 2-l
Juv, vacc 22.8 Fig. 4 14.0 15.7 2.68 1.90 1.00 Fig. 4 0.65 0.56
Juv, unvacc 2.15 — 2.00 2.66 6.85 3.09 2.86 — 0.61 0.46
Adults 0.12 — 1.87 4.23 0.25 0.11 x2.81 — 0.45 0.32
Infants, vacc 1.51 — 1.46 1.58 22.3 19.5 13.5 — 0.34 0.22
Infants, unvacc 2.59 — 2.08 2.29 17.2 18.9 11.4 — 0.54 0.31
Time since infection as a function of titre
In order to describe the time elapsed since infection (numbers of days since the appearance of 
symptoms) as a function of titre, we determined the inverse func tion of (1). 
Given the short duration of the rising part of the response, we considered only the decreasing part 
of the response. Each response curve had a maximum titre, dependent on the parameter values 
for an indi vidual patient. Any titres higher than this maximum therefore had no corresponding 
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This inverse function described (log-)time since last infection as a function of (log-)titre. 
Figure 6 shows that this inverse function was also subject to considerable individual variation. 
Given a certain measured IgG-level we now estimated the (variation in) time elapsed since 
infection.
When doing this, we took into account the fact that not every individual response reached the 
same maximum IgG titre. Therefore, with IgG titres rising above a certain level, the inverse 
function did not exist for an increasing number of patients. This is shown in Figure 7a, where 
the fraction of the individual responses (of vaccinated juvenile patients) that reached a given 
log-titre Y, is shown as a function of Y.
Figure 7b shows histograms of the times from infection for a range of IgG-titres, constructed 
from the inverse responses in Figure 6. Returned estimates were based on decreasing numbers 
of responses: only those that reached the level of interest were used. Some technical details are 
given in the Appendix. 
Fig. 6. Expected log-time since infection (j) as a function of
anti-pertussis log-IgG titre (y). Inverse function of the two-
level regression model, using maximum likelihood values for
all parameters. Also shown (heavy lines) median and 95%
range, and (hatched) arithmetic mean response. Each light
grey curve represents an individual response, with its own
maximum level. Titres higher than this individual maximum
cannot be reached and the inverse response jumps to zero.
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Fig. 7. (a) Fraction of the patients (vaccinated juveniles) who failed to reach a level y (log-titre). Even at low titres a considerable
proportion of the patients do not reach that level and cannot contribute to the estimated time since infection. (b) Variation in
log-time since infection (j) for various levels of anti-pertussis IgG titre.
Discussion
The serum IgG-response in patients diagnosed with pertussis can be described by a simple 
parametric model but variation among subjects is a prominent phenomenon that must be 
included in the analysis. IgG titres rise steeply after infection to reach a maxi mum within a few 
weeks and then decline slowly over several years. Although this is probably true in any infected 
subject in a population, incidental measurement of a single IgG titre gives little information 
about the time since infection. In particular, maximum IgG titres appear to show considerable 
heterogeneity; a modestly enhanced IgG titre of 20 IU/ml may correspond to very recent
infection, or may equally correspond to infection several months earlier, depending on the 
particular response of the patient. Current prac tice of characterizing population immune 
responses with their geometric mean titres neglects the import ance of heterogeneity [8, 9, 17]. 
If the group of patients in the study used here is representative of the general population, 
at least with respect to their IgG response to pertussis toxin, our results may be employed 
to estimate times from infection from cross-sectional samples of IgG-PT titres. Any given 
(measured) IgG-PT titre may thus be assumed to correspond with a time from infection (first 
diagnosis). Our results also indicate the existence of considerable variation among individual 
responses. With increasing IgG-PT levels, there also seems to be an increasing fraction of 
subjects who do not reach that level at any time during their post-infection response. High 
IgG-PT levels therefore indicate recent infection but only in a small part of the population. 
Data set
To apply the results of this analysis to the estimation of incidences of pertussis in the general 
population, the observed responses should be representative of the responses that would 
be found in a random sample of this general population. The age distribution in our test 
population differed substantially from that of the population at large, with juveniles aged less 
than 20 years strongly overrepresented. Older subjects were hardly present. The heterogeneity 
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among all patient categories in this study complicates the use of these results for back-
calculation of infection from a cross-sectional sample of a completely different population. 
Estimation of times from infection only involved the decaying phase of the response, where 
differences may have been least marked. This would easily be tested in a practical application, 
which we intend to report shortly. 
Newborns may be important for illness burden and they should possibly be treated separately 
when back-calculating times from infection. Unfortunately, we had responses from only a few 
of these patients but since infection cannot have occurred before birth, time from infection 
was limited in these infants. 
Recorded responses started at the first date of symp toms, as reported by the patients (or their 
parents). In very young children this may have been earlier than in older patients because of 
the severity of symp toms. On the other hand, in newborns symptoms may be non-specific, 
making diagnosis diffcult or delaying diagnosis. An alterative model employing a variable 
shift in onset (at the expense of yet another parameter per patient) only produced minor 
offsets indicating that the data offered little support for such differences. Nevertheless, the 
difference in response shapes between infants and adults (Fig. 5c–e) is striking and seems to 
support an effect of late onset of symptoms. 
The patients included in this study all presented symptoms of respiratory illness. Asymptomatic 
or mild infection is probably more frequent in adults and could be associated with a different 
IgG response: a smaller amplitude, or different time course. No in formation was available 
to test this hypothesis. Most of the juvenile patients also suffered from chronic respiratory 
symptoms (asthma); it remains unclear whether this condition increases the susceptibility 
to infection or could lead to a different immune response to pertussis. Are younger subjects 
more susceptible to infection, or is there a higher probability that infection is symptomatic 
[18, 19]? Recently, an animal model with infection and clinical symptoms similar to those in 
humans has been described [20]. It is conceivable that such a model could be utilized to study 
details of the differences in susceptibility between adults and infants. 
Regression procedure
Heterogeneity in immune responses has been studied for various pathogens. In order to 
assess immunity, Gay used mixture models to describe the variation in age stratified IgG 
levels against parvovirus B19 [21]. Hierarchical Bayesian models have been used to de scribe 
the decline in immunity and its variation in hepatitis B [15] and Haemophilus influenzae 
[22, 23]. These models assumed linear decline of IgG titres (on a log scale). The immune 
response against hepatitis A vaccine has been studied by van Herck and colleagues [17, 24]. 
They studied the decline in geometric mean antibody titre of their subjects with time but 
also re ported on individual responses, presenting evidence of considerable variation among 
subjects [17]. 
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Since our data included not only the decline but in many cases also the rising slope of the 
immune re sponse, we needed a model that accommodated both parts of the response, 
necessarily a non-linear model. Our data also contained strong evidence of censoring; in 
accounting for this, the fitted responses were steeper than they would have been without 
correction for censoring. 
Part of the variation in the measurements appeared to be explained by individual variation, 
in amplitude and/or in shape (descending slope) of the response, rather than by some 
measurement error. In addition to this, other parameters, like incubation period, could also 
have contributed to the heterogeneity of the re sponses. We investigated this by incorporating 
indi vidual variation in shift along the time axis (not shown here). However, this did not result 
in signifi cant improvement in goodness of fit (judged by log-likelihood); estimated delay 
times were also very small and appeared to vary little among individual patients.
Biological interpretation of the hyperbola model
The extremely slow decline in IgG antibody titres with time following infection, probably 
associated with long-term protection, precludes use of a first order model of antibody decay. 
Such a model would lead to a convex curve, with an increasing downward slope on a log 
time–log titre scale. For our data, such a slope is much too steep, with poor fit to the measured 
re sponses. This may not be always a problem. Tiru et al. [25] reported successful use of a 
simple exponential model to describe the immune response to diphtheria toxin. The model 
we used had asymptotically linear decline on a log–log scale at long times from infection. 
Although at first sight perhaps biologically un attractive, such a hyperbolic response function 
may result from an intrinsically first order system, when there is heterogeneity. Suppose IgG 
production and removal are distributed among several locations, all with different properties 
(different time constants and amplitudes). Sufficient heterogeneity among these sites could 
then result in a varying contribution of any given subsystem with time, with fast systems 
providing the bulk of the IgG in the initial phase of the response and ‘ recruiting’ a smaller 
fraction of slower systems in the tail of the response. 
Our analysis indicates that the IgG-PT response to an infection with B. pertussis shows a 
typical pattern, with a rapid transient increase over a few days to weeks, followed by slow 
decay extending over several years. This response can be described with a mathematical 
model; there appears to be considerable variation among responses from individual patients. 
The remarkably large variation in responses cannot be neglected when these are employed to 
estimate the time since infection from a given IgG-titre in a randomly chosen subject. 
Chapter 4

Appendix
Calculation of times since infection
From the above analysis of the longitudinal study we have a function describing the IgG-PT 
level against time from infection (first diagnosis) 
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This is different for each individual patient. 
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Integration is done over all possible parameter com binations and may be based on the 
posterior Markov chain. 
If we now have a cross-sectional sample of IgG-PT titres: 
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Summary
To investigate the possible dependence on age of the rate of decline of IgG antibodies to 
pertussis toxin (IgG-PT) after natural infection with Bordetella pertussis we measured IgG-
PT in follow-up sera of 121 patients (age 0-94 years) obtained after 123 episodes B.pertussis 
infection. For analysis we applied a dynamic model for the inactivation of B.pertussis by the 
immune system. There were no significant differences in rise, peak and decline of IgG-PT 
between different age groups, although there was a tendency for a more rapid increase, a 
higher peak and a faster decline with increasing age. The IgG-PT cut-off of 100 U/ml for 
serodiagnosis of pertussis appeared valid in all age groups. A decline of IgG-PT to < 10 U/ml 
was associated with increased risk of re-infection with B.pertussis.
Introduction
Neither vaccination against pertussis nor natural infection with Bordetella pertussis affords 
lifelong immunity (1-12). However, the rate of waning of immunity and possible differences 
after both vaccination and natural infection are difficult to establish, because no method exists 
to unequivocally measure (non)-susceptibility for pertussis for each individual. A simple single 
correlate of protection has not been found; both humoral and cellular immunity play a role 
(13,14). However, a relationship between protection and levels of IgG antibodies against the 
virulence factors pertussis toxin, pertactin and fimbriae has been demonstrated (2,13,15-17). 
In accordance with the concept of waning immunity, it has been observed that elevated levels 
of these IgG antibodies, whether induced by vaccination or natural infection, quite rapidly 
decrease again (9,13,18,19). However, the rate of decline and its possible age dependency have 
not been established. Also the question of whether or not after infection IgG-antibodies to PT 
(IgG-PT) eventually persist at some level or completely disappear, remains unanswered. 
Of the mentioned virulence factors, pertussis toxin is of special interest: when used as a 
single component in an acellular vaccine, it induces considerable protection and is the only 
virulence factor which is present in each of the newly developed acellular pertussis vaccines 
(20). Furthermore, IgG-PT is  an important parameter for serodiagnosis of pertussis, because 
cross-reactivity of pertussis toxin with antibodies induced by heterologous proteins has never 
been established and most individuals produce high levels of IgG-PT in response to infection 
with B.pertussis (19,21,22). 
In our first study of the longitudinal course of IgG-PT after typical symptomatic infection 
with B.pertussis, practically all 57 participating pertussis patients were young children and 
an established model for assessing the rate of decline of IgG-PT antibodies was lacking (19). 
For assessment of the possible age dependence of the rate of IgG-PT decline after natural 
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infection, we extended our studies to a larger group of pertussis patients of various ages for 
whom follow-up sera were available and to a group of elderly adult patients with pertussis for 
whom a follow-up serum sample had been drawn 1 year after infection with B.pertussis (23). 
For analysis we applied an adapted version of a recently described dynamic model for the 
inactivation of Bordetella pertussis by the immune system (24). 
 
Materials and Methods
Patients and sera
The first group of pertussis patients studied (A) consisted of 87 subjects (80 children and 
adolescents between 0 and 18 years and seven adults between 30 and 42 years), who suffered 
from clinically typical whooping cough (paroxysmal coughing for ≥ 2 weeks) between 1989 
and 1999, confirmed by positive IgG-PT serology (for criteria see below). These patients were 
from the paediatric practice of one of the authors (F.G.A.V.) in Gouda, The Netherlands. 
After the pertussis episode (diagnosed by F.G.A.V.), they remained as a patient in that 
practice, often because of asthma or other respiratory problems. At the time of the pertussis 
episode, these patients or their parents gave informed consent to use future sera, which 
might be obtained for various reasons at irregular control visits or at consultations with new 
complaints, for measurement of IgG antibodies to pertussis toxin. The adults in this group 
were parents of participating children who had pertussis at the same time as their child and 
who had volunteered to participate in this study. Only the patients for whom at least one 
follow-up serum, obtained > 6 months after onset of disease, was available, were included in 
this analysis. The Medical Ethical committee of the Groene Hart Hospital approved the study.
The second group (B) of pertussis patients studied consisted of 34 people from a convent in 
the southern part of The Netherlands, 33 nuns (age between 59 and 94 years) and 1 employee 
(aged 26 years). All of them had clinically typical pertussis during an outbreak of pertussis 
in this convent in 1992, which was confirmed by positive IgG-PT serology (for criteria see 
below) (for a detailed description of this outbreak see ref. 23). Approximately 1 year after the 
outbreak one follow up serum sample had been obtained from all patients. All patients gave 
informed consent.
Laboratory Evaluation
In both patient groups the clinical diagnosis of pertussis had been confirmed by finding a 
significant (i.e. ≥ fourfold) increase of IgG-PT in paired sera to a level of at least 20 U/ml 
in sera obtained within 3 months after onset of disease, or by the finding of a high IgG-PT 
concentration in a single serum sample, i.e. above a defined diagnostic cut-off of 100 U/ml 
as measured in an in-house IgG-PT ELISA of the National Institute of Public Health and the 
Environment, Bilthoven, The Netherlands (19). Previously, it was shown that the sensitivity of 
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these criteria for diagnosis of actual or very recent infection with B.pertussis was 90% in paired 
sera of two groups of patients with culture- or PCR-confirmed pertussis, studied several years 
apart (respectively n=89 and n=56) (19,25). The specificity of these criteria in paired sera 
of control-patients with respiratory infection of other etiology (n = 58) was 96% (25). The 
specificity of the ≥ 100 U/ml criterion for single sera was 99% when assessed in population 
sera (n=7756) and was independent of age (19). This ELISA, in which purified pertussis 
toxin is coated after pre-coating with fetuine, was developed and described at the start of 
the 1980s (26) and has been in use since then for serodiagnosis of pertussis for the whole 
country. For long-term consistency of potency expression in U/ml a serially diluted nationally 
standardized reference serum is applied on each ELISA plate. Routinely, two dilutions (1:100 
and 1:400) of patient-sera are used and depending on the magnitude of optical densities (OD) 
of those dilutions, the OD of one of those is used to calculate the IgG-PT concentration of the 
patient-serum relative to the defined potency of the reference serum. Although the minimal 
quantitation in this assay is 1 U/ml, the coefficient of variation, being ~ 20% in the 5-500 
U/ml range, is >30% in sera with values < 5 U/ml (27). Therefore, the detection-level of the 
assay is considered to be 5 U/ml. Due to the limited number of dilutions of patient sera used 
in the assay there is an upper limit of quantitative differentiation of 500 U/ml. However, the 
sera of patients from group B with IgG-PT ≥ 500 U/ml were subsequently retested in higher 
dilutions (1:800, 1:1600 and 1:3200) to obtain an exact value. 
Recently, the IgG-PT ELISA used here (19,26) has been compared to an internationally 
standardized IgG-PT ELISA which was recommended by the United States Food and Drug 
Administration (FDA) for use in clinical trials of pertussis vaccines and in which the “lot 3 
pertussis serum” of the FDA, with predefined content of IgG-PT in IU/ml, is used as reference 
serum (27-29). It was shown by Giammanco et al that there was a good correlation between 
both assays and that the relation between IU/ml in the internationally standardized ELISA and 
U/ml in our ELISA as calculated through linear regression of log-transformed concentrations 
is as follows: 5 IU/ml (detection level) = 6.5 U/ml and 125 IU/ml = 100 U/ml (diagnostic 
cut-off) (29). 
Data analysis
IgG-PT responses show considerable variation among individual patients, as is clear in Figure 
1. Therefore we analyse these responses with a hierarchical model allowing for variations 
between individual patients. For any individual patient the amount of information is 
limited: only a few measurements at best. For that reason we have described longitudinal 
responses with a model of the interaction between bacteria and the immune system. The 
model assumes that during infection bacteria are growing exponentially in the host. At the 
same time, bacteria are inactivated (killed) by antibodies (or by some action associated with 
the antibody response) according to a mass-action mechanism: inactivation depends on 
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the product of the concentrations of bacteria and antibodies (or antibody producing cells). 
Conversely, antibody production is controlled by the probability of antibodies (or antibody 
producing cells) encountering bacteria (or being presented with antigens derived from these 
pathogens). Antibody removal is considered an autonomous first order process. This is the 
simplest possible model for the interaction between host and pathogen and it is well known in 
population biology as a Lotka-Volterra model (30). The model can be formulated as a system 
of ordinary differential equations (see Appendix). 
This set of equations can be solved numerically and the solution is used for fitting to the 
patient data. Rather than fitting the model to data from any patient at any sampling time, 
individual records are fitted separately producing a set of parameters for each of the patients. 
We further use population distributions to describe the variation of these parameters among 
all the patients in an age group thereby generalizing the set of responses from individual 
patients to the age group level. Sampling from these population distributions then allows 
us to construct generalized immune responses typical for the whole age group instead of 
individual patients in that group. All our conclusions are based on these predicted responses. 
The model is fitted by means of a Markov Chain Monte Carlo (MCMC) algorithm (31) that 
allows efficient sampling of the parameter space for such complex multilevel problems. Some 
details are given in the appendix.
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Fig. 1. Measured IgG-PT levels against time from infection [log10 (IgG-PT) against log10 (time)]. Diﬀerent age groups are in
separate panels ; data from individual patients are connected.
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Results
Descriptive analysis 
The age distribution of the 87 patients of group A is given in Figure 2. Pertussis-vaccination 
in The Netherlands at the time of the study consisted of 4 immunisations in the first year of 
life, with a nationally produced whole cell pertussis vaccine. Fifteen of the 19 patients < 1 year 
were not vaccinated at onset of pertussis or were incompletely vaccinated (fewer than three 
immunizations). In only one of those 15 was it documented that the patient had received 
immunisations against B.pertussis after the pertussis episode (note: at the time of the study it 
was normal practice to abandon [further] vaccination against B.pertussis in infants who had 
pertussis). In the other 68 patients five were not vaccinated. For two subjects the vaccination 
status was unknown (aged 30.2 and 35.6 years).  
In three of the 87 patients in group A during serological follow-up after pertussis a second 
infection with B.pertussis was serologically documented, respectively 3.4, 5.8 and 6.6 years 
after the first (see below for details). In those three patients the follow-up of the first infection 
with B.pertussis was considered to have ended with the last serum obtained before onset 
of the second infection with B.pertussis. The serological follow-up of the second episode 
in two of these three patients was > 6 months and inclusion of the follow-up of these two 
second episodes therefore resulted in follow-up in group A of 89 episodes of infection with 
B.pertussis in 87 patients. From the 89 follow-up periods in group A, 403 sera were available. 
The distribution of those sera over time since onset of pertussis is shown in Table 1. The 
mean number of sera for each follow-up period was 4.5 (range of 2-12). As shown in Figure 
3 the time between onset of infection with B.pertussis and obtaining the last follow up serum 
sample ranged from 6 months to 10.7 years with a median of 3.1 years. 
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The age distribution of the 34 patients of group B is also given in Figure 2. Since the national 
vaccination program in The Netherlands against pertussis started in 1952, the 33 patients of 
group B who were born before 1952 (i.e. all the nuns) had not been vaccinated. 
The one patient born after 1952 (the employee) had been completely vaccinated. From the 34 
pertussis-episodes of the 34 patients of group B 99 sera were available, with 64 sera in the first 
6 months after onset, six sera from six patients in the second half year and 29 sera from 29 
patients in the second year (Table 1). The mean number of sera per patient/episode was 2.97 
(range of 2 to 3). The time between onset of pertussis and obtaining the last follow up serum 
sample ranged from a minimum of 11.1 months to a maximum 17.6 months with a median 
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Table 1. Percentages of pertussis episodes with indicated category of IgG-PT serum-concentration within the
indicated time category
Time after onset of disease
0–6 mo. >6–12 mo. >1–2 yr >2–4 yr >4–6 yr >6–11 yr
Group A
No. episodes (no. sera) … 89 (180) 39 (49) 32 (44) 48 (75) 30 (40) 8 (15)
IgG-PT concentration (U/ml)
>400 57 5 0 0 0 0
>100 tof400 43 18 19 0 0 0
>20 tof100 0 51 41 42 27 0
>5 tof20 0 26 28 48 46 38
f5 0 0 12 10 27 62
Group B
No. episodes (no. sera) … 34 (64) 6 (6) 29 (29)
IgG-PT concentration (U/ml)
>400 74 0 7
>100 tof400 21 17 14
>20 tof100 5 83 48
>5 tof20 0 0 24
f5 0 0 7
Separate data for group A (89 episodes in 87 patients) and group B (34 episodes in 34 patients). Times in months (mo.) or
years (yr). In case of availability of multiple sera from one episode within one time category, the serum with the highest value
has been used. Apart from the numbers of episodes with at least one serum available in the indicated time category (no.
episodes) also the total numbers of sera available from those episodes in that time category (no. sera) is indicated.
Fig. 3.Number of times patients of group A have been in the
study; numbers of patients as a function of the time between
onset of disease and last serum sample. The arrows denote
time points of conﬁrmed re-infections (one at each time
point).
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of 12.6 months.
Categorization of IgG-PT values (< 5, 5-20, 20-100, 100-400 and > 400 U/ml) and of time 
elapsed since onset of pertussis (0-6 months, 6-12 months, 1-2 years, 2-4 yrs, 4-6 yrs, 6-11 yrs) 
yielded the results shown in Table 1. All 89 episodes followed in group A were associated with 
an IgG-PT of > 100 U/ml at some time-point in the first six months after pertussis, while in 
the second half year and in the second year after pertussis the IgG-PT in >70% of cases had 
fallen below the level of 100 U/ml and in some had already fallen below the detection-level 
of 5 U/ml. Six to 11 years after pertussis the IgG-PT had declined to < 5 U/ml in five out of 
eight cases (62%); in the other three IgG-PT had declined to a level between 5 and 20 U/ml 
(Table 1).
Of the patients of group B 95% had an IgG-PT value of > 100 U/ml at some point in the first 
6 months after pertussis (Table 1). In the two patients with IgG-PT < 100 U/ml in the first six 
months, a more than fourfold increase of IgG-PT in paired sera to a value between 50 and 100 
U/ml had been found during the pertussis episode. In the second half year and in the second 
year after onset of pertussis > 70% of the patients of whom sera of that period were available 
had an IgG-PT < 100 U/ml and in one patient a value < 5 U/ml was found in the second year 
after infection. 
The distribution of IgG-PT categories in groups A and B in the first 6 months after infection 
(for each individual the highest value in that period is taken) and in the second year after 
infection (also highest value) are remarkably similar suggesting that the rate of decline over 
time in both groups was similar (Table 1).
Re-infections
In the three patients in group A with re-infection after 3.4, 5.8 and 6.6 years, the maximum 
IgG-PT titre in the first months after the first typically symptomatic infection was >500, >500 
and 248 U/ml respectively, the high titres had declined in sera obtained after 2.8, 2.9 and 3.1 
years respectively (i.e. the last serum before onset of the second episode of infection), to 10, 8 
and 6 U/ml respectively. The maximum IgG-PT titre reached in the first months after onset of 
the second episode was 492, 156 and 270 U/ml respectively. The patient with re-infection after 
3.4 years (first infection at age 4.2 years) had had a very mild cough, lasting 1 week, 4 weeks 
before sampling of the serum in which a high IgG-PT, diagnostic of very recent infection, 
was found. At the same time a sibling had serological confirmed pertussis. The patient with 
re-infection after 5.8 years (first infection at age 0.4 years) was discovered when blood was 
sampled at that time for other reasons of; the parents recalled no recent coughing illness. The 
patient with re-infection after 6.6 years (first infection at age 2.7 years) suffered from mild 
coughing during 3 weeks; besides the finding of a high IgG-PT concentration diagnostic for 
very recent infection, this patient was also pertussis-PCR positive.
In Figure 3 the times (after first infection) of occurrence of the three re-infections have been 
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indicated. It can be seen that the one re-infection after 3.4 years was among 40 patients with a 
follow up of 3.4 years or more (2.5%), the one re-infection after 5.8 years was among 9 patients 
with a follow up of 5.8 years or more (11%) and the one re-infection after 6.6 years was among 
4 patients with a follow up of 6.6 years or more (25%).
Analysis in dynamic model
For analysis in the dynamic model, the patients of group A and B were taken together and 
divided into seven age groups: (a)<1 year (n=19), (b)1–4 years (n=19), (c)4-7 years (n=21), 
(d)7-18 years (n=23), (e)18-65 years (n=14, seven from group A, seven from group B), (f)65-
80 years (n=11) and (g) > 80 years (n=16).
Figure 1 shows the individual responses of IgG-PT to infection with B. pertussis in these 
different age groups. In groups (a)-(d) and part of group (e) (i.e. the patients in this age group 
derived from group A) the IgG-PT concentrations are censored at an upper level of 500 U/ml 
(see Laboratory evaluation section above). In part of group (e) (those derived from group 
B) and in groups (f)-(g) the IgG-PT concentrations are given. The regression model allows 
for censoring of IgG-PT data from group A (as reported previously (24)), making groups A 
and B comparable. Note that in Figure 1 both IgG-PT concentrations and time elapsed since 
onset of pertussis are log-transformed, which is common for antibody concentrations but is 
unusual for time. However, in this manner both the rapidly increasing as well as the slowly 
decreasing phase of the immunoresponse can be shown in a single graph. 
In Figure 4 the estimated variation in individual IgG-PT responses in the different age groups 
as calculated in the dynamic model is shown as the median (50th percentile) and the 5th and 
95th percentiles of simulated responses for each age group. In all groups there is considerable 
variation. The older groups (e)-(g) tend to have a higher median peak response, also with 
a wide range. The time to reach peak levels seems inversely correlated with age (Table 2). 
Group (b) (1-4 years) seems to have the lowest predicted peak level (Table 3) and the longest 
time to reach peak levels (Table 2). However, the response range in the 1-4 year age group was 
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Table 2. Predicted times (in months post onset of symptoms), to reach peak levels of the IgG-PT response,
and (during the declining phase of the IgG-PT response) to reach 100 U/ml and times to reach 5 U/ml:
Q0.05–0.50–0.95=5th, 50th (median) and 95th percentiles
Age (years)
Time to peak Time to 100 U/ml Time to 5 U/ml
Q0.05 Q0.50 Q0.95 Q0.05 Q0.50 Q0.95 Q0.05 Q0.50 Q0.95
0–1 0.55 1.18 2.94 1.34 8.28 38.90 15.11 36.48 104.36
1–4 0.47 1.45 2.72 1.48 5.30 97.83 4.63 26.27 257.39
4–7 0.41 0.96 1.86 1.80 14.06 34.40 21.74 62.06 159.55
7–18 0.38 0.77 1.63 3.12 12.25 29.09 20.11 47.93 113.90
18–65 0.09 0.31 1.34 2.29 8.73 25.23 4.56 23.16 100.32
65–80 0.14 0.45 1.20 2.73 10.63 24.61 8.63 25.48 75.67
o80 0.15 0.40 1.52 2.08 6.61 19.44 3.75 17.13 68.55

wide and overlapped the corresponding ranges in the other age groups. The median time-
periods in the different age groups for IgG-PT to reach the peak level and to decline to levels 
of respectively < 100 U/ml (the diagnostic cut-off) and < 5 U/ml (detection level) are given 
in Table 2. These data also indicate that there might be an age dependent tendency for older 
people to have a faster decline. Eventually, the median time for IgG-PT to decrease below 
the detection-level of 5 U/ml varied per age group from 1.4 to 5.2 years, with wide inter-
individual variations (Table 2).
The estimated variation in the older groups (e)-(g) is higher than in groups (a)-(d). While it 
cannot be excluded that this is also -in part- caused by the influence of censoring, it should 
also be noted that the records of older patients (of group B) consist of fewer measurements 
(two or three) than those of the juvenile patients (of group A). We checked the influence 
of censoring by recalculation after artificially censoring the data from group B, and found 
similar results, confirming that correction for censoring of the data from group A in the 
dynamic model was appropriate (data not shown).
In Figure 5 the predicted age profile of IgG-PT responses at different time-points after onset 
of pertussis is given (10, 20, 50, 100, 200, 365 and 730 days). At 10 and 20 days there is large 
variation in response in all age groups, possibly partly due to large variations in the rapidity of
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Fig. 4. Predicted IgG-PT antibody responses to infection in each of the age groups, on a log10 (IgG-PT)xlog10 (time) scale
to show both initial rise and ﬁnal decline of the responses. Intervals show (95%) range of variation in response among
individual patients. Circles indicate observed IgG-PT titres. Also indicated are 3 weeks and 1 year past onset of symptoms
(vertical lines), and IgG levels (horizontal lines) of 5 U/ml (detection level), and 100 U/ml (diagnostic cut-oﬀ).
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the increasing phase of the IgG-PT response to infection and possibly partly due to inaccurate 
reports of the first day of the disease. 
However, at both time-points the IgG-PT concentrations in the three adult subgroups tended 
to be higher, suggesting that the IgG-PT response to infection in adults may be somewhat 
more rapid. At 50 days and at 100 days all predicted median IgG-PT levels are > 100 U/ml 
and the variation of responses is small, without substantial differences among age groups, 
although peak responses in the oldest two subgroups appeared to be somewhat higher. At 200 
days antibody decay has started in all age groups. In the older patients (65 to <80 and >80 
years) there seemed to be a tendency towards a more rapid decline of IgG-PT after 365 and 
730 days than in younger patients.
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Fig. 5. Age proﬁles of (log10) IgG-PT responses : predicted antibody levels against age (category) at various times from
infection. As in Figure 4 the intervals show (95%) range of variation in response among individual patients.
Table 3. Predicted peak levels (U/ml) of the IgG-PT
response: Q0.05–0.50–0.95=5th, 50th (median) and 95th
percentiles
Age
(years)
Peak titre (U/ml)
Q0.05 Q0.50 Q0.95
0–1 85.9 244.3 624.7
1–4 46.2 136.2 575.1
4–7 100.3 213.0 621.6
7–18 124.3 303.0 653.7
18–65 138.7 695.2 2631.6
65–80 188.2 792.6 2384.2
>80 162.1 720.5 2503.3

The second youngest age group (1-4 years) appears to show a response which is slightly 
different from the other age groups (slower increase, lower magnitude). As already stated, 
data in this group show markedly high dispersion, as may also be appreciated by comparing 
error bars (illustrating variation) in Figure 5 (see also Fig.4 and Tables 2 and 3). 
Discussion
This study in 121 pertussis patients aged 0-94 years shows that elevated levels of IgG-PT 
induced by infection with B.pertussis consistently decline again to below detection levels 
within several years, unless this course is interrupted by re-infection with B.pertussis, which 
was observed in three cases. In each of the different age groups there was wide variation in 
rapidity, intensity and rate of decay of IgG-PT and between groups there was a wide overlap 
of the ranges of these variables. Although the pattern of IgG-PT response is not significant 
age dependant, there was a tendency for the IgG-PT response after infection to be faster and 
stronger and the decay to be more rapid with increasing age. The pattern in the 1-4 y age 
group was different from all other age groups in that the IgG-PT response tended to be slower 
mounting and smaller in amplitude and in most cases decayed rapidly. 
Our study is unique with respect to the high number of participating patients, the wide age 
range of the patients, the long follow up times in part of the patients and also the method of 
analysis using a hierarchical model for induction and decay of antibodies after infection. The 
few studies of the course of IgG-PT after infection with B.pertussis that have been published all 
show decline over time but assessment of possible differences in children and adults is lacking 
and follow up times are relatively short. In the studies of Hodder et al (9) and Heininger et 
al (32) the course of IgG-PT over a period of 20 months after pertussis in 48 adults aged >65 
years (9) and over a period of 28 months in 11 adults (32) was remarkably similar to the 
pattern over the same time span in adults in our study. In those studies the internationally 
standardized IgG-PT ELISA, recommended by FDA, was used of which the relationship with 
our ELISA is known (see Materials and Methods section; (29)). For instance, the geometric 
mean IgG-PT titre of 11 adult pertussis patients was 242 IU/ml at 2 months after onset of 
infection and 45 IU/ml at 28 months after onset (32). However, in none of those patients IgG-
PT had declined below detection levels, which may be related to the limited follow up time. 
Two other studies, one comprising both adults and children (2) and one comprising young 
children (33), also showed a significant decline of geometric mean IgG-PT titre 1 year after 
pertussis. The study with the longest follow up time was from Tomoda et al. who measured 
IgG-PT during an outbreak of pertussis in a semi-closed adult community and again 5 years 
later (34). He showed that in the large majority of the 21 pertussis-patients of that outbreak 
(37.5 + 12.1 years) IgG-PT was > 50 U/ml several weeks after onset of pertussis; 5 years later 
the IgG-PT in all patients had declined to < 10 U/ml and in most to undetectable levels. 
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These findings support our conclusion that in the majority of cases or perhaps in all cases 
of pertussis, the subsequent decay of infection-induced IgG-PT does not level off well above 
detection thresholds but progresses to undetectability.    
The relatively short persistence, in all age categories, of infection-induced peak levels of 
IgG-PT supports our previous finding that a diagnostic cut-off of 100 U/ml (equivalent to 
125 IU/ml) for serodiagnosis of actual or very recent infection with B.pertussis is valid for 
all ages (19). Although vaccination can induce IgG-PT levels > 100 U/ml, interference with 
serodiagnosis of pertussis is minimal because IgG-PT induced by vaccination with whole cell 
pertussis vaccines or acellular pertussis vaccines also declines quite rapidly. Multiple studies 
show a decrease after primary and booster vaccination to very low or undetectable levels 
within 1 to 8 years (13, 35-38). For instance, Taranger et al (39) followed 813 children after 
pertussis vaccination with a monovalent pertussis toxoid vaccine. There was a strong IgG-
PT response to a geometric mean of 143 IU/ml at 1-2 months after vaccination and a rapid 
decrease to a geometric mean of 8 IU/ml at 21-32 months after vaccination. 
One explanation for our finding of a relatively slow and low IgG-PT response in the 1-4 years 
age group, the large majority of whom had been (recently) vaccinated, might be that children 
who suffer from B.pertussis infection shortly after vaccination are a separate category, i.e. are 
children with a relatively poor immunoresponse to pertussis antigens. Indeed, Taranger et 
al (39) showed that previously vaccinated children who within 33 months after completing 
vaccination developed pertussis upon exposure in their household had had a significantly 
lower IgG-PT response 1-2 months after the third vaccination with a monocomponent (PT) 
acellular vaccine (mean peak-response 79 U/ml) than children who did not develop pertussis 
upon household exposure within that time-frame (mean peak response after vaccination 212 
U/ml).  
The tendency of the IgG-PT response to be more rapid and strong with increasing age may 
indicate the involvement of specific memory immunity through encounters with B.pertussis 
antigens earlier in life. Also Granström et al (40) have shown that adults have a faster peak 
response than children after a natural infection. The intuition that such rapid and strong 
responses would persist longer evidently is not true. Perhaps the rapid decay of IgG-PT 
after a rapid and strong response may be explained by a faster eradication of the pathogen 
and shorter duration of antigenic stimulation of the immune system. The phenomenon as 
such has been noted before: Blennow & Granström (41) showed that children receiving a 
booster vaccination with an acellular vaccine containing pertussis toxin and filamentous 
haemagglutinin showed a more rapid decay of neutralizing antibodies to pertussis toxin in 
the Chinese hamster ovary cells assay than after the primary vaccination. This despite the fact 
that after the booster vaccination the median of the neutralizing antibodies titres was higher 
than after the primary vaccination. 
The three re-infections documented in this study were in children whose IgG-PT at the time 
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of the second infection had declined to <10 U/ml. Although the number of re-infections was 
small, their timing and incidence was compatible with the statement that natural infection 
initially induces protection against re-infection but that susceptibility to (re-)infection re-
emerges when IgG-PT concentrations have fallen to < 10 U/ml and that subsequently 
susceptibility for disease in association with infection increases over time. In a previous paper, 
we have described two other patients who had infection with B.pertussis 12 years after the 
first episode. In contrast to the three re-infections 3.4, 5.8 and 6.6 years after the first in this 
study, the re-infections after 12 years were associated with typical symptoms i.e. long-lasting 
paroxysmal cough (12). 
In conclusion this study shows that the high IgG-PT concentrations induced by infection with 
B.pertussis consistently decline to low or undetectable levels within 5-6 years, this decline is 
associated with emergence of susceptibility for re-infection and disease. Although the pattern 
of decline is largely independent of age, there is a tendency for older people to have a more 
rapid increase, higher peak and faster decline. This study also shows that a diagnostic cut-off 
of 100 U/ml is not only valid in children (19) but is true for all ages.
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Appendix
The predator-prey model of the interaction between the immune system and invading bacteria 
can be formulated as:
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(pathogen concentration )(tx ; antibodies )(ty ; pathogen growth rate a; antibody dependent 
pathogen inactivation b; antibody decay rate c; pathogen dependent antibody production rate 
d).
Numerical solutions to these equations (a simple analytical solution does not exist) can be 
fitted to the longitudinal antibody data, treating the unknown pathogen concentration as a 
nuisance variable. 
Measurement errors were assumed lognormal: both data and model function were log-
transformed (TBS: Transform Both Sides) so that we could use a normal likelihood function. 
This also allows treatment of censoring as previously reported (24)). Variation between 
individual patients is considerable, we therefore used a hierarchical Bayesian model. For 
statistical analysis, parameters were transformed:
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and these new parameters were log transformed to restrict them to positive values. Parameters 
u and v were assumed equal in all patients, w and z vary among individuals. Parameter 
estimation for the hierarchical model was performed using a MCMC method, employing the 
Metropolis-Hastings algorithm (31).
Posterior predictive intervals for the longitudinal response to pertussis were constructed by 
applying the longitudinal model to a parameter sample from the MCMC output (by addition 
of a subject with missing data only, for conveniently sampling from the population parameter 
distributions).
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Abstract 
Objectives: Bordetella pertussis circulates even in highly vaccinated populations and there 
is a considerable amount of asymptomatic infection in adults. For designing more effective 
vaccination schedules it is important to quantify the age-dependent relation between the 
number of notified cases and the number of infections. 
Methods: We used a statistical relationship between the time-since-infection and the IgG 
pertussis titers, derived from a longitudinal data set, to estimate time since infection for all 
individuals in a cross sectional population-based study (1995-1996) based on their titers. 
Age-specific incidence of infection with B. pertussis was calculated and compared with the 
age distribution of notified cases of pertussis in 1994-1996. 
Results: Estimated incidence of infection was 6.6% per year for 3 to 79-years olds, annual 
incidence of notified cases 0.01%. Estimated age-specific incidence of infection was lowest 
for 3-4 year-olds and increased up to the age of 20-24 years. The number of notified cases was 
highest for 3 to 9 year olds. 
Conclusions: B. pertussis infections occur frequently in the Dutch population, particularly 
in adults whose reported incidence is low. The age-distribution of infections differs notably 
from those of notified cases. Vaccination strategies should take into account age-specific 
circulation and contact patterns between age groups. 
Introduction 
Despite widespread vaccination, infection with Bordetella (B.) pertussis remains a cause of 
considerable morbidity even in countries with high vaccination coverage [1-5]. The continuing 
circulation of the pathogen is attributed to waning of vaccine-induced immunity, which leads 
to the occurrence of pertussis infection among previously vaccinated children, adolescents 
and adults [6-9]. In those groups, an infection with B. pertussis often goes undiagnosed, since 
the disease in many cases is atypical and mild and laboratory diagnosis is very insensitive, if 
only culture and/or PCR is available [8,10-13]. Like others, we have shown that availability of 
pertussis serology and particularly the definition of reliable criteria for positivity associated 
with high levels of IgG to pertussis toxin (IgG-PT) in a single serum sample (one-point 
serology) can greatly enhance the detection of pertussis infections [4,7,10]. 
Inclusion of positive one-point serology as laboratory confirmation for notification in the 
Netherlands has increased the notification rate considerably, especially among older children 
and adults [1]. However, the use of surveillance data of notified infections for understanding 
the epidemiology of pertussis remains limited by the lack of registration- or notification 
discipline. Furthermore, the fraction of infections diagnosed or reported is age-dependent 
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because the severity of the disease as well as the sensitivity of diagnostic methods is age- 
dependent [1]. Circulation of B. pertussis in vaccinated children, adolescents and adults plays 
an important role in the continuing transmission of the pathogen to infants too young to be 
vaccinated, in whom disease is most severe and possibly fatal [8,11-20]. 
To design better preventive measures, for example by determining the optimal ages for booster 
vaccinations, insight is needed into the age-specific incidence of all infections with B. pertussis 
as opposed to only those symptomatic infections that are diagnosed and reported. Information 
about the seroprevalence of IgG-PT antibodies in the general population in combination with 
knowledge about the rate of decline of IgG-PT antibody levels after infection with B. pertussis 
offers the opportunity to study the incidence of infection in various age-groups irrespective 
of clinical course, diagnosis and reporting frequency. Pertussis toxin is expressed only by B. 
pertussis and cross-reacting antigens have not been described [21,22]. 
Furthermore IgG-PT responses occur in most patients with B. pertussis infection and high 
levels persist only temporarily [10]. We estimated the incidence of B. pertussis infections 
in the population using a novel two-stage approach. A statistical description of the decline 
in antibody levels after infection as derived from a small scale longitudinal study [23] was 
combined with data about the age-specific distribution of IgG antibodies against pertussis 
toxin (IgG-PT) in sera derived from a large scale cross sectional study of the general population 
[10] to estimate the age-specific incidences of infection for the age range 3-79 years. These 
were compared to notification data of reported clinical cases of pertussis. Implications for 
vaccination-strategy are discussed. 
Material and Methods 
Collection of sera from population and patients 
Detailed descriptions of the collection of sera from the general population in the Netherlands 
(n=7756) and of follow-up sera from patients with diagnosed clinical pertussis (n=85) have 
been published elsewhere [10, 23, 24]. In short, for the cross sectional study in the general 
population, eight municipalities were sampled with probabilities proportional to their 
population size within each of five geographical Dutch regions with similar population sizes. 
An age-stratified sample (classes 0, 1-4, 5-9, … 75-79 years] of 380 individuals was randomly 
selected from each municipality. Subjects were asked to give a blood sample. Samples were 
collected in the period from October 1995 to December 1996 and stored at –70 °C until use. 
The participation rate was 55 percent. Sufficient serum for pertussis serology was available 
for 7756 of 8359 participants. 
In a longitudinal study [23], follow-up samples from 85 patients clinically diagnosed with 
pertussis (paroxysmal cough lasting more than two weeks) were obtained from one pediatric 
practice in the period 1989-2000. The follow-up period ranged from 6 months to 11 years 
Chapter 6

and the number of serial sera per patient ranged from 2 to 11. Eleven patients were less than 
6 months of age at the time they contracted pertussis, 69 patients were between 6 months and 
17 years of age and six patients were between 30 and 41 years old. 
Notification data 
Pertussis notification data for the period 1994 to 1996 were obtained from the Dutch 
Inspectorate of Health. The case definition included clinical symptoms and laboratory 
confirmation (or close contact with a person with laboratory-confirmed pertussis). The clinical 
symptoms in the case definition are a serious cough, lasting more than two weeks, coughing 
attacks, or coughing followed by vomiting in combination with at least one of the following 
symptoms/findings: apnea, cyanosis, characteristic cough with whooping, subconjunctival 
bleeding, or leucocytosis. 
Laboratory confirmation was defined as either a positive culture of B. pertussis or B. parapertussis, 
or positive two-point serology. Two-point serology was considered positive if a 4-fold rise of 
IgG antibodies against pertussis toxin in paired sera was found. Only since April 1997, positivity 
of one point serology has been formally included in the case definition as being acceptable as 
laboratory confirmation of pertussis for notification. However, already in the years before 1997, 
a small fraction of the patients with positive one-point serology was reported [1]. 
Antibody assay 
In the longitudinal study, patient sera had been submitted immediately after sampling and 
were assayed in the routine setting of the serology laboratory of our institute within 4 days 
after receipt. In the cross-sectional study, sera that had been collected in 1995/1996, were 
assayed in 1997/1998 in the same routine setting at a rate of approximately 200 sera per week. 
The IgG-PT was measured by ELISA as previously described [25]. In short, the procedure 
was as follows: purified PT (source: National Institute of Public Health and the Environment) 
was coated to 96-well ELISA plates after precoating with fetuin (50 mg/l in phosphate-
buffered saline). Peroxidase labeled rabbit antihuman IgG was used as a conjugate and 3,3’,5,5’ 
tetramethylbenzidine (TMB) was used as the substrate. Negative, low-positive and medium-
positive control serum with defined IgG-PT content was run on each plate. The sera were 
tested in duplicate in a 1:100 and 1:400 dilution against serial dilutions of a positive reference 
serum with a range of 1.6-100 “local” U/ml. The optical density (OD) of the 1:100 dilution 
was used for calculation of the IgG-PT concentration. When the OD of the 1:100 dilution of 
a serum was above the range that constituted the steep part of the dose response curve of the 
reference-serum, the OD of the 1:400 dilution was used. Due to the use of only two dilutions 
for the sera, the IgG-PT assay has an upper limit (500 U/ml) above which the values are not 
further differentiated. The lower detection limit of the assay is 5 U/ml. Results are expressed 
in “local U/ml”. 
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Analysis 
In Teunis et al [23], a skewed hyperbolic function was used to describe the relationship 
between the log time since infection and the log antibody titer. This four-parameter function 
was fitted to the data for each individual patient from the longitudinal study of diagnosed 
clinical pertussis patients yielding a set of response curves with variation among individuals 
(Figure 1). On a linear time scale, the antibody response rises very fast (within a few days) 
and then declines very slowly over a period of several years. Therefore, the rising part of the 
response curve may safely be neglected and an inverse function can be determined on the 
basis of the long monotone declining part of the response. The inverse can be determined 
for each individual response curve separately. For every value of the log titer an average time 
since infection can be calculated (Figure 1). 
We used those point-wise averages of the inverse response curves to estimate the times since 
last infection for the cross-sectional study population, assuming that the distribution of
responses in the longitudinal study population is the same as that of the cross-sectional study 
population. Figure 2 shows the IgG-PT antibody distribution in the participants from the 
cross sectional population based study (adapted from [10]). 
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Fig  1:  Measured IgG-PT concentration (titer) as a function of the time since last infection (for the study population in 
Teunis et al [23]). The black line shows the point wise average of individual estimates, the gray lines the point wise 
2.5%, 50% (median) and 95% percentiles illustrating the magnitude of individual variation in responses. The dots 
are individual results.
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Fig 2: The age-specific IgG antibody levels in the population-based cross-sectional study in the Netherlands. Note 
that the categories are cumulative, i.e. individuals in the lower categories also belong to all higher categories. 
A series of cut-off values was chosen (10, 20, 30, 40, 50, 60, 80, 100 and 150 U/ml) for which 
we calculated the (age-specific) incidence of infection with B. pertussis in the population. The 
estimated numbers of infected individuals were corrected for the discrepancy between the 
age-distribution of the cross-sectional study population and the age-distribution of the Dutch 
population in 1996 by weighting each one-year age class with an appropriate correction factor. 
The estimates of incidence of infection were limited to 3 to 79 year-olds. We did not estimate 
the incidence of infection in younger age-classes because IgG-PT in infants can be maternally 
derived and can be induced by vaccination (at the time of the study given in the Netherlands 
at 3,4,5 and 11 months of age). Above 3 years of age those factors do not influence the IgG-
PT because maternally derived antibodies disappear within one year and IgG-PT induced by 
vaccination declines rapidly to very low or undetectable levels within one year after the last 
immunization [25, 26]. 
The average numbers of notified cases per 100,000 by age group in the period 1994 to 1996 
were calculated using the age distribution of the Dutch population in 1994 to 1996. The 
period of 1994 to 1996 was chosen for reasons of comparability with the period for which 
the number of infections was estimated. For each age-class, the case to-infection ratio could 
then be estimated by dividing the average numbers (per 100,000) of notified cases by the age-
specific estimates of incidence of infection. 
To assess the influence of individual variation in responses on the uncertainty of the incidence 
estimates we chose to compute a confidence interval for every cut-off value based on the 
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following assumptions: (a) the longitudinal study population and the cross-sectional study 
population are the same in their responses to pertussis infection; (b) the variability in times 
since infection for different cut-off values is the same for the longitudinal and the cross 
sectional study population; and (c) the log times since infection are normally distributed 
with mean and standard deviation calculated from the log times since infection from the 
longitudinal study. 
Results 
We describe the results for some of the cut-off values, namely the values 40, 50, 80 and 100 U/
ml, because those values are considered to be most conclusive for identifying recently infected 
individuals. After infection with B. pertussis the average time needed for the high IgG-PT 
level induced by infection to decline to 100 U/ml is 58.6 days (CI [54.2, 63.2]), to 80 U/ml it 
is 102.6 (CI [95.8, 109.8]) days, to 50 U/ml it is 208.9 (CI [195.4, 223.3]) days and to 40 U/ml 
it is 297.6 (CI [279.2, 317.2]) days (compare Figure 1). Using a cut-off level of 100 U/ml the 
estimated percentage of the population that has been infected in the past 58.6 days was 0.84% 
(i.e. 0.84% of the population sera contained IgG-PT of = 100 U/ml) resulting in an estimated 
incidence in the year before serum sampling of 5.2% (365.25 / 58.6 times 0.84%). A cut-off of 
80 U/ml yielded an estimated incidence of 6.6% (365.25 / 102.6 times 1.86%), a cutoff value of 
50 U/ml an estimated incidence of 6.6% and a cut-off value of 40 U/ml an estimated incidence 
of 7.2% in the year before serum sampling. 
In summary, after standardization of the estimated incidences for various cut-off values to 
the time period of one year, one obtains remarkably consistent incidence estimates for a wide 
range of cut-off values (Figure 3). 
The above results also hold for an age-stratified analysis, where the incidence of infection is 
estimated separately for each age category using the same range of cut-off levels of antibody 
titers. The consistency of the estimates for the yearly incidence of infection across different 
cut-off values indicates that the functional relationship between time since last infection and 
antibody titer as inferred from the longitudinal study in [23] is a useful description of the 
immune response to IgG-PT. In Figure 4 the estimated age-specific incidence of infection 
with B. pertussis in the population is shown as calculated for the cut-off of 50 U/ml. The 
estimated incidence of infection the year before blood sampling (1995-1996) amounted to 
6571 per 100,000 (6.6%) on average for 3 to 79-years olds. This was 685 times higher than 
the incidence of notified cases in the period 1994 to 1996 of 9.6 per 100.000 (0.01%) for 3-79 
year-olds (10.9 per 100.000 for all age groups), meaning that only 1 of 685 cases of infection 
is reported. 
As shown in Figure 4, the estimated incidence of infection is considerably higher for all 
age groups in comparison to the incidence of notified cases (note the different scales).
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Fig 3: The estimated yearly incidence (as a fraction of the population) for different cut-off values and confidence 
intervals. 
      
Fig 4: Estimated incidence of infection with B. pertussis per age group per 100.000 per year (open circles, right 
scale) and the annual incidence of notified cases of pertussis per age group per 100.000 averaged over the period 
1994 to 1996 (filled circles, left scale). 
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The incidence of notified cases is high among 0-year-olds (77.2 per 100.000), 3-4 (87.4 per 
100.000) and 5-9 year-olds (63.1 per 100.000) and decreases sharply till 20-24-years (1.2 per 
100.000). For 30-44 year olds a somewhat higher reported incidence is observed (2.6-2.8 per 
100.000). For those aged between 45 and 69 years the incidences fluctuate between 1.2 and 1.6 
per 100.000, while the incidence is lowest for the oldest age groups (=70 years). In contrast, 
the estimated incidence of infection is lowest for 3-4-year olds (3299 per 100.000). It increases 
sharply up to the age of 20-24 years (10831 per 100.000) and decreases again afterwards to a 
level of around 6500 per 100000 in the age groups 25-59 years. In the oldest age groups (60 
– 79 years) a further decrease to around 3500 per 100000 can be seen. 
In Figure 5 the case-to-infection ratio by age group is shown. The ratio is highest for the 
youngest age-group - 1 out 38 infected children aged 3 to 4 is reported, - while it decreases 
afterwards. For 20 to 24-year olds the ratio is lowest, showing that only 1 out of 8966 infected 
cases are reported. For the remaining age groups it fluctuates between about 1 to 1500 and 1 to 
6000. As the notification numbers for those age groups are small, there is a large uncertainty 
connected to those estimates. 
           
Fig 5: Ratio of incidence of notified cases to estimated infection incidence per age group.
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Discussion 
Incidence and age profile of infections 
There has been a long-standing discussion in the literature, whether vaccination against 
infection with B. pertussis reduces transmission of infection as opposed to only reducing 
the incidence of clinical infections [27-29]. While there is agreement about the fact that 
vaccination does indeed reduce transmission, to estimate the amount of that reduction requires 
knowledge about the fraction by age of clinical cases among all infections. This fraction is 
determined by a complex interplay of the age-dependent force of infection, immunity and 
reporting behavior. Techniques of the analysis of serologic data have made it possible to 
identify individuals with recent B. pertussis infections and compare seroprevalence data with 
notifications of symptomatic disease [30-32]
IgG-PT levels in the Netherlands can be interpreted as markers of recent infection, because 
firstly the amount of pertussis toxin in the Dutch whole cell vaccine is very low and second, 
because vaccine-induced IgG-PT levels are minimal and short-lived [10]. However, also in 
populations in which pertussis vaccines are used that contain moderate to high amounts of 
pertussis toxin, vaccine induced IgG-PT declines to barely detectable levels within 2 to 4 years 
[33-36]. 
Two major issues clearly emerge from our analysis. Firstly, the estimated incidence of 
infections with B. pertussis is considerable in all age groups and much higher than the reported 
incidence [1]. We estimated that around 6.6% of the Dutch population had experienced 
infection with B. pertussis in the year before serum sampling, while, in contrast, the incidence 
of notifications in 1994 to 1996 amounted to 0.01% per year [1]. Secondly, the age-specific 
profile of the reported cases diverges remarkably from the estimated age-specific profile of 
incidence of infection with B. pertussis. While the highest incidence of reported symptomatic 
cases is observed among children aged 3 to 9 years, the incidence of infection is lowest among 
3-4-year-olds, increases with age and peaks for 20 to 24-year-olds. Therefore, most cases are 
notified in those age-categories with the lowest incidence of infection. 
Our cross-sectional study was performed in a limited time period (1995-1996). Therefore, 
the estimated incidence of infection and its age-distribution are a snapshot in time and it is 
not clear whether those estimates apply to other time periods. We believe that the age-specific 
profile of incidence of infection with B. pertussis is rather stable over time. Repeating the 
cross-sectional study can only assess whether or not this is correct. However, some support for 
our hypothesis is found in the similarity of the sero-profile of IgG-antibodies against pertussis 
toxin in 548 vaccinated children of 1-12 years in 1980, the sero-profile of about 800 individuals 
of all ages in 1992-1993 (pilot study for the large cross-sectional study) and the sero-profile in 
the present study in 1995-1996 [37]. Also, the fact that our findings in adolescents and adults 
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are in agreement with the high incidences found in prospectively followed cohorts of small 
numbers of adolescents and adults in the USA in other time period may be seen as supporting 
our hypothesis [6, 38, 39]. In those studies significant increases in sequential sera of IgA/IgG 
antibodies against pertussis toxin were taken to indicate infection with B. pertussis. In the 
studied cohorts incidences of 3.3% to 8% per year were estimated. As discussed by Teunis et 
al. [23], the immune response of IgG-antibodies against pertussis toxin after infection with 
B. pertussis shows large variation among individuals. Here, we worked with the point wise 
(for each titer value) averages of the individual response curves (Figure 1). This means that 
we neglected the dependence within individual responses but, as we applied this procedure 
to a large representative population sample, we assumed that variation on the individual level 
averages out on the population level. We assumed that the longitudinal study population and 
the cross-sectional study population are identical in their responses to pertussis infection. 
With the size of the longitudinal sample as it is available to us at present, we can only say that 
the responses in different patient categories did appear to be similar [23]. 
Several factors are responsible for the large discrepancies between reported pertussis cases 
and the estimated cases of infection in their incidences and age-profiles. The amount of 
underreporting varies by age, because severity of disease, medical care seeking and diagnostic 
power are varying with age. Indeed, a high rate of underreporting has been observed mainly 
in older children, adolescents and adults [7,9,12,13,40]. Recently, Strebel et al. performed 
active case finding among older children and adults (10-49 years) from a well-defined 
population, who consulted the physician with cough lasting at least 14 days [41]. An incidence 
of symptomatic infection with B. pertussis of 0.5% per year was found, which was about 100 
fold higher than the incidence of notified cases in that age-category. A similar high incidence 
of symptomatic infections with B. pertussis among adults was found in a highly vaccinated 
region of France [42]. 
Another set of factors that influence the age-specific incidence profile of pertussis infections 
is related to the dynamics of transmission and immunity. The transmission of air-borne 
infections is strongly determined by the age-dependent patterns of mixing in a population 
[43]. The contact rates between age groups, in conjunction with age-specific fractions of 
susceptible, infectious and immune individuals, channel the transmission of the infection 
through the population. The peaks observed in Figure 4 of age-specific incidence in the 
population might be related to high contact rates, the lower infection rate for those aged 60 
years and older to a lower contact rate in that age group. The gradual increase with age of 
the incidence of infection to a peak of 10.8% in 20-24 year-olds suggests that there is a high 
variability in the duration of vaccine-induced immunity, which in some may be less than 
2 years, in others more than 5 years. However, the incidence of notified cases of pertussis 
is highest among 3-9 year-olds, suggesting a strong reporting bias in that age category but 
also showing that susceptibility for symptomatic infection with B. pertussis may re-emerges 
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shortly after vaccination. In the USA, sero-prevalence data of IgG-PT in the population have 
been seen as an indication that immunity after vaccination with whole-cell vaccines wanes 
after about 10 years [44]. However, in that study the investigators did not take the decline of 
IgG-PT after infection into account. 
The mean incidence of 6.6%, if constant in time, indicates that on average, within a period of 
20 years the entire population experiences infection, i.e. that vaccination against pertussis will 
be followed on average by 3 episodes of natural infection during life. Indeed, there are strong 
indications that immunity wanes also after natural infection and that re-infection is possible. 
German investigators estimated the duration of the protective period following natural 
infection at 20 years [45]. Recently, we observed laboratory-confirmed mildly symptomatic 
infection with B. pertussis in 4 children 3,5-12 years after the first laboratory-confirmed 
clinically typical episode of pertussis [46]. 
Implications for vaccination 
In the Netherlands, the age-specific profile of notifications with the highest incidence in those 
aged 3 to 9 years led to the decision of the Dutch Health Council to introduce a booster 
vaccination with acellular pertussis vaccine at 4 years of age [47]. Since siblings play a role in 
transmission to vulnerable infants [14, 15], one expects the incidence of severe pertussis in 
infants to decline. However, on the basis of the incidence estimates presented here, we expect 
that the introduction of the booster vaccination at 4 years on the long run will lead to a shift 
of the peak of infections to older age groups. Those older age groups, being the peak child 
bearing ages, may have more contacts with vulnerable infants, implying that on the long run 
booster vaccination might lead to an increase of the incidence of severe pertussis in infants. 
This is consistent with the fact that in the USA, where a booster vaccination at preschool age 
has been included in the vaccination-scheme for several decades, the proportion of infants 
among the notifications of pertussis is relatively high [4]. 
Conclusion
More insight is needed into the role of adults as compared to siblings in the transmission 
of B. pertussis to young unvaccinated infants. The results of the present study support the 
findings of others in that adults are an important source of infection [8,12-14,16]. More 
effective than booster vaccinations for adults given in 10 yearly intervals might be a strategy 
that directly targets (future) parents and caregivers [11]. Mathematical modeling studies are 
needed for a precise quantitative analysis of the effects of different vaccination strategies on 
the age-specific incidence of (symptomatic and asymptomatic) pertussis infections. Previous 
modeling studies [48, 49] had to cope with the lack of data concerning the force of infection 
and the age dependent fractions of symptomatic and notified cases of infection. While we are 
still far from having a solid quantitative basis on which to build reliable mathematical models, 
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we think that our study investigated an essential link between the transmission dynamics 
as described by mathematical models and notification data of pertussis infections. To our 
knowledge, the methodology we used to estimate the frequency of infection with B. pertussis 
has not previously been described and can be used more generally to estimate infection 
frequency from sero-prevalence data. 
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Abstract
Whooping cough is a serious, contagious disease. With the recent increase in Bordetella 
pertussis infections in the vaccinated population the risk for perinatal whooping cough (in 
mother and child) has increased. The infants too young to be vaccinated are at greatest risk for 
severe complications and fatal outcome of pertussis. Because Bordetella pertussis infections in 
adults ànd in young infants may present as atypical disease the diagnosis may be missed in 
first instance. Symptoms, diagnosis, treatment and prophylaxis are discussed. The purpose of 
this paper is to improve knowledge about the risks and prevention of perinatal pertussis in 
mother and child.
Inleiding
Kinkhoest, een zeer besmettelijke luchtweginfectie met de obligaat humane bacterie Bordetella 
pertussis (Bp), is, ondanks vaccinatie, blijven voorkomen en de incidentie lijkt toe te nemen, 
vooral bij gevaccineerde kinderen en volwassenen. (1,2) Ook het aantal gevallen onder de leeftijd 
van 3 maanden neemt toe, met een mortaliteit van 1-2 %. (2,3) Kinkhoest bij pasgeborenen 
vindt bovendien vaker plaats dan wordt herkend (4). Het probleem van perinatale kinkhoest 
wordt onderschat, alhoewel er de laatste jaren toenemend aandacht voor is. (4-16) Tegen deze 
achtergrond is het voor de gynecoloog/obstetricus belangrijk om te beseffen dat zwangeren 
die kinkhoest in de laatste maanden van hun zwangerschap doormaken hun pasgeboren kind 
kunnen besmetten en dat bij een bewezen infectie behandeling van de zwangere en preventieve 
behandeling van de pasgeborene geïndiceerd is. Het doel van dit artikel is obstetrici en 
verloskundigen van een belangrijk en mogelijk toenemend probleem bewust te maken door 
op de grote risico’s van perinatale Bordetella pertussis infectie te wijzen en gegevens wat betreft 
symptomen, diagnose, behandeling en profylaxe op een rijtje te zetten. 
Etiologie, Vaccinatie, Incidentie:
Kinkhoest bij de mens wordt meestal veroorzaakt door Bp, soms door de Bordetella 
parapertussis. De bacterie hecht zich aan het trilhaarepitheel van de nasopharynx, waarna hij 
zich lokaal vermenigvuldigt en toxinen produceert die schade in de luchtwegen aanrichten 
waardoor de typische uitputtende, aanvalsgewijze hoest ontstaat. De bacterie zelf is niet 
invasief. Wel kunnen er systemische effecten van geabsorbeerde toxines optreden, zoals een 
sterke leucolymfocytose. 
Sinds 1954 worden in Nederland kinderen op de leeftijd van 3, 4, 5 en 11 maanden gevaccineerd 
tegen kinkhoest met een whole cell vaccin dat geproduceerd wordt door het RIVM. Sinds 
1999 zijn de eerste drie immunisaties vervroegd van 3, 4 en 5 naar 2, 3 en 4 maanden, om de 
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kwetsbaarheid van de jongste kinderen zo klein mogelijk te maken. Sinds 2000 is bovendien 
een boostervaccinatie met een acellulair vaccin op 4 jarige leeftijd ingevoerd, om de circulatie 
van Bp en ziektegevallenbij lagere schoolkinderen te verminderen. Wel heeft de Inspectie voor 
de Gezondheidszorg zeer recent zijn grote zorg uitgesproken over de toenemende kritische 
houding van ouders tegen het vaccineren o.a. onder invloed van de Nederlandse Vereniging 
Kritisch Prikken.
Noch vaccinatie, noch een infectie levert een blijvende immuniteit op. Infecties met Bp, 
hetzij symptoomloos, hetzij met milde atypische symptomen, hetzij met typische symptomen 
(kinkhoest) kunnen dus ook op latere leeftijd optreden. Ook mensen die een infectie met Bp 
hebben doorgemaakt kunnen later opnieuw die infectie krijgen, vaak gemitigeerd en deels 
symptoomloos. (17-23) Waarschijnlijk maakt ruim 6 % van de bevolking jaarlijks een infectie 
met Bp door. (24)
Nederland heeft al decennia lang een hoge vaccinatiegraad (ongeveer 96%). Desondanks 
worden jaarlijks 300 tot 500 kinderen in het ziekenhuis opgenomen wegens kinkhoest(60% 
jonger dan 3 maanden, 18% tussen 3 en 12 maanden). Vrijwel alle sterfgevallen ten gevolge 
van kinkhoest (in Nederland 2-5 per jaar volgens registratie van het CBS) vallen in de groep 
jonger dan 3 maanden.(2,3)
Symptomatologie:
Het typische ziektebeeld kenmerkt zich door drie stadia. Het eerste stadium is het catarrale 
stadium dat een à twee weken duurt en wordt gekarakteriseerd door niet specifieke symptomen 
van milde hoest, verkoudheid en soms lichte koorts. Dit is de meest besmettelijke fase. Hierna 
volgt het paroxysmale stadium dat zich kenmerkt door plotseling heftige en herhaaldelijke 
hoestaanvallen met de typische gierende inademing aan het einde van de paroxysme. Deze 
periode kan enkele weken tot maanden duren. Vervolgens treedt het convalescentie stadium 
in met een geleidelijke afname van de klachten. 
Kinkhoest en Zwangerschap:
De belangrijkste bron voor een infectie met Bp zijn vermoedelijk volwassenen met geringe 
symptomen die kinderen in hun omgeving besmetten. Waarschijnlijk zijn de moeders de 
belangrijkste infectiebron voor kinderen, en met name pasgeborenen. Maar ook andere 
gezinsleden kunnen als infectiebron fungeren.
Het doormaken van een infectie met Bp geeft geen levenslange bescherming. (17) De antistoffen 
verdwijnen na een infectie met Bp relatief snel. Na een jaar is de gemiddelde waarde voor IgG-
PT 32 U/ml. (25) Onbekend is op welk niveau er geen bescherming meer is, echter algemeen 
wordt aangenomen dat bij een titer lager dan 20 U/ml er onvoldoende bescherming is. 
Indien de moeder antistoffen opbouwt tegen Bp, tijdens de zwangerschap of kort daarvoor, 
gaan deze via de placenta over naar het kind. (26-31) Uit de beschikbare data blijkt, dat indien 
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de infectie met Bp vroeg genoeg in de zwangerschap plaatsvindt en de moeder voldoende 
tijd heeft om antistoffen te vormen, er weinig risico is voor het kind. (9,10) Indien de infectie 
met Bp bij moeder optreedt kort voor de partus (laatste 1 à 2 maanden), is er onvoldoende 
bescherming voor de baby en als de besmetting bij moeder optreedt na de bevalling, is er 
evenmin bescherming en ook niet als de infectiebron een van de anderen gezinsleden is (of 
een van de bezoekers). (4,6,7,16,32) 
Dat maternale antistoffen bescherming aan het kind kunnen bieden is in verschillende studies 
aangetoond. Al in 1943 toonden Cohen en Scadron (31) aan dat antistoffen van moeders 
die tijdens de zwangerschap werden gevaccineerd tegen kinkhoest overgingen naar de 
pasgeborenen. Oda laat in muizen zien dat babymuizen geboren uit gevaccineerde moeders 
beschermd waren tegen Bp infectie en dat ook colostrum een dergelijk beschermend effect 
heeft. (27,30) Ook Arciniega laat zien dat antistoffen tegen Bp in muizen passieve bescherming 
kunnen geven en dat deze antistoffen ook gevonden worden in de sera van pasgeborenen. (26)
Er zijn slechts enkele studies beschreven betreffende kinkhoest gedurende de zwangerschap. 
(9,10,23,32) Meestal verloopt de ziekte voor de moeder zonder al te veel problemen. (9) Gedurende 
een langetermijn studie van zwangere vrouwen met een besmettelijke ziekte tijdens de 
bevalling vonden Granström et al in de periode 1975-1985 35 vrouwen met kinkhoest, 
waarvan 19 in 1984-1985. Kinkhoest bleek daarmee in de laatste twee jaar van die studie de 
meest voorkomende “kinderziekte” bij zwangere vrouwen te zijn. (23) MacLean en Calder (9) 
beschrijven 4 gevallen van kinkhoest in de zwangerschap van de 43 zwangerschappen (9,3%) 
die zich in die periode voordoen in een praktijk in Schotland.
Als besmetting van de pasgeborene tijdens of kort na de bevalling heeft plaatsgevonden 
ontwikkelt het ziektebeeld zich meestal rond de tweede, derde week. (4,6,7,11,13,14,16,32) 
Besmetting in utero is wel eens vermoed, maar nooit bewezen. (6) De klachten bestaan uit 
voedingsproblemen, snelle ademhaling en hoesten. Bij de jongste kinderen kan echter het 
klassieke ziektebeeld van kinkhoest achterwege blijven en staan algeheel ziek zijn en apneus 
op de voorgrond. Ook bradycardiën kunnen het eerste symptoom zijn. (6,13) Deze aspecifieke 
presentatie is waarschijnlijk ook de reden dat het ziektebeeld vaak niet of laat herkend wordt 
bij hele jonge kinderen. 
Het ziektebeeld wordt mogelijk verergerd als er sprake is van dubbelinfecties. (33) Beiter (32) 
beschrijft een casus, waarbij de kinkhoest bij moeder niet werd herkend, de baby een week na 
de geboorte ziek wordt en overlijdt. Er bleek sprake van een dubbelinfectie met adenovirus. 
MacLean (9) vindt bij 1 van zijn 4 beschreven patiënten één co-infect met Influenza B, en 
Smith et al(11) beschrijven 9 kinderen met ernstige vroege kinkhoest, waarvan 4 met een virale 
co-infectie. Van de 9 baby’s overlijden er 6, waarvan 3 met een co-infectie. 
De incidentie van perinatale pertussis in Nederland is onbekend echter uitgaande van 
tweehonderd duizend partussen per jaar in Nederland en een infectiefrequentie bij 
volwassenen van ongeveer 6% per jaar (zie hoofdstuk 6), zou dit betekenen dat er per jaar 
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ongeveer negenduizend vrouwen een infectie met Bp doormaken in de zwangerschap. Dit wil 
zeggen dat ongeveer 3000 vrouwen een infectie met Bp doormaken in de laatste twee maanden 
van de zwangerschap en de eerste maand erna. Zoals beschreven hoeft het klinisch beeld 
niet altijd even duidelijk te zijn en kan variëren van een milde luchtweginfectie tot typische 
kinkhoestklachten. Daartegenover staat dat ook andere verwekkers van luchtweginfecties een 
kinkhoestachtig beeld kunnen veroorzaken. (34,35)
Gezien de hoge morbiditeit en mortaliteit van perinatale pertussis bij de neonaat is het 
belangrijk, zowel in de laatste weken van de zwangerschap als rondom de partus, bedacht te 
zijn op het ziektebeeld kinkhoest bij de moeder en na afname van diagnostiek moeder en kind 
direct te gaan behandelen.
Diagnostiek:
De diagnostiek bij volwassenen en oudere kinderen met een verdenking op een infectie 
met Bp bestaat uit nasopharyngeale kweek en/of PCR op een nasopharyngeale wat en/of 
serologie.(36) De kweek is erg gevoelig maar slechts korte tijd betrouwbaar af te nemen, 1 à 
2 weken na de eerste ziektedag. Voor de PCR geldt hetzelfde, al is de afnameperiode 3 tot 4 
weken na de eerste ziektedag. Serologie wordt pas enige weken na de eerste ziektedag positief 
en is daarom in de acute fase niet behulpzaam. Bij baby’s dient ongeacht de ziekteduur altijd 
naast de serologie een kweek en/of PCR te worden ingezet, aangezien bij hen de afweer tegen 
Bp langzamer op gang komt en er langer een kans bestaat op een positief resultaat. Daarnaast 
zijn er ook andere ziekteverwekkers (o.a. adenovirus, influenzavirus, para influenzavirus, 
respiratoir syncytieel virus, Mycoplasma pneumoniae), die vergelijkbare hoestbeelden kunnen 
geven. Bovendien geven co-infecties waarschijnlijk meer morbiditeit. Voordat de uitslagen 
van de diagnostiek echter bekend zijn gaat er enige tijd voorbij. Het is dan ook belangrijk na 
afname van diagnostiek snel met behandeling te beginnen. (10)
Behandeling: (10,16,28,29,37-40)
Medicamenteus:
Granström et al (10) adviseren de moeder te behandelen met Erythromycine 3 keer daags 250 
tot 500 mg gedurende 10 dagen. Dit is niet nodig als de klachten langer dan 7 weken geduurd 
hebben op moment van diagnose, omdat het dan zelden meer voorkomt dat de patiënt nog 
Bp bij zich draagt en besmettelijk is. Wanneer de bevalling plaatsvindt binnen 7 weken na 
het ontstaan van de kinkhoest wordt geadviseerd bij opname een Erythromycine kuur te 
geven, zelfs als de moeder al een Erythromycine kuur gehad heeft. Dit omdat er geen 100 % 
zekerheid is dat de eerste kuur de Bp volledig heeft verwijderd. Ook de nieuwe macroliden 
(clarithromycine, azithromycine) zijn effectief gebleken in de behandeling van kinkhoest. (40)
De bevalling moet gebeuren in een eenpersoons verloskamer en na de bevalling dienen 
moeder en kind op een eenpersoonskamer behandeld te worden. Het kind van de moeder 
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met kinkhoest krijgt, gedurende 5 dagen na de geboorte, 40 tot 50 mg. Erythromycine 
per kilo lichaamsgewicht. (10,16) Er is geen bezwaar tegen borstvoeding. Voordat moeder en 
kind naar huis ontslagen worden dienen alle gezinsleden, die mogelijk verdacht kunnen 
worden van een kinkhoestinfect, ook behandeld te worden met Erythromycine, gedurende 
minstens 5 dagen, omdat zij als mogelijke infectiebron een risico kunnen vormen voor de 
pasgeborene. Een probleem hierbij is natuurlijk dat bij volwassenen de kinkhoestinfectie 
praktisch symptoomloos of met atypische symptomen kan verlopen, zodat het moeilijk kan 
zijn mensen, die een risico vormen in de omgeving van het kind, te identificeren. 
Behandeling met pertussis immunoglobuline lijkt succesvol, maar wordt niet op grote schaal 
gebruikt en is in Nederland niet beschikbaar. (37,38)
Preventie:
Kinkhoest is, ondanks de bestaande vaccinatie programma’s, nog steeds een probleem, met 
name voor de heel jonge kinderen die niet of onvolledig gevaccineerd zijn. Om te komen 
tot een wereldwijde aanpak is de Global Pertussis Initiative opgericht, een internationale 
samenwerking van deskundigen vanuit verschillende disciplines . (41)
Er zijn verschillende vaccinatie strategieën na het eerste levensjaar mogelijk voor de preventie 
van kinkhoest (41):
-het vaccineren van alle volwassenen: hiervoor is het in veel landen (ook Nederland) nog nodig 
een infrastructuur op te zetten om alle volwassenen hiervoor te motiveren en vervolgens te 
kunnen vaccineren.Voor een effectieve reductie van het aantal kinkhoest gevallen bij jonge 
kinderen is waarschijnlijk een vaccinatiegraad van >85% nodig en moet de vaccinatie iedere 
10 jaar herhaald worden. (42,43) Dit wordt al aanbevolen in Canada en Oostenrijk.
-het vaccineren van alle adolescenten: omdat de immuniteit door vaccinatie tegen kinkhoest 
sterk gedaald is na 10-12 jaar vormen ook adolescenten een belangrijke bron voor pertussis 
infectie. De geschatte incidentie van kinkhoest in de leeftijdsgroep van 20-24 jaar is het hoogst 
van alle leeftijden (bijna 11%)(zie hoofdstuk 6). Revaccinatie alleen bij adolescenten (en niet 
bij volwassenen) zal onvoldoende bescherming bieden. Ook hier geldt dat in veel landen eerst 
een programma opgezet zal moeten worden om ook adolescenten te motiveren en vervolgens 
te vaccineren. Dergelijke programma’s worden aanbevolen in b.v. Australië, België, Canada, 
Duitsland, Finland, Frankrijk, Oostenrijk en Zwitserland.
-revaccineren op de leeftijd van 4-6 jaar: het revaccineren van kinderen in deze leeftijdsgroep 
gebeurt al in veel landen, in Nederland sinds 2000. Met het opnieuw vaccineren van kinderen 
rond het 4e jaar wordt verwacht dat de immuniteit tegen kinkhoest zal aanhouden tot verder 
in de adolescentie.
-selectief vaccineren van aanstaande moeders, familie en nauwe contacten: vaccinatie van 
zwangeren in het 3e trimester met de nieuwe acellulaire vaccins staat op dit moment ter discussie, 
mede gezien de onbekende risico’s voor de foetus. (29) Middels een dergelijke vaccinatie zouden 
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echter wel beschermende antistoffen aan het kind kunnen worden overgedragen, zoals bij een 
natuurlijke infectie, die mogelijk voldoende bescherming zouden kunnen bieden gedurende 
de eerste twee maanden tot de eerste vaccinatie. Een andere mogelijkheid is moeder direct 
post partum te vaccineren, en familieleden en andere nauwe contacten ook, deze zo mogelijk 
al voor de bevalling. Ook kan nog overwogen worden vrouwen met kinderwens te vaccineren 
voor de zwangerschap.
-het vaccineren van personeel werkzaam in de gezondheidszorg of kinderopvang: 
Ziekenhuispersoneel loopt ook het risico kinkhoest op te lopen, zowel thuis als in het 
ziekenhuis, door patiënten met kinkhoest. Granström et al (10) geven aan dat voor medisch 
personeel het risico kinkhoest te krijgen van opgenomen patiënten met kinkhoest minimaal 
is. Ze adviseren wel dat medewerkers met hoestklachten niet zouden moeten mogen zorgen 
voor patiënten (moeders en pasgeborenen) totdat een diagnose is gesteld. (10) Ook in de recente 
studie van Riffelmann et al blijkt dat er geen hogere antistoftiters voorkomen bij ziekenhuis 
personeel in vergelijking met bloeddonors en matrozen, echter zij geven niet aan of er ten 
tijde van het onderzoek patiënten met Bp infecties waren opgenomen. (44) Kurt et al (12) en 
Linnemann et al (45) laten echter zien dat personeel wel degelijk kinkhoest kan overbrengen 
op patiënten. Weber et al (40) geven een overzicht van verschillende studies waarin kinkhoest 
epidemieën in ziekenhuizen worden beschreven, veroorzaakt door patiënten, ziekenhuis 
medewerkers en bezoekers. Er is dus oplettendheid geboden ten aanzien van hoestklachten 
in het algemeen en kinkhoest in het bijzonder bij ziekenhuispersoneel.
-verbeteren/aanpassen huidige vaccinatieschema bij jonge kinderen: Vaccinatie van de neonaat 
kort na de geboorte heeft weinig zin. Englund et al laten zien dat een preëxistent hoger gehalte 
aan maternale antistoffen tegen kinkhoest bij het jonge kind een verminderde antistofreactie 
geeft na vaccinatie met een whole cell vaccin, maar niet bij een acellulair vaccin (28). Bovendien 
zijn pasgeborenen nog niet goed in staat antistoffen te vormen. 
Conclusies en Aanbevelingen:
1. Het niet overwegen van een infectie met Bp bij hoogzwangere vrouwen met 
luchtweginfecties kan fatale gevolgen hebben voor de pasgeborene.
2. Een infectie met Bp kan voorkomen bij volwassenen ook al zijn zij gevaccineerd of 
hebben zij eerder een infectie met Bp doorgemaakt. Bovendien kan een infectie met Bp 
bij volwassenen gemitigeerd en zelfs onherkenbaar verlopen.
3. Als de moeder geen infectie met Bp gedurende de zwangerschap of het jaar ervoor heeft 
doorgemaakt zijn er waarschijnlijk geen of onvoldoende beschermende antistoffen die 
transplacentair kunnen worden overgedragen.
4. Het klinisch beeld van een infectie met Bp bij pasgeborenen verschilt van het klassieke 
kinkhoestbeeld en wordt daardoor vaak laat of niet herkend.
5. Bij (verdenking op) perinatale pertussis bij de moeder dienen moeder èn kind 
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adequaat behandeld te worden evenals naaste familie. Overwogen dient te worden ook 
(para)medisch personeel dat in nauw contact is geweest met de patiënt te behandelen. 
6. Andere infectieuze verwekkers kunnen een kinkhoestachtig beeld veroorzaken.
7. Dubbelinfecties van een infectie met Bp met een andere verwekker kunnen een ernstiger 
beeld laten zien.
8. Om de bescherming van pasgeborenen tegen kinkhoest te verbeteren zijn nieuwe 
vaccinatiestrategieën nodig.
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Abstract
Background: In pertussis-like respiratory infections, once pertussis has been laboratory 
confirmed, other potential causative pathogens will seldom be looked for. Probably most 
mixed infections are found accidentally and since these mixed infections might cause a more 
severe disease we performed a retrospective study of their incidence.
Patients and methods: We selected from 2 groups of patients with serologically confirmed 
Bordetella (B.) pertussis infection those in whom serology for other respiratory pathogens 
had also been performed. Group 1 consisted of 50 pertussis patients with 51 episodes of 
B.pertussis infection selected from 100 patients with serologically confirmed pertussis. They 
participated in a long term follow up after a B.pertussis infection. In group 2, 31 pertussis 
patients were selected from 98 consecutive patients with positive pertussis serology from one 
routine practice. 
Results: In 23 of 82 pertussis infections (28%) serological evidence of one (n=21) or two 
(n=2) additional infections were demonstrated. These involved para-influenza virus (n=6), 
RSV (n=6), Mycoplasma pneumoniae (n=5), adenovirus (n=4), influenza A virus (n=3) and 
influenza B virus (n=1). 
Conclusions: We conclude that in patients with B.pertussis infection, co-infection with another 
respiratory pathogen is often present.
Introduction
Because both viral and bacterial infections are common during early childhood, dual 
infections are not unexpected. However, clinical manifestation of such combined infections 
may be difficult to interpret (1) despite an increase in knowledge concerning microbial agents 
associated with acute respiratory infections of childhood (2,3). For many years there has 
been an interest in the dynamic interaction between pathogens and the influence on disease 
interference (1,4-12). Studies on Bordetella (B.) pertussis infection often associated adenoviruses 
and other respiratory viruses with the pertussis-like syndrome in the absence of clear evidence 
of B.pertussis infection (5,13-15). The presence of more than one respiratory pathogen in an ill 
infant may have important diagnostic, therapeutic, prognostic, epidemiological and infection 
control consequences (6). Despite the relatively high frequency with which both viral and 
B.pertussis infection may occur in the community, the occurrence of a combination of two 
or more microbiological agents (or mixed infection) is underestimated (6), both in infants 
and in adults. We retrospectively investigated the incidence of mixed infections with other 
respiratory pathogens in pertussis patients.
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Materials and Methods
Patients
We considered two groups of patients, both with serologically confirmed B.pertussis infection 
and further selected those patients in whom serology for other respiratory pathogens had also 
been done. 
The first group consisted of 100 patients taken from one clinical practice between 1992 and 
1999, except 1998 (see below). They were all evaluated for prolonged coughing and had 
clinically documented (≥2 weeks paroxysmal cough) with serologically confirmed pertussis.
Group 2 consisted of 98 consecutive patients with serologically confirmed pertussis from one 
clinic (Groene Hart Hospital Gouda) in 1998. In that year the in- and outpatients physicians 
of the hospital tested a total of 416 patients for B.pertussis infection on account of prolonged 
coughing, 
In these two groups we looked retrospectively whether serological data on other respiratory 
pathogens were available from the same sera positive for B.pertussis infection.
The study was approved by the Medical Ethical Committee of our hospital.
Serology for pertussis
In group 1 the clinical diagnosis of pertussis was confirmed by a significant (i.e., ≥ 4-fold) 
increase of IgG antibodies to pertussis toxin (IgG-PT) in paired sera to a level of at least 20 U/
ml or a high IgG-PT concentration in a single serum, i.e. above a defined diagnostic cutoff of 
100 U/ml, as measured by the in-house IgG-PT ELISA (16) of the National Institute of Public 
Health and the Environment (Dutch acronym: RIVM), Bilthoven, The Netherlands. 
In group 2 the clinical suspicion of pertussis was confirmed by a significant increase of IgG 
antibodies to a mixture of pertussis toxin and filamentous haemagglutinin (IgG-PT/FHA) in 
paired sera. The criterion being either the value [OD-ratio*10] in second serum minus value 
in first serum ≥ +8) or a high IgG-PT/FHA in a single serum, i.e. above a defined diagnostic 
cutoff (criterion: value [OD-ratio*10] in first and/or second serum ≥ 28 ), as measured in a 
commercial IgG-PT/FHA ELISA (Virotech, Germany) (17).
Serology for other respiratory pathogens
Sera of patients in group 1 and 2 had also been tested with the complement fixation 
method (Serion Immunodiagnostics GmbH, Germany) and in some cases an indirect IgM 
immunofluorescent assay (Serion Immunodiagnostics GmbH, Germany) for antibodies 
against respiratory syncytial virus (RSV), influenza virus A and B, adenovirus, para-
influenza virus 1, 2 and 3, Mycoplasma (M.) pneumoniae, Chlamydia species and Coxiella (C.) 
burnetii. Two point serology was considered as proof of a recent infection when there was a 
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significant i.e. fourfold increase or decrease in titer. In one point serology a titer ≥128 was 
always considered as indicative of a recent infection. A titer of ≥ 64 was considered suspect, 
except in Coxiella burnetii (≥ 4 suspect) and in Chlamydia (≥8 suspect)(18). An indirect IgM 
immunofluorescent assay (Serion Immunodiagnostics GmbH, Germany) was performed 
when the complement fixation method was suspect or not conclusive. A positive IgM was 
also considered as proof of a recent infection (18). Between para-influenza virus type 1, 2 and 
3 there are serological cross reactions therefore they are reported together. 
Results
First we compared characteristics of the two groups of pertussis patients. The median age 
of the patients in group 1 was 4.1 year (IQR 1.7 – 7.2; range 4 weeks to 12 years) and in 
group 2 this was 4.9 years (IQR 2.8 – 8.0, range 6 weeks tot 15 years)(p=0.20); the median 
disease duration at presentation was 30 days (IQR 11 – 49) days and 30 days (IQR 16 – 38) 
respectively (p=0.92). In group 1 54% was male and in group 2 61% (p=0.82). The proportion 
completely vaccinated against pertussis (≥ 3 immunizations with pertussis whole cell vaccine 
in the first year of life) was 78% and 74%, respectively. 
From 50 of the 100 pertussis patients in group 1 serology data for other respiratory pathogens 
were available. One of the selected patients suffered from 2 episodes of B.pertussis infection 
(19), with an interval of 6 years and 7 months. Thus in group 1 there were 51 episodes of 
B.pertussis infection. 
In group 2 from 31 of the 98 pertussis patients serology data for other respiratory pathogens 
was found. In group 1, sera of 14 of 51 (27%) patients showed signs of a mixed infection. In 2 
of these sera, two other respiratory pathogens besides B.pertussis, were detected. In group 2, 
one other respiratory pathogen was detected in 9 sera of 31 patients (29%). Since no statistical 
significant differences were found in these parameters we decided to combine the groups for 
further analysis.
The age-distribution of all pertussis patients, with differentiation of those with and those without 
mixed infection, is shown in Figure 1. In 23 out of 82 pertussis episodes (28%) serological 
evidence for mixed infection was found. In 21 episodes one other respiratory pathogen was 
found (26%) with involvement of para-influenza virus (n=5), RSV (n=5), M. pneumoniae 
(n=4), adenovirus (n=4) and influenza A virus (n=3). In 2 episodes two other respiratory 
pathogens were found (2%), with in one case para-influenza virus and M. pneumoniae and 
in the other case influenza B virus and RSV (Fig 1). As shown in table 1 the median ages in 
patients with mixed (n=23) and patients with non-mixed infection (n=59) were 5.0 (IQR 
3.0 – 8.1) years and 4.2 (IQR 1.8 – 7.3) years respectively (p=0.38); the median duration of 
disease at presentation was 17 days (IQR 13 – 36) and 31 days (IQR 20 – 46), respectively 
(p=0.09). The proportion completely vaccinated was respectively 78% and 75% (p = 0.84). 
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Fig 1: All patients in whom serology was performed for both Bordetella pertussis and other respiratory 
pathogens, distributed by age. In black those with Bordetella pertussis infection only (n=59), the 
others (n=23) with mixed infection of Bordetella pertussis and one or two other respiratory pathogens.
In 11 of the 23 patients with mixed infection (48%), both pertussis serology and serology for 
other respiratory pathogens showed high (diagnostic) values in the first serum-sample. The 
median time these sera were obtained was 39 days after the first day of the disease (range 7-92 
days).
Table 1: Data on patients with mixed or non-mixed infection
Mixed Infection (N=23) Non-mixed Infection (N=59) p-value
 Age (years) 5.0(3.0-8.1)* 4.2(1.8-7.3)* 0.38
Age range (years) 0.7 – 11.1 0.1 – 15.3
Proportion < 1 year of age 4% 22% 0.10
Proportion completely vaccinated 78% 75% 0.84
Vaccinated 83% 82% 1.0
Disease duration at presentation 17(13-36)* 31(20-46)* 0.09
*= median and interquartile range.  
Disease duration = number of days between first day of disease and first presentation to the clinic
In 2 of the patients (9%) pertussis serology was already high in the first sample while serology 
for other respiratory pathogens showed a significant increase in paired sera. The first sera were 
obtained 9 and 22 days after the onset of disease, the second after 31 and 40 days respectively. 
In 6 patients (26%) pertussis antibodies in paired sera had significantly increased, while the 
first serum already contained high (diagnostic) antibody titers against another respiratory 
pathogen (first serum: median 11 days (range 6-22), second serum: median 41,5 days (range 
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29-54)). Finally, in 4 of the 23 patients (17%) there was a significant increase in paired sera 
for antibodies against both, B.pertussis and one other pathogen (first serum: median 14 days 
(range 8-29), second serum: median 41 days (range 29-55)).
There were 3 patients younger than 2 years, in whom vaccination might have influenced 
B.pertussis serology. In one, 1.6 years, there was an increase in IgG-PT from 1 to 500 U/ml, 
another, 1.7 years, had approximately 3 months after the first day of the disease and 9 months 
after his last vaccination a titer of 500 U/ml (both RIVM). The third, aged 0.7 years, about 
4 months after his third vaccination and with a concomitant RSV infection, had a titer of 33 
(Virotech).
Discussion
In this retrospective study we evaluated two groups of patients with a serological confirmed 
B.pertussis infection in whom also serology against other respiratory pathogens was performed. 
The first group had a cough ≥ 2 weeks, consistent with clinical pertussis. And the second 
group at least was suspected to have pertussis. That we don’t have more detailed clinical data 
on these patients limits the use of this study a little, especially regarding disease severity with 
or without mixed infection. 
We found that the incidence of mixed infection in both groups was similar (27 and 29%). 
The specific property of the first group of pertussis-patients was that after the pertussis 
episode they had returned to the same physician (F.V.) for other reasons, mostly because of 
asthma and therefore could participate in a long-term follow-up study of antibody-titers after 
pertussis (20). This may have introduced a selection-bias with respect to chance of mixed 
respiratory infection. However, the second group, with 29% mixed infection, consisted of 31 
of 98 consecutive pertussis-patients (32%) testing positive in pertussis-serology at one clinic. 
It can therefore be inferred that the incidence of mixed respiratory infection in all pertussis 
patients from group 2 was at least 9% (0.32x29%) and probably higher. By our knowledge 
there was no mechanism associated with decisions whether or not to do serology for other 
respiratory infections. We consider therefore both groups to be a random sample from the 
total of patients and evaluated them together because there were no significant differences 
between the two.
Data in the literature vary greatly in their percentages of mixed infections, between 8 and 44% 
(7,8,21-23). This is possibly due to differences in studied groups, used methods and different 
respiratory pathogens looked for (table 2). 
As might be expected, RSV, para-influenza virus, M. pneumoniae and adenovirus were the 
most encountered agents (24,25) (Fig1). The role of adenovirus infection in association with 
B.pertussis has not been clearly defined (26). Nelson et al reported their data suggesting that 
many adenoviruses isolated from their patients were latent viruses that had been activated 
Chapter 8

during the infection with B.pertussis rather than having been acquired exogenously (5). 
Discovery of new pathogens like the human meta-pneumovirus or a new human coronavirus 
(2,3) may also give rise to detection of more mixed respiratory infections.
Table 2: Data on mixed infection in different studies (7,8,21-23)
study No patients studied for mixed infection
B.pertussis 
infection
B.pertussis and 
mixed infections(%) comment
Moshal (7) 25 25 5 (20%) children<6months
Jackson (8) 319 47 17 (36%) students
MacLean (21) 43 4 1 (25%) pregnant women
Smith (22) 9 9 4 (44%) babies, 6 died, 3 with mixed infection 
Ferrer (23) 905 114 9 (7,9%) children
The frequency of B.pertussis infection measured by serology only might be influenced by 
recent vaccination in children < 2 years. But Nagel showed that vaccination with the Dutch 
whole cell vaccine induced only rather low IgG-PT levels (16). But other vaccines might 
induce higher IgG-PT levels since the response to PT varies between different whole-cell 
vaccines and acellular vaccines (20). Of the 3 patients <2 years, the 2 oldest had proof of recent 
infection. In the youngest B.pertussis serology might be influenced by recent vaccination.
The mentioned interpretation-criteria of the IgG-PT ELISA have been shown to yield a 
sensitivity in paired sera of PCR or culture confirmed pertussis patients (n=89) of 94% (in 
76% of the patients a value ≥ of 100 E/ml in first and/or second serum was found). The 
specificity, in population sera (n=7759), was 99% (20) and, in paired sera of patients with 
respiratory disease of other etiology (n=59) 95% (in 3 of 59 patients a value > 100 U/ml was 
found in first or second serum; significant dynamics were absent) (17). 
In a previous investigation of the performance of this commercial ELISA in paired sera of a 
group of patients with culture- or PCR-confirmed pertussis (n=56) and a control group with 
respiratory disease of other etiology (n=59), the mentioned criteria for significant dynamics 
in paired sera and diagnostic values in single sera have been shown to yield a sensitivity of 
91% (87% had a value ≥ 28 in first and/or second serum). The specificity was 95% (3 of 59 
control-patients had a value ≥ 28 in first and/or second serum; significant dynamics were 
absent) (17). 
The IgG-PT/FHA ELISA (Virotech, Germany) is not specific for B.pertussis but may also 
indicate a B.parapertussis infection. In this study there is no possibility to discriminate 
between these 2 agents.
From our data it is difficult to conclude whether or not mixed infections were simultaneous 
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or consecutive. In 48% of the patients with mixed infection, the finding of already high 
diagnostic titers in a first serum against two or more pathogens, cannot differentiate whether 
the infections were concurrent or consecutive. An increase of antibodies against two or more 
pathogens in two consecutive sera occurred in 17% of the patients with mixed infection. This 
strongly supports the view that the infections have occurred at the same time. A high titer 
in the first serum for one agent and an increase for the other in a second serum favors a 
consecutive infection. This occurred in 35% of the patients with mixed infection.
Although mixed infections of B.pertussis with another respiratory pathogen seem to be more 
frequent than expected, their clinical relevance is still being discussed. In some studies, 
mixed or super-infection with B.pertussis is considered to be a major contributing factor 
to complications (9,22). Aoyama et al (9) presented two cases illustrating that RS-viral 
infection could cause pneumonia in pertussis patients that was severe enough to result in 
respiratory failure. In contrast, Moshal et al state that there are no specific clinical features 
that distinguish patients with only B.pertussis infection from those with a mixed infection 
with other respiratory viruses (7). Nelson et al (11) also could not find laboratory or 
clinical differences between B.pertussis, RSV or mixed infections in hospitalized children. 
One might hypothesize that patients with mixed infections are more likely to seek medical 
help because of more severe disease and doctors are possibly more likely to perform more 
extensive investigations when patients are seriously ill. We have however no sufficient data 
regarding the clinical status of all the patients in our study. The median duration of disease at 
presentation was shorter in patients with mixed infection (17 days) than in patients without 
mixed infection (31 days). Although this difference is not statistically significant (p=0.09), it 
may be taken as some support for the hypothesis that mixed infections are associated with 
more severe symptoms, prompting earlier presentation to the physician. It is also possible that 
mixed infections started with a respiratory viral infection which might be the reason why they 
were studied earlier.
The diversity of the other respiratory agents makes cross-reacting antibody responses unlikely 
but does not rule out nonspecific polyclonal responses (8).
Theoretically, the immature immune system of infants and lack of previous exposure to 
respiratory viruses could increase susceptibility to simultaneous infection with two or more 
respiratory pathogens. In a study where double respiratory viral infections were compared 
to patients with single respiratory viral infections a greater percentage of the first group are 
under the age of one year. However, in our patients the incidence of mixed infection in < 
1 year olds was not higher than in other age-groups. Thus, it is unclear whether younger 
patients are more often infected with mixed respiratory infection or suffer more (10,23).
Failure to recognize one of the involved pathogens in hospitalized children may result in 
incorrect management. It also puts other patients, especially the immunocompromised and 
those with underlying heart or pulmonary disease, at risk of contracting potentially fatal 
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nosocomial infections. This is particularly important in winter when the hospitals are full and 
children are often cohorted according to the pathogen identified (e.g. respiratory syncytial 
virus). In addition patients are kept in isolation according to the pathogen causing the illness. 
It is imaginable that contracting a second agent might influence the course of the disease 
(duration, severity). Whether the mixed infections are really mixed or consecutive might, in 
this regard, not be very important.
Persistent cough in infants is a medical problem with different therapeutic options depending 
on etiology. Increased knowledge about the incidence of various possible causative micro-
organisms is therefore important. Until the present day it remains unclear what the precise 
relationship is between pathogens in mixed infection. 
In conclusion we think that mixed respiratory infections are an underestimated problem 
in children. Often when one agent is discovered the search for others is stopped. What is 
not looked for, will not be found. Infection with more than one microbiological agent 
may influence the clinical course of the disease (duration, severity). In this retrospective 
study we did not analyze the clinical impact of mixed infections of B.pertussis with other 
respiratory pathogens. Only a prospective study of children with prolonged cough 
with both B.pertussis and simultaneous identification of other respiratory agents could 
resolve this question. In view of the possible clinical importance of mixed infections, 
the recent progress in rapid viral diagnoses and the potential of new anti-bacterial and 
antiviral drugs, the possibility of dual infection should be investigated more often.
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Abstract
To investigate in children with prolonged coughing the frequency of different respiratory 
pathogens, the rate of mixed infections and possible differences in severity of disease between 
single and mixed infections, we performed a 2 years prospective study.
Children from 0-18 years with coughing lasting 1 to 6 weeks were included. Sera of 135 
children (with 136 episode of prolonged coughing) were tested for antibodies against different 
viruses and bacteria. Swabs were taken for culture and PCR on different viral and bacterial 
pathogens.
One or more pathogens were found in 91 patients (67%). In 49 (36%) one infectious agent was 
found, in 35 (26%) 2 and in 7 (5%) more than 2. The most frequent pathogens encountered 
were rhinovirus (43 patients-32%), Bordetella pertussis (23 patients-17%) and respiratory 
syncytial virus (15 patients-11%). 
The most frequent encountered mixed infection consisted of a combination of Bordetella 
pertussis and rhinovirus (n=14-10%).
No significant differences were observed regarding clinical symptoms between patients 
without pathogens and those in whom one or more pathogens were found, except that 
patients with a mixed infection were significantly older. There is a strong seasonal influence 
in the number of infections but not in the number of mixed infections.
In children with prolonged coughing there is a high frequency of mixed infections occurring 
during the whole year regardless of the season. Mixed infection however does not cause 
increased disease severity. Although patients with mixed infection were significantly older, 
no clinical symptoms were found that discriminate for specific pathogens.
Introduction
Prolonged coughing is a frequent symptom in children and often is associated with respiratory 
infection [1]. Although prolonged coughing is a prominent feature in Bordetella (B.) pertussis 
infection, infections with other respiratory pathogens may cause prolonged coughing as well 
[2]. Mixed infections with a combination of 2 or more pathogens do occur. However data on 
clinical manifestations of such combined infections may be difficult to interpret and it often 
concerns retrospective studies with different results [2, 3-5]. It has been suggested that mixed 
infections may cause more severe illness, especially in younger children [3, 4, 6]. In an earlier 
retrospective observational study (data not published) among 81 children with serologically 
proven B.pertussis infection we found in 28% of the patients evidence for concomitant 
infections with other respiratory pathogens. It is known that many respiratory pathogens may 
cause prolonged coughing in children, however prolonged coughing is not always caused by 
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a respiratory infection [1, 7, 8].
We conducted this study to investigate the role of different respiratory pathogens in prolonged 
coughing in children and the frequency of possible mixed infections. We also studied whether 
patients in whom one or more pathogens were detected suffered from more severe disease 
than patients without pathogens. 
History
Patients:
All patients between 0 and 18 years, referred by general practitioners from September 2001 
till September 2003 to the outpatient clinic of the department of Pediatrics of the Groene 
Hart hospital, a 500-bed general hospital in Gouda, The Netherlands, with the complaint 
of coughing one week or more and not longer than 6 weeks at the first visit were asked to 
participate in the study. Disease duration was defined as the time between onset of symptoms 
and first visit to the hospital. Prolonged, chronic or persistent cough is defined differently in 
various studies ranging from 5 days to more than one month [2, 7,9-12]. Our patient selection 
was based on a 1 to 6 weeks lasting cough since this is in agreement with most studies.
Patients with an aspiration of a foreign body or known to have cystic fibrosis were excluded. 
At the first visit blood samples were taken for erythrocyte sedimentation rate (ESR), C 
reactive protein (CRP), leukocyte count and differentiation and serology for respiratory 
pathogens (see below). In all patients oropharyngeal, nasal and nasopharyngeal swabs were 
also taken for culture and PCR on respiratory pathogens (see below). When disease duration 
at presentation at the first visit was less than 14 days, serology was repeated after two weeks 
except for B.pertussis. When serology and PCR at the first visit were negative for B.pertussis, 
serology was repeated 4 weeks after the first visit (6 weeks in children < 1 year). The patients 
or their parents were asked to complete a questionnaire about complaints, previous diseases 
and vaccination status. All gave their written informed consent to participate in the study. A 
follow-up telephone interview was conducted approximately 4 weeks after enrollment. The 
study was approved by the Medical Ethical Committee of our hospital. A healthy control 
group was not included in this study. 
Pathogens:
In our observational study we sought to identify agents and studied their occurrence in 
relationship to prolonged coughing. Therefore we define pathogens as agents known to be 
able to cause disease. For sake of clarity we refer to these agents as pathogens whether or 
not they caused the illness of interest. In tables 2 and 3 these bacteria considered to reflect a 
carrier state are indicated in the light gray area.
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Serology:
Serology for B.pertussis was considered positive by the finding of a significant, ≥ 4-
fold increase of IgG antibodies to pertussis toxin (IgG-PT) in paired sera to a level of 
at least 20 U/ml or a high IgG-PT concentration in a single serum, i.e. above a defined 
diagnostic cutoff of 100 U/ml, as measured in the in-house IgG-PT ELISA of the National 
Institute of Public Health and the Environment (Dutch acronym: RIVM), Bilthoven, 
The Netherlands [13]. The mentioned interpretation-criteria of the IgG-PT ELISA 
have been shown to yield a sensitivity and specificity of respectively 90% and 97% [14].
All sera also were tested for antibodies against respiratory syncytial virus (RSV), influenza 
virus A and B, adenovirus, para-influenza virus 1, 2 and 3, Mycoplasma (M.) pneumoniae, 
Chlamydia species and Coxiella (C.) burnetii (by the Regionaal Medisch Microbiologisch 
Laboratorium, Rotterdam, The Netherlands) with the complement fixation method (Serion 
Immunodiagnostics GmbH, Germany). Two point serology against these pathogens was 
considered as proof of a recent infection when there was a significant i.e. fourfold or more 
increase or decrease in titer. In one point serology a titer ≥128 was always considered 
indicative of recent infection. A titer of ≥ 64 was considered suspicious, except in C. burnetii 
(≥ 4 suspicious) and in Chlamydia (≥8 suspicious) [15]. An indirect IgM immunofluorescent 
assay (Serion Immunodiagnostics GmbH, Germany) was performed when the complement 
fixation method was suspicious. A positive IgM together with suspicious serology 
was also considered as proof of a recent infection. Between para-influenza virus type 
1, 2 and 3 there are serological cross reactions therefore they are reported together. 
PCR:
The detection of B.pertussis and B.parapertussis was based on the polymerase chain reaction 
(PCR), using a MagNa Pure LC Total Nucleic Acid Isolation Kit (Roche) and primer pairs 
based on insertion sequence elements IS481 and IS 1001. The final PCR product was analyzed 
by gel electrophoresis and by dot blot hybridization [16,17]. 
PCR for Chlamydia (C.) pneumoniae, M.pneumoniae, influenzavirus A and B, coronavirus 
229E and OC43, RSV, human metapneumovirus (hMPV), rhinovirus and enterovirus were 
performed on a nasal and a throat swab. A negative control (virus transport medium) was 
included for every 4 clinical samples. A positive control containing each pathogen was included 
in each DNA and RNA extraction and PCR run. DNA was isolated with a proteinase-K/SDS 
extraction essentially as previously described [18]. RNA was isolated with a high pure RNA 
isolation kit (Roche Molecular Biochemicals) with the addition of poly A RNA as carrier 
according to the instructions from the manufacturer. An aliquot of the isolated DNA was used 
in a PCR detecting either M.pneumoniae [18]or C.pneumoniae [19]. An aliquot of the eluted 
RNA preparation was used for rhino/enterovirus [20], influenzavirus A [21] and B [22] and 
hMPV [23] were separately amplified in a single-tube RT-PCR. RSV [24] and coronavirus 
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OC43 and 229E [25] were amplified in a multiplex single-tube nested RT-PCR.  
Culture for respiratory bacterial pathogens: 
A oropharyngeal swab was inoculated onto a blood agar plate, a blood agar plate + oxolinicacid 
(10 mg/L) plate and a chocolate agar plate. Βeta-hemolytic streptococci group A, Haemophilus 
(H.) influenzae, Streptococcus (S.) pneumoniae and Moraxella (M.) catharralis were considered 
potential pathogens. Staphylococcus aureus, Neisseria meningitides, β-hemolytic streptococci 
not group A and Candida (C.) albicans were also reported but not considered pathogenic. 
Only those cultures with predominant growth were considered positive [26]. Non pathogenic 
oropharyngeal flora (i.e viridans streptococci, difteroids, coagulase negative staphylococci 
etc) is not reported.
Statistical Analysis:
For the description of patient characteristics median and interquartile ranges were obtained. A 
statistical comparison was done between three groups of children: those in whom no pathogen 
could be found, children with only one pathogen and those with two or more pathogens. For 
this purpose chi-square test was used or, in case of continuous variables, analysis of variance 
(ANOVA) was used. 
Results
During a 2 year period starting September 2001 a total of 152 patients were referred to our 
hospital for prolonged coughing; 11 patients refused to participate in the study. Five patients 
were not included due to protocol violation. The remaining 136 episodes were obtained from 
135 patients since one patient had 2 episodes of coughing with an interval of 5.2 months 
which were considered as 2 independent events. To study seasonal influences patients were 
included in this prospective cohort study during a 2 year period. Most patients were included 
in the first year of the study.
Of these 136 patients 59% were male and the median age at inclusion was 2.7 years (interquartile 
range (IQR): 0.6 to 6.4 years) and the median duration of complaints at presentation was 14 
days (IQR: 10 to 20 days). A total of 51 (38%) patients were hospitalized for treatment. Of the 
136 children 124 (92%) were vaccinated against B. pertussis (table 1). Patient characteristics 
are summarized in table 1. 
In 91 patients (67%) one or more pathogens were found. Of those, 49 had one pathogen (36%), 
35 had 2 (26%), 6 patients had 3 pathogens (4%) and one had 4 pathogens (1%). In our study 
we found in 31% of the patients more than 1 respiratory pathogen (table 1). The presence of 
more than one pathogen in patients was found during the whole year and in all ages. In 33% no 
pathogen was found. The means of detection of the different pathogens are reported in table 2. 
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All respiratory pathogens found in this study were considered possible cause of the prolonged 
coughing complaints, although patients may be colonized by some of the pathogens found, 
without causing disease. 
Table 1: Clinical data on all patients together and divided in patients without, one or more than one respiratory pathogen. 
All Without pathogen 1 pathogen More than 1 pathogen p-value
N 136 45 (33%) 49 (36%) 42 (31%)
Age yearsA 2.7 (0.6-6.4) 1.3 (0.6–5.8) 1.0 (0.4–5.0) 4.4 (1.8–9.0) 0.005
Male 80 (59%) 27 (60%) 31 (63%) 22 (52%) 0.56
Disease duration daysA 14 (10 – 20) 15 (13–21) 14 (9–17) 14 (9–20) 0.33
Vaccinated * 124 (92%) 41 (91%) 44 (90%) 39 (95%) 0.64
Admission 51 (38%) 16(36%) 22 (45%) 13 (31%) 0.37
Length of stay daysA 5 (3 – 7) 3.5 (2–6) 5 (3–7) 5 (4–7) 0.49
Antibiotics 68 (50%) 22 (49%) 23 (47%) 23 (55%) 0.75
* 1 missing information on vaccination status, A (median and interquartile range), § one missing culture.
Disease duration: time between first day of illness and first presentation in the hospital.
Vaccinated: received the regular vaccinations appropriate for their age.
Length of stay: days in hospital when admitted.
In these 91 patients the most frequently seen pathogens were rhinovirus in 43 patients (47%), 
B.pertussis in 23 patients (25%) and RSV in 15 patients (16%) (table 2). In the 42 patients 
with a mixed infection the most frequent combination was B.pertussis and rhinovirus (N=14) 
(table 3). 
Rhinovirus, the most prevalent pathogen, was in 23 patients found together with one or 
more other pathogens. In 14 of the cases of rhinovirus this other pathogen was B.pertussis. 
B.pertussis, the second most frequent pathogen, was found in 18 patients together with another 
pathogen. In 14 patients this other pathogen was rhinovirus (table 3). RSV was found in 12 
patients together with another pathogen (table 3). 
Six patients had a combination of 3 pathogens: one with adenovirus, RSV and B.parapertussis, 
one with B.pertussis, M.pneumoniae and rhinovirus, one with B.pertussis, adenovirus and H. 
parainfluenzae, one with M.pneumoniae, β-hemolytic streptococci group B and rhinovirus, one 
with RSV, rhinovirus and H.parainfluenzae and the sixth had a combination of M.pneumoniae, 
H.influenzae no type b and β-hemolytic streptococci group G. The one patient with 4 pathogens 
had parainfluenzavirus, RSV, rhinovirus and H.parainfluenzae. 
In this study 15 of the 27 positive bacterial cultures were found in patients with more than one 
pathogen (see table 3). There were 11 patients with a positive oropharyngeal culture and one 
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other pathogen. In only 1 of these 11 patients (with a CRP of 109 mg/L) we considered the 
bacterial infection of influence on the course of the disease. In the other 10 there was no sign of 
a bacterial infection. In 4 patients there were 2 or more other pathogens apart from the positive 
oropharyngeal swab (table 3). 
Table 2: Number of respiratory pathogens detected in this study and means of detection.
Children 
with pathogen
n=91 (67%)
Diagnostic test
Pathogen Serology PCR Both culture
Bordetella pertussis 23 (25%) 3 8 12 -
Bordetella parapertussis 1 (1%) - 1 - -
Influenzavirus A or B 5 (5%) 5 0 0 -
Adenovirus 6 (7%) 6 - - -
Mycoplasma pneumoniae 6 (7%) 4 1 1 -
Parainfluenzavirus 9 (10%) 9 - - -
Respiratory Syncytial virus 15 (16%) 14 1 0 -
Rhinovirus 43 (47%) - 43 - -
Humane metapneumovirus 1 (1%) - 1 - -
Enterovirus 4 (4%) - 4 - -
Chlamydia pneumoniae 1 (1%) 0 0 1 -
Streptococcus pneumoniae 1 (1%) - - - 1
Haemophilus parainfluenzae 7 (8%) - - - 7
Staphylococcus aureus 1 (1%) - - - 1
Haemophilus influenzae no type b 12 (13%) - - - 12
Haemophilus influenzae type b 1 (1%) - - - 1
β-hemolytic streptococci group C 1 (1%) - - - 1
β-hemolytic streptococci group G 1 (1%) - - - 1
β-hemolytic streptococci group B 1 (1%) - - - 1
Candida albicans 2 (2%) - - - 2
total 141
Between brackets the percentages of patients. This is more than 100% because in 42 patients 2 or more 
pathogens were found. Bacteria considered to reflect a carrier state are indicated in the light gray area.
-: not done
Thus, from the 42 (31%) patients with more than 1 pathogen, in 10 patients with a positive 
oropharyngeal culture and one other pathogen, it is difficult to say whether there is a mixed 
or a consecutive infection or whether the bacteria found represent a carrier state. Therefore 
these 10 were not considered as possible mixed infection. On the basis of serology, PCR and 
culture 21 from the remaining 32 (24%) patients were considered to have had a possible mixed 
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infection (14 of these with a positive PCR for 2 or 3 pathogens), 9 a consecutive infection and 
2 both. 
There are no significant differences between patients with and without pathogens regarding 
disease duration at presentation (i.e. time between first day of illness and first presentation 
at the hospital), disease severity (antibiotics, hospitalization, length of stay, coughing, other 
symptoms like headache, sore throat, or pain) or vaccination status (tables 1 and 4). Except 
that children with more than 1 pathogen were on average 3 years older compared to children 
without or with only 1 pathogen (p=0.005) (table 1). Although there was no significant 
difference in coughing during different parts of the day, there seemed a tendency for children 
with more than 1 pathogen to have more coughing (table 4). Also there were no significant
Table 3: Nature and number of respiratory pathogens in 42 patients with more than one pathogen found. Bacteria 
considered to reflect a carrier state are indicated in the light gray area.
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Bordetella pertussis
Bordetella parapertussis
Influenzavirus A or B 
Adenovirus 2☐ 1* 1
Mycoplasma pneumoniae
Parainfluenzavirus
Respiratory Syncytial Virus 1 1 1
Rhinovirus 14** 2 2% 2☐
Humane metapneumovirus
Enterovirus 1 1 1
Chlamydia pneumoniae
Streptococcus pneumoniae 1
Haemophilus parainfluenzae 1 1
Staphylococcus aureus
Haemophilus influenzae no type b 1 3 1
Haemophilus influenzae type b 1
β-hemolytic streptococci group C
β-hemolytic streptococci group G 1@
β-hemolytic streptococci group B 1**
Candida albicans 1
In 6 patients 3 pathogens were found and in one patient 4 pathogens: 
*  1 also respiratory syncytial virus   **  1 also Mycoplasma pneumoniae  
☐ 1 also Haemophilus parainfluenzae   @  1 also Haemophilus influenzae no type b 
%  1 also respiratory syncytial virus and 
 Haemophilus parainfluenzae
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differences in coughing or other symptoms between the 3 possible pathogens most frequently 
found, except that patients with B. pertussis had less fever. 
All our patients recovered in due time although in our study design it proved too difficult to 
record time to recovery accurately. Therefore there are no data on this subject available. Data 
on coughing in the family or other contaminators were not recorded.
Table 4: Number (percentage between brackets) of patients with coughing complaints and with different other 
symptoms. There are no significant differences. Also there are no significant differences between the 3 most frequent 
pathogens, except that there is less fever in Bordetella pertussis
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All (n=135)* 45 (33%) 49 (36%) 41 (31%)* 23 (17%) 43 (32%) 15 (11%)
Coughing
Morning   (n=82) 25 (30%) 26 (32%) 31 (38%) 16 (20%) 30 (37%) 11 (13%)
Afternoon (n=70) 22 (31%) 21 (30%) 27 (39%) 17 (24%) 26 (37%)  9 (13%)
Evening    (n=88) 25 (28%) 32 (36%) 31 (35%) 20 (23%) 31 (35%)  9 (10%)
Night        (n=89) 25 (28%) 32 (36%) 32 (36%) 17 (19%) 29 (33%) 13 (15%)
Symptoms
Fever         (n=47) 18 (38%) 14 (30%) 15 (32%) 1 (2%) 13 (28%) 7 (15%)
Tachypnea (n=51) 16 (31%) 20 (39%) 15 (29%) 6 (12%) 15 (29%)  9 (18%)
Dyspnea    (n=63) 22 (35%) 21 (33%) 20 (32%) 9 (14%) 14 (22%)  7 (11%)
* Missing data for 1 patient.
Discussion
In our 2-year observational study of 136 children with coughing lasting for 1 to 6 weeks, we 
investigated the occurrence of respiratory pathogens. The presence of one or more pathogens 
(mixed infection) was subsequently studied in relation to the occurrence of clinical symptoms 
and the treatment given. We found 91 patients (67%) who had 1 or more respiratory pathogens 
and overall a high incidence of infection with rhinovirus (32%), B.pertussis (17%) and RSV 
(11%). To our knowledge this is the first study where a broad spectrum of respiratory pathogens 
has been studied in a prospective manner in children selected because of their coughing pattern. 
Others have also reported rhinovirus to be a frequently found pathogen in respiratory disease 
in all ages [27-29] among which a long-term surveillance of acute respiratory infections in the 
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Netherlands [30]. There seems an age dependency in the incidence of rhinovirus infection, 
the incidence being lower in older people. Incidences ranged from 21% to 40% in children 
with infection but in one study [29] in children without nasal symptoms the incidence was 
also 20%. Although rhinovirus was considered earlier to cause mild upper airway disease, 
it becomes more and more clear, using more advanced diagnostic techniques, that it may 
play an important role in more severe respiratory infection. It is difficult to compare our 
results with the frequency of pathogens reported in other studies on respiratory infections 
among children since these were mainly retrospective studies focusing on specific pathogens 
or specific combinations of pathogens [2,4-6,8-10,30-44]. The incidence of pathogenic agents 
for respiratory infection in our study was 67%, which is comparable to some studies, with 
incidences ranging from 56% to 64% [2,9,33,40] but different from other studies reporting 
incidences from 80% to 90% [9,30,37]. The incidence is age dependent with a high frequency 
observed among the youngest patients and ranged from 80-90% in children up to 6 years 
to 40% in adults [30,31]. In our study, we did not find this relationship since the incidence 
among children from 1-4 years old was 63% and did not differ from the oldest children. 
We observed a relatively high incidence of co-infection of rhinovirus and B.pertussis (10% 
of all patients). Among children infected with B.pertussis a co-infection with rhinovirus was 
found in 61% of the cases. The role of B.pertussis in rhinovirus infection is complicated since it 
has been reported that rhinovirus-induced changes in airway smooth muscle responsiveness 
in isolated rabbit and human airway smooth muscle (ASM) tissue and cultured ASM cells 
were largely prevented by pre-treating the tissues with pertussis toxin or with a monoclonal 
blocking antibody to intercellular adhesion molecule-1, the principal endogenous receptor for 
most rhinoviruses [45]. This might indicate that the co-infection of rhinovirus and B.pertussis 
is not as severe as one would expect. This hypothesis is confirmed by our observation where 
coughing and other clinical symptoms, did not differ significantly from patients with either 
rhinovirus or B.pertussis and the fact that despite 61% of co-infection of B.pertussis and 
rhinovirus, there was less fever in the B.pertussis group, as expected in B.pertussis infection.
In all clinical parameters studied, like disease duration at presentation or treatment (table 1), 
coughing or disease symptoms no significant differences could be found between patients 
with and patients without demonstrable pathogen(s), except the fever, (table 4). Even when 
comparing children with rhinovirus, B.pertussis and RSV separately there were no statistical 
significant differences (table 4) nor in patients with a combined infection with rhinovirus 
and B.pertussis. This is in accordance with others [46]. Thus, decisions on treatment still will 
mainly be made on the physicians’ clinical judgment.
In our study RSV infection might be underrepresented (11%), since many and especially 
young children with severe coughing were referred within one week after onset of cough and 
were excluded by definition.
We often encountered a negative PCR for RSV, influenzavirus and M.pneumoniae whereas a 
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positive serology was found for these agents (table 2). A false negative result is very unlikely, 
since positive controls were tested on a regular base throughout the study without false negative 
results. Therefore a short duration of pathogen replication might be the explanation. 
In 33% of the patients in our study no pathogens or positive serology could be detected. This 
percentage is in agreement with other studies [2,9,31,44,46]. As yet unidentified pathogens 
may be associated with prolonged coughing in the serology-, culture- and PCR-negative 
group. The hMPV and human corona virus -NL63 are good examples of such pathogens that 
have been described recently [23,47]. Although hMPV is recently reported to be an important 
agent in respiratory disease especially in young children [48] we could neither confirm this in 
our study, nor say whether it influenced disease severity in mixed infection. 
Unfortunately, we did not recruit asymptomatic children as a control group, because this was 
considered too distressing for children. However the occurrence of pathogens in subjects 
without coughing would provide data on the incidence of carrier rate without disease. 
Some researchers identified fewer viral agents in non-symptomatic controls compared to 
patients [32-35]. Gunnarsson et al. [31] found in patients with long standing cough more 
S. pneumoniae, H.influenzae and M.catarrhalis compared with healthy individuals of the 
same age. In the ARI-EL study, a case control study in general practitioner patients of all ages 
with acute respiratory infections in the Netherlands from October 2000 till October 2003, 
statistically significant fewer viruses were detected in controls (54% vs. 19%) [36]. Therefore 
it remains to be determined to what extent the presence of a pathogen is responsible for the 
coughing pattern.
Most patients with a positive culture for pathogenic bacteria will not have a bacterial 
respiratory infection. Since carriage rates for potential pathogenic bacteria in healthy young 
children may vary between 11 and 48% [31,49] it is difficult to establish what clinical influence 
these bacteria might have had in our patients. In tables 2 and 3 these bacteria considered to 
reflect a carrier state are indicated in the light gray area. In a logistic regression analysis, 
although not statistically significant, we found a greater association with coughing in the 
morning from pathogens diagnosed by PCR or serology as compared to diagnosed by the 
oropharyngeal bacterial culture method (odds ratio 2.0 vs. 0.8). Similar associations were 
found when coughing patterns on other parts of the day were analyzed. Therefore it could be 
argued that a positive bacterial oropharyngeal culture is not of much value in the search for 
respiratory pathogens causing prolonged cough.
We observed an occurrence of more than one pathogen in 31% of all included children. 
This might support the theory that the presence of one (viral) respiratory pathogen may 
predispose to a second or third (bacterial) infection [39,42,46]. The proportion of mixed 
infections reported by others varies largely 10 to 74% of the patients [9,33,34,38,39,46]. This 
might considerably be influenced by the period of observation. We have tried to exclude the 
seasonal influence by taking an observation period of 2 years. During this 2-year enrolment 
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of patients the seasonal influence varied significantly between the first and the second year. In 
the second study year a lower incidence of prolonged coughing was observed and there were 
fewer referrals, possibly due to the milder winter of 2002-2003 and the rather warm summer 
of 2003 in the Netherlands as compared to 2001-2002. Remarkable was therefore that the 
frequency of two or more pathogens during both years of the study in every season remained 
the same. 
In previous studies it has been demonstrated mixed infections to be related with a more severe 
course of the disease [3-6,43,44,48]. In contrast, we found no evidence of a more severe illness 
in our patients with mixed infections (table 1). Apparently there is one dominant pathogen 
without a cumulative or synergistic effect of a second pathogen. Although it may be speculated 
that a viral infection might make the patient more vulnerable to a bacterial infection.
However, patients with more than 1 pathogen were significantly older than those with one or 
no pathogens. This might indicate that they were more ill than children of similar age with no 
detectable pathogen or just one. This is supported by the fact that there is a slight tendency for 
coughing complaints to be higher in patients with 2 or more pathogens (table 4).
Still it seems important to look for mixed infections [48] because when there is a high 
incidence of a respiratory infection (for instance RSV), sometimes patients are hospitalized 
in one room, increasing the risk of nosocomial infection. Although it seems mixed infections 
don’t produce more severe disease, it is questionable if this is correct policy because of the 
possibility of a high incidence of infections with more than one pathogen. When they are 
consecutive, this may prolong admission.
In conclusion we found in children with prolonged coughing in 36% one pathogen and in 
31% more than 1 pathogen. There is a strong seasonal influence on the number of cases 
but not on pathogens found nor on the percentage of multiple infections. Clinical data did 
not distinguish between pathogens, whether pathogens were found or not, or differences in 
treatment. In mixed or consecutive infection there was no increase in disease severity regarding 
symptoms and hospitalization. The only difference being that this group was significantly 
older suggesting that they had a more severe disease than their peer groups without, or with 1 
pathogen found. It is obvious that not all possible pathogens found will cause illness, although 
it is still not clear whether and how the presence of a colonizing potential respiratory pathogen 
influences or facilitates other possible pathogens. It is therefore important to extend studies 
on respiratory infections with more than one pathogen to evaluate the influence on disease 
severity.
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Summary and Conclusions
In this thesis we report the results of the studies we performed to answer the questions, 
which were put forward in chapter 1. The first part of this thesis focuses on the interpretation 
of Bordetella (B.) pertussis serology and the epidemiological consequences of our results 
evaluating surveillance data. The second part of this thesis shows data on other respiratory 
pathogens besides B.pertussis in mixed infections and prolonged coughing.
In this last chapter the most relevant findings will be summarized following the questions from 
chapter 1. Also practical implications and suggestions for future research will be proposed.
1: which titer of immunoglobulin G antibodies against pertussis toxin (IgG-PT) in one 
point serology is proof for recent infection?
Our results show that an IgG-PT level of at least 100 U/ml is a specific tool in laboratory 
confirmation by one-point serology of patients with a suspected pertussis infection. 
Independently of age, these levels are diagnostic of very recent or actual infection with 
B.pertussis. Such levels are present in less than 1% of the population and are reached in 
most pertussis patients within 4 weeks after disease onset. High IgG-PT levels persist only 
temporarily. The IgG-PT levels after natural infection with B.pertussis decrease within less 
than 1 year to a level below 100 U/ml for almost all patients who had high IgG-PT levels. 
The regression model we used in this study predicts that peak levels > 100 U/ml occur 4-8 
weeks after infection. In the declining phase a level of 100 U/ml is reached in 4.5 months after 
infection onset. A level of <40 U/ml is reached within 1 year after disease onset. At diagnosis 
the number of patients with IgG-PT levels ≥ 100 U/ml is considerably larger (4.5-fold) than 
the number of patients with at least a 4-fold increase in IgG-PT. IgG-PT levels > 100 U/ml 
provide a useful laboratory tool for the diagnosis of pertussis in both the individual patient as 
in epidemiological studies.
2: may a patient suffer from B.pertussis infection more than once in a lifetime?
In chapter 3 we demonstrate that children, vaccinated or not, may have serologic evidence of 
re-infection with B.pertussis. Although it is known that people may suffer from re-infection 
with B.pertussis, these patients are the first in whom symptomatic re-infection with B.pertussis 
has definitely been proven. The infection took place 3.5-12 years after the first infection. But 
it is obvious that clinical complaints not necessarily comply with typical pertussis infection. 
It was shown that the severity and duration of respiratory symptoms in patients with proven 
and relatively early re-infections with B.pertussis increased with time elapsed since the first 
infection.
B.pertussis infection should be considered in patients with symptoms of typical or atypical 
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whooping cough, irrespective of age, their vaccination status or previous whooping cough.
3: what is the natural course of antibodies against B.pertussis after infection?
Evolution in data evaluation:
In the chapters 2, 4 and 5 in this thesis we have used different ways of evaluating the decline 
of immunoglobulin G to pertussis toxin (IgG-PT) after natural infection with B.pertussis. 
These 3 methods reflect gradual improvement and advancing understanding. In response 
to an infection, IgG titers typically show a rapid increase, followed by a steady, slow decline 
over several years. IgG-PT responses appear to show considerable variation among individual 
patients.
In chapter 2 we used a linear mixed model (PROC Mixed in SAS version 6.12) to analyze the 
association between 2log IgG-PT levels and time in 2log days after the first day of illness. The 
rapid increase of IgG-PT in the first weeks after illness was not taken in account, nor were 
effects of age or vaccination status. Fitting a straight line to the log-log transformed data can 
only account for the decaying phase of the response and requires the omission of data from 
the initial rapid increase. Since there is no clearly defined criterion by which observations can 
be excluded, the following study (chapter 4) continued with a response model, that includes 
the initial rising phase.
In chapter 4 we assumed that the slow decline in IgG antibody titers with time following 
infection disallows use of a first order model of antibody decay. On a log time – log titer scale 
such a model would lead to a convex curve, with an increasing downward slope. For our data, 
such a slope might be too steep, leading to a poor fit to the observed responses. The model we 
used, a skewed hyperbola, has asymptotically linear decline on a log-log scale at long times 
from infection. In this model there seems a significant effect of age or vaccination status but 
because the numbers of adults and unvaccinated infants were small and because there was a 
wide variation of data it remains unclear whether this is clinically relevant.
For any individual patient the amount of information is limited: only a few measurements at 
best. Although the previous regression model adequately fitted the data, this model did not 
help much in interpreting the observed immune responses. For that reason we continued with 
a biologically based model in chapter 5. We describe longitudinal responses with a dynamic 
model of the interaction between bacteria and the immune system. The model assumes that 
during infection bacteria are growing exponentially in the host. At the same time, bacteria 
are inactivated (killed) by antibodies (or by some action associated with the antibody 
response) according to a mass-action mechanism: inactivation depends on the product of 
the concentrations of bacteria and antibodies (or antibody producing cells). Conversely, 
antibody production is controlled by the probability of antibodies (or antibody producing 
cells) encountering bacteria (or being presented with antigens derived from these pathogens). 
Antibody removal is considered an autonomous first order process. This so-called predator-
Chapter 10

prey model is the simplest possible model for the interaction between host and pathogen. 
Combining data from patients aged 0-94 years, we found no significant differences in rise, 
peak and decline of IgG-PT between different age groups. But there seems a tendency to age-
related differences where older people tend to have a more rapid increase, a higher peak and a 
faster decline after infection than younger age groups. This could be caused by immunological 
memory.
4: what is the yearly incidence of B.pertussis infection?
In chapter 2 we already showed that an IgG-PT level of at least 100 U/ml is present in less than 
1% of the population. In chapter 6, using the statistical model described in chapter 4 on the 
IgG-PT data of a cross-section of the general Dutch population we conclude that B.pertussis 
infections occur frequently in the Dutch population, particularly in adults for whom the 
reported incidence is very low. On average the estimated incidence of infection is 6.6% per 
year for 3 to 79-years olds, where as the annual incidence of notified cases was 0.01%! The 
age-distribution of all infections differs notably from the age-distribution of notified cases. 
We therefore suggest that vaccination strategies should not be based on notification data but 
on knowledge about the circulation of B.pertussis in different age groups and contact patterns 
between age groups.
5: what is the best way to protect newborns and not yet (fully) vaccinated babies against 
B. pertussis infection?
In chapter 7 we review the risks of perinatal infection with B.pertussis, the diagnosis, treatment 
and prophylaxis. Also we consider the possible influence of different vaccination schemes on 
the rate of B.pertussis infection in young children and the disease burden in older age groups. 
Although the best way seems to be to vaccinate the adolescent and adult population every 10 
years, the feasibility of this regime requires large investments in making people aware of the 
necessity of these booster vaccinations and to develop a new infrastructure to deliver these 
vaccinations. Another option is to vaccinate pregnant women or women before pregnancy 
and their families.
6: how often mixed infections occur in B.pertussis infection? 
During the prospective study on the longitudinal course of IgG-PT we regularly observed 
mixed infections. Therefore in chapter 8 we retrospectively looked for mixed infections in this 
group and in a group of patients in whom the diagnosis pertussis was made in 1998. In 28 % 
of the patients with proven B.pertussis infection there was evidence of mixed infection with 
para-influenza virus, RSV, Mycoplasma pneumoniae, adenovirus or influenza virus. Since 
infection with more than one pathogen might cause more severe or prolonged disease we 
suggest the possibility of dual infection should be investigated more often.
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7: what is the role of other respiratory pathogens in the pertussis like syndrome?
To investigate the role of different respiratory pathogens in prolonged coughing in children 
and to analyze the clinical impact of mixed infections of B.pertussis with other respiratory 
pathogens we performed a prospective study in children with coughing complaints lasting 
1 to 6 weeks (chapter 9). One third of the patients had one pathogen (n=49, 36%), one third 
more respiratory pathogens (n=42, 31%). The most frequent pathogens encountered were 
rhinovirus, B.pertussis and respiratory syncytial virus. In the patients with a mixed infection 
the most frequent combination was B.pertussis and rhinovirus. Infections with more than one 
pathogen occurred during the whole year regardless of the season. No signs of more disease 
severity could be demonstrated in children with more than 1 pathogen, although children 
with more than 1 pathogen were significantly older than those with none or 1 pathogen. 
There were no clinical data found that discriminated between pathogens, whether pathogens 
were found or not, or differences in treatment.
The threshold for IgG-PT of 100 U/ml as proof of recent infection made it possible to improve 
the diagnosis of B.pertussis infection, by one-point serology. It becomes clear from the long 
term data on notification of B.pertussis infection, two-point and one-point serology that the 
discrepancy between notifications and positive serology became smaller since the acceptation 
of one-point serology and the notification rate has increased. Before 1996 all serological tests 
for pertussis were performed at the LIS-RIVM. However, since 1998 at least three of the 16 
regional Public Health Laboratories and also some other (hospital) laboratories have started 
to perform serology with commercial available assays. Consequently, the population coverage 
of serological surveillance based on serological data of LIS-RIVM is now estimated to have 
decreased from 100% to less than 50%. This explains why the notification rate since 1999 is 
higher than the number of patients with positive serology at LIS-RIVM. Because there is no 
longer one central laboratory for the diagnosis of B.pertussis infections it is more difficult to 
gain insight in the epidemiology of B.pertussis infections in the Netherlands; notification data 
differ significantly from estimated infections and are very much lower.
It became clear that people may suffer from B.pertussis infection more than once in a lifetime. 
When the time between infections is longer the more severe disease occurs in the second 
infection. There is some evidence that the moment of re-infections might be influenced by 
booster vaccination against B.pertussis. This, together with the increasing awareness about the 
importance of adolescents and adults as a source of B.pertussis infection, makes it important 
to gain more insight in the incidence of B.pertussis infection and the influence of booster 
vaccination. Therefore studies should be designed to investigate this interaction in order to 
develop new vaccination strategies. 
The development and validation of models of the kinetics of IgG-PT after B.pertussis infection 
makes it possible to compare patients of different ages, from different places or different 
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time periods. This will help to increase the knowledge about the epidemiology of B.pertussis 
infection. Since there seems a tendency of an age dependent course of IgG-PT after B.pertussis 
infection further studies are needed to confirm this finding. If this age dependency holds true 
it influences the results of demographic studies about the incidence of B.pertussis infection. 
It might also influence decisions about vaccination schedules for adult booster vaccination. 
Comparison of the different methods used in this thesis to calculate the course of IgG-PT 
after B.pertussis infection is therefore the first step. When this swifter and higher response in 
older people means they will suffer from B.pertussis infection with less pronounced disease 
and therefore will not as easily be recognized as pertussis patients, more attention should be 
paid to identify B.pertussis infection in this age group. 
Although there is a significant number of mixed infections both in B.pertussis infection and 
in prolonged coughing, we could not demonstrate more severe disease in mixed infection. 
Also many people are carrier of respiratory infectious agents without disease. This leaves 
open the question of the relevance of mixed infections. When mixed infections are not true 
mixed infections but consecutive infections they still may prolong disease. Also an increased 
knowledge about mixed infection might influence the management of patients.
Most important is how to control B.pertussis infection, especially for the vulnerable, not or 
partially vaccinated, young children. Isolating patients is effective but impossible to execute 
regarding the number of patients and the difficulty to identify the majority of the older 
patients because of their aspecific or subclinical symptoms. Another possibility is antibiotic 
prophylaxis for the ones at risk and all people around this patient, or only for those at risk. 
Although passive immunization with human hyperimmune anti-pertussis gammaglobulin 
is still used occasionally elsewhere, it is no common practice in the Netherlands, where the 
hyperimmune anti-pertussis gammaglobulin is not available. 
The best way to control B.pertussis infection is vaccination either with whole-cell or acellular 
vaccine. Since asymptomatic re-infection may occur rather a short period after infection 
or vaccination protective immunity against disease lasts longer than the immunity against 
infection. Thus it seems that natural infection or vaccination provides better protection 
against the toxic effects of B.pertussis infection than against adhesion but the protection is not 
life-long. The duration of the protective immunity acquired by vaccination lasts about as long 
as by natural infection (4-12 years vs. 4-20 years), although data are not unequivocal.
The interaction between vaccination and boosting of pertussis immunity by B. pertussis 
infection on one hand and waning immunity against B. pertussis on the other influences the 
epidemiology and the dynamics of pertussis in the population. Therefore it is necessary to 
study the influences of changes in vaccination schedules. 
The studies presented in this thesis made us understand better some things about B.pertussis 
infection but also raised new questions. New studies have to be performed to answer some of 
these questions but for sure will raise other ones.
Chapter 10
Chapter 
Kinkhoest: nieuwe inzichten 
in diagnose, voorkomen 
en klinische aspecten
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Inleiding
Kinkhoest is een besmettelijke ziekte van de luchtwegen, veroorzaakt door de kinkhoest 
bacterie: Bordetella pertussis. Deze infectie kan voorkomen op alle leeftijden, maar de 
klachten zijn het ergst bij kleine kinderen. Jaarlijks hebben wereldwijd 20-40 miljoen mensen 
kinkhoest, vooral in de ontwikkelingslanden. Er wordt geschat dat per jaar ongeveer 200 000-
400 000 mensen aan kinkhoest overlijden.
De eerste epidemie van kinkhoest is beschreven door Guillaume de Baillou (1538-1616) in 
1578, maar al veel eerder, in 1190, was in Engeland een ziektebeeld bekend dat kinkehost 
werd genoemd. En Dodonaeus (1517-1585) beschrijft in zijn Cruijde boeck uit 1554 al een 
therapie voor kieckhoest!
Kinkhoest manifesteert zich als een heftig hoesten met stikbuien, maar afhankelijk van 
voorafgaande vaccinaties en/of eerdere infecties kan de ziekte milder verlopen. Het klinische 
beeld kent drie stadia, 1: de catarrale fase, gekenmerkt door een verkoudheidsbeeld en 
beginnend hoesten, 2: de paroxysmale fase, met de typische hoestaanvallen, en 3: de herstelfase, 
waarin de klachten langzaam afnemen. De totale ziekteduur bedraagt ongeveer drie maanden. 
In het Chinees wordt de ziekte dan ook de “honderd dagen ziekte” genoemd.
De bacteriesoort Bordetella kent op dit moment acht verschillende typen: Bordetella pertussis, 
Bordetella parapertussis, Bordetella bronchiseptica, Bordetella avium, Bordetella hinzii, 
Bordetella holmesii, Bordetella trematum en Bordetella petrii. Bordetella pertussis komt alleen 
bij de mens voor, de andere komen vooral bij dieren voor maar kunnen ook klachten geven 
bij mensen, vooral de Bordetella parapertussis. 
Bij een infectie met Bordetella pertussis komt een aantal ziekmakende stoffen vrij, zoals onder 
andere pertussis toxine, filamenteus haemagglutinine, fimbriae en pertactin. Tegen deze 
stoffen, antigenen, vormt het lichaam antistoffen die een rol spelen in de immuniteit tegen 
infectie met Bordetella pertussis. Het aantonen van deze antistoffen wordt gebruikt in de 
diagnostiek van kinkhoest.
De afgelopen tien jaar is er een duidelijke toename van het aantal kinkhoestgevallen 
geconstateerd, vooral in ontwikkelde landen met een hoge vaccinatiegraad. In Nederland was 
tussen 1989 en 1994 de gemiddelde incidentie (aantal nieuwe gevallen) van kinkhoest 2,4 per 
100.000 mensen op basis van meldingen en 2,3 per 100.000 mensen op basis van positieve 
serologie (aantonen van antistoffen in bloed). In 1996 was er sprake van een sterke stijging van 
de incidentie tot 27.3 per 100.000 en sindsdien is deze hoog gebleven. Een belangrijke oorzaak 
voor de toename van Bordetella pertussis infecties is dat er veranderingen zijn opgetreden in 
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het genoom (complex van erfelijke factoren) van de Bordetella pertussis na het starten van de 
vaccinaties in de vijftiger jaren.
Kinkhoest is voortdurend aanwezig in de bevolking, en daarbovenop komen epidemieën 
voor met een cyclus van ongeveer 4 jaar in landen waar gevaccineerd wordt en een cyclus van 
2 tot 3 jaar elders. In Nederland zijn deze cycli, ondanks de vaccinatie, sinds 1996 ook om de 
2 à 3 jaar. Bordetella pertussis is erg besmettelijk en wordt vooral door hoestdruppeltjes van 
mens op mens overgedragen.
Natuurlijke infectie of vaccineren geeft een langdurige maar geen levenslange bescherming 
tegen kinkhoestinfectie. Door gedeeltelijke bescherming kan een milder ziektebeeld ontstaan, 
dat vaak niet als kinkhoest herkend wordt. Dit is vooral het geval bij adolescenten en 
volwassenen. Deze mensen kunnen echter wel anderen besmetten, vooral ongevaccineerde of 
gedeeltelijk gevaccineerde jonge kinderen.
De diagnose kinkhoest wordt gesteld op klinische symptomen: langer dan twee weken 
hoesten, met daarbij of hoestbuien, en/of kinken (gierende inademing) en/of overgeven 
direct na het hoesten. De diagnose kinkhoest kan bevestigd worden door het kweken van 
de Bordetella pertussis of door het aantonen van deze bacterie middels de polymerase chain 
reaction (PCR). Ook kunnen er antistoffen tegen antigenen in het bloed aangetoond worden. 
Daarbij moet in twee verschillende bloedmonsters minstens een viervoudige stijging van de 
antistoffen optreden. Een positieve kweek met Bordetella pertussis is de gouden standaard 
voor het vaststellen van kinkhoest, maar het kweken van de Bordetella pertussis is erg moeilijk. 
PCR maakt het mogelijk ook nog Bordetella pertussis aan te tonen als de bacterie niet meer 
leeft; maar 3 à 4 weken na de infectie is de kans op een positief resultaat van de kweek of 
PCR niet erg groot meer. Als de ziekte langer aanhoudt heeft het meer zin antistoffen in het 
bloed aan te tonen. Bepaling van de antistof immunoglobuline G tegen pertussis toxine (IgG-
PT) is de meest gebruikte en best gevalideerde test. IgG-PT wordt uitsluitend aangemaakt na 
een infectie met Bordetella pertussis, niet met andere Bordetella’s. Antistoffen tegen andere 
antigenen worden ook wel gebruikt, maar zijn minder gestandaardiseerd. Bovendien zijn 
deze antigenen ook bij infecties met andere Bordetella’s te vinden. Het vaststellen van een 
viervoudige stijging van de antistoffen in het bloed wordt bemoeilijkt doordat veel patiënten 
pas later tijdens hun ziekte medische hulp zoeken. Dan hebben de antistoffen vaak al (bijna) 
hun piek bereikt (meestal na 4 à 5 weken) en kan geen viervoudige stijging meer worden 
aangetoond. Heel jonge kinderen hebben nog een onrijpe afweer. Daardoor wordt de bacterie 
langzamer uit het lichaam verwijderd en heeft het zin ook na langere tijd nog een kweek en/of 
PCR in te zetten. 
Een klinisch beeld lijkend op kinkhoest kan ook veroorzaakt worden door andere verwekkers 
als adenovirus, influenzavirus, parainfluenza virus, respiratoir syncytiaal virus, Chlamydia 
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pneumoniae of Mycoplasma pneumoniae. Ook zijn gemengde infecties beschreven met 
verschillende verwekkers.
Kinkhoest kan behandeld worden met antibiotica, macroliden hebben daarbij de voorkeur. 
Vaccinatie beschermt tegen infectie met Bordetella pertussis. Meestal gebeurt dit met een 
combinatievaccin, waarin ook difterie, tetanus, en polio zitten. Jarenlang is gebruik gemaakt 
van vaccins op basis van geïnactiveerde bacteriën, het whole-cell vaccin. Vanwege de 
bijwerkingen zijn nieuwe vaccins ontwikkeld met daarin een of meer geselecteerde antigenen, 
zoals pertussis toxine. Dit zogenaamde acellulaire vaccin is in 2001 opgenomen in het Rijks 
Vaccinatie Programma.
Doel van dit proefschrift
Door de plotselinge stijging in 1996 van het aantal kinkhoest gevallen in Nederland stelden 
wij ons een aantal vragen: 
- Kunnen we met één enkel bloedmonster de diagnose kinkhoest stellen?
- Kun je meer dan één keer in je leven kinkhoest krijgen?
- Hoe snel verdwijnen de antistoffen tegen kinkhoest na een infectie uit je bloed?
- Hoe vaak komen kinkhoest infecties elk jaar voor en bij wie?
- Hoe kun je de meest kwetsbaren (pasgeborenen en jonge kinderen die nog niet volledig zijn
 gevaccineerd) het best beschermen tegen kinkhoest?
- Hoe vaak komen menginfecties voor bij kinkhoest en zo ja welke verwekkers spelen een
 rol?
- Is ernstig hoesten altijd kinkhoest en wat is de rol van andere verwekkers van hoestklachten 
 in het beeld lijkend op kinkhoest?
Opzet
Vanaf 1993 werd bij ongeveer 100 patiënten die kinkhoest hadden doorgemaakt, als er om 
een andere reden toch bloed afgenomen moest worden, na verkregen toestemming, wat extra 
bloed afgenomen voor het opnieuw bepalen van het IgG-PT. Daarnaast werd bij een deel van 
deze patiënten gekeken of er nog andere verwekkers van luchtweginfecties aangetoond konden 
worden. Deze gegevens werden op zich en in samenhang met andere gegevens bewerkt.
Daarnaast werd in een tweejarige prospectieve studie vanaf 2001 onderzocht welke verwekkers 
aangetoond konden worden bij kinderen met langdurig hoesten.
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Resultaten
In hoofdstuk 1 wordt een overzicht gegeven van de huidige stand van zaken met betrekking 
tot Bordetella pertussis infecties. Daarnaast wordt uiteen gezet wat de vraagstellingen zijn van 
dit proefschrift.
Hoofdstuk 2 beschrijft de studie waarin wij aantonen dat een titer (gehalte) van IgG-PT van 
100 U/ml of hoger bewijzend is voor een recente Bordetella pertussis infectie, en dat daarmee 
voor de diagnose kinkhoest bepaling in één bloedmonster (eenpuntsserologie) mogelijk is. 
Minder dan 1% van de bevolking heeft titers boven de 100 U/ml. In het wiskundig model 
dat we gebruiken in deze studie bereikt de IgG-PT titer een piek na 4-8 weken, waarna een 
geleidelijke daling optreedt. Na ongeveer 4½ maand wordt in de dalende fase gemiddeld de 
100 U/ml grens weer bereikt, en na een jaar bedraagt de gemiddelde titer < 40 U/ml. Het 
aantal patiënten met een IgG-PT titer > 100 U/ml in één bloedmonster is 4,5 maal zo groot 
als het aantal patiënten met een viervoudige titerstijging in twee bloedmonsters. Een IgG-PT 
titer > 100 U/ml is daarmee een zeer bruikbaar hulpmiddel in de diagnostiek van kinkhoest 
in de individuele patiënt èn in epidemiologische studies.
In hoofdstuk 3 beschrijven we vier patiënten die serologisch bewezen voor de tweede keer 
een kinkhoest infectie doormaken, 3,5 tot 12 jaar na de eerste infectie. Drie van de vier 
kinderen zijn in hun eerste levensjaar gevaccineerd. Ofschoon wel vermoed werd dat mensen 
opnieuw kinkhoest kunnen doormaken, zijn deze patiënten de eersten waar dit ook in beide 
gevallen is bewezen. Bij deze patiënten was de tweede infectie niet altijd herkenbaar als een 
typische kinkhoestinfectie. Wel waren de klachten ernstiger en leken meer op een typische 
kinkhoestinfectie naarmate de eerste infectie langer geleden had plaatsgevonden. Het is dus 
belangrijk bij mensen met hoestklachten ook aan een kinkhoestinfectie te denken, ondanks 
eerdere vaccinatie en/of kinkhoestinfectie.
In de hoofdstukken 2,4 en 5 zijn verschillende methoden/wiskundige modellen gebruikt om de 
daling van het IgG-PT te beschrijven. Deze drie methoden zijn het gevolg van opeenvolgende 
verbeteringen en voortschrijdend inzicht. In de in hoofdstuk 2 gebruikte methode wordt 
uitsluitend rekening gehouden met de gegevens uit de dalende fase van het IgG-PT. 
Daarom werd in hoofdstuk 4 een model ontwikkeld dat ook gebruik maakt van de eerste 
stijgende fase van de antistofrespons. Het hierbij gebruikte model van een scheve hyperbool 
past beter op de gevonden data dan het eerste model, maar geeft nog steeds weinig 
aanknopingspunten bij het interpreteren van de gevonden immuun respons. 
Vervolgens werd in hoofdstuk 5 het beloop van de antistofrespons in de tijd beschreven 
middels een dynamisch model van de interactie tussen de bacterie en het immuunsysteem. 
Dit model gaat er van uit dat de bacterie exponentieel groeit in de gastheer. Tegelijkertijd 
echter wordt de bacterie onschadelijk gemaakt door de antistofreactie. Het onschadelijk 
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maken van de bacterie hangt af van de kans dat antistoffen bacteriën tegenkomen. Daarnaast 
hangt de productie van antistoffen af van de ontmoetingskans tussen antistoffen en bacteriën. 
Dit zogenaamde roofdier-prooimodel is het meest eenvoudige model om de interactie tussen 
gastheer en ziekteverwekker te beschrijven.
In hoofdstuk 5 wordt het beloop van IgG-PT in een groep kinkhoestpatiënten van 0 tot 94 jaar 
beschreven. Hierbij werden geen significante verschillen gevonden tussen de verschillende 
leeftijdsgroepen wat betreft stijging, piek en daling van het IgG-PT. Maar er was wel een 
tendens dat oudere mensen een snellere stijging, een hogere piek en een snellere daling van 
het IgG-PT lieten zien. Dit zou kunnen wijzen op een vorm van immunologisch geheugen. 
Een goed wiskundig model is onder andere belangrijk voor het stellen van de diagnose maar 
ook bij het ontwikkelen van vaccinatiestrategieën. 
Een belangrijke vraag is hoe vaak komt kinkhoest nu eigenlijk voor? 
Gebruik makend van de IgG-PT data van een doorsnede van de Nederlandse bevolking, zoals 
beschreven in hoofdstuk 2, en met behulp van het model uit hoofdstuk 4, wordt in hoofdstuk 
6 berekend dat jaarlijks 6,6% van alle 3 tot 79 jarigen in Nederland kinkhoest doormaken. 
Echter, jaarlijks worden maar 0,1% kinkhoestinfecties gerapporteerd! Ook is er een groot 
verschil in leeftijdsverdeling tussen de berekende en gerapporteerde kinkhoestinfecties. De 
meeste gerapporteerde gevallen zijn jonger dan 1 jaar en tussen het 3 en 4e jaar, volgens de 
modelberekening ligt het hoogste aantal infecties in de leeftijd van 20 tot 24 jaar. De meeste 
overdracht vindt plaats bij jonge volwassenen: daarbij gaat het om infecties met weinig of geen 
symptomen, die daarom ontsnappen aan herkenning en rapportage. Het is dus belangrijk dat 
beschermingsstrategieën niet worden gebaseerd op het aantal gemelde kinkhoestpatiënten, 
maar op kennis van en inzicht in het voorkomen van Bordetella pertussis in de verschillende 
leeftijdsgroepen en hoe de contacten tussen de verschillende leeftijdsgroepen plaatsvinden.
In hoofdstuk 7 wordt een overzicht gegeven van de risico’s van kinkhoestinfecties in de 
zwangerschap en rondom de bevalling, de diagnostiek, behandeling en profylaxe. Tenslotte 
worden een aantal vaccinatiestrategieën besproken om met name de circulatie van Bordetella 
pertussis in de bevolking te reduceren en daarmee de risico’s op een kinkhoestinfectie voor de 
risicogroepen te verminderen.
Gedurende de studie over het beloop in de tijd van de IgG-PT na een kinkhoestinfectie 
zagen we regelmatig een gemengde infectie. In hoofdstuk 8 beschrijven we retrospectief het 
voorkomen van gemengde infecties in deze groep patiënten en een groep kinkhoestpatiënten 
uit 1998. Hierbij werd in 28% van de patiënten met een bewezen kinkhoestinfectie tevens 
een infectie gevonden met parainfluenza virus, respiratoir syncytiaal virus, Mycoplasma 
pneumoniae, adenovirus of influenza virus. Omdat gemengde infecties ernstigere of langere 
ziekte zouden kunnen veroorzaken is het belangrijk meer aandacht te besteden aan gemengde 
infecties.
Om de rol van verschillende verwekkers van luchtweginfecties te onderzoeken bij kinderen 
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met langdurig hoesten en om te zien wat de klinische invloed is van gemengde infecties 
van Bordetella pertussis met andere verwekkers van luchtweginfecties werd een tweejarige 
prospectieve studie opgezet. 
Deze studie wordt in hoofdstuk 9 beschreven. Bij ongeveer een derde van de patiënten werd 
geen verwekker (n=45, 33%) aangetoond, bij een derde één verwekker (n=49, 36%), en bij een 
derde meerdere (n=42, 31%). De meest voorkomende verwekkers zijn rhinovirus, Bordetella 
pertussis en respiratoir syncytiaal virus. Bij patiënten met een gemengde infectie is de meest 
voorkomende combinatie Bordetella pertussis en rhinovirus. Gemengde infecties komen het 
hele jaar voor ongeacht het seizoen. Kinderen met meer dan een verwekker zijn niet zieker, 
al zijn ze wel significant ouder dan kinderen zonder aantoonbare verwekker of slechts één 
verwekker. Ook zijn er geen klinische gegevens gevonden die een onderscheid mogelijk 
maken tussen de verschillende verwekkers, de aanwezigheid van verwekkers, of verschillen 
in behandeling.
Het feit dat een IgG-PT titer van 100 U/ml in een enkel bloedmonster een bewijs is van een 
recente kinkhoestinfectie heeft de diagnostiek van kinkhoest verbeterd en vereenvoudigd. 
Ook konden we aantonen dat mensen vaker dan één keer kinkhoest kunnen krijgen, 
gevaccineerd of niet. Tevens bleek dat hoe langer de tijd was tussen twee kinkhoestinfecties 
hoe zieker de patiënt de tweede keer was. Het modelleren van het beloop van IgG-PT 
titers na een kinkhoestinfectie maakt het mogelijk patiënten van verschillende leeftijden, 
verschillende plaatsen en verschillende tijdvakken te vergelijken. Hierdoor zal onze kennis 
over de epidemiologie van kinkhoest verder toenemen. Wel zal er verder onderzoek gedaan 
moeten worden naar het mogelijke leeftijdsbepaalde beloop van IgG-PT. Het door ons 
gevonden leeftijdspatroon heeft invloed op de uitkomsten van studies naar het voorkomen 
van kinkhoest en op de vaccinatieschema’s voor volwassenen. De snellere en hogere reactie 
bij ouderen op een kinkhoestinfectie betekent dat zij minder ernstig ziek worden en daardoor 
ook moeilijker te herkennen zijn als een kinkhoestpatiënt. Er moet daarom extra aandacht 
besteed worden om kinkhoest in deze leeftijdsgroep te kunnen herkennen. Zowel bij 
kinkhoestinfecties als bij langdurig hoesten bestaan een groot aantal gemengde infecties. Er 
zijn echter geen aanwijzingen voor ernstigere ziekte bij gemengde infecties. Ook zijn veel 
mensen drager van een verwekker van luchtweginfecties zonder dat zij ziek zijn. Is er dan wel 
sprake van gemengde infecties? Meer kennis omtrent gemengde luchtweginfecties kan van 
invloed zijn op de behandeling van de patiënt.
Het belangrijkste is kinkhoest onder controle te krijgen ter bescherming van het jonge, niet 
of gedeeltelijk gevaccineerde, kind. De beste manier hiervoor is vaccinatie. Aangezien een 
klachtenvrije herinfectie met Bordetella pertussis al kort na een infectie of vaccinatie kan 
ontstaan lijkt de bescherming tegen ziek worden langer te bestaan dan de bescherming tegen 
infectie. Maar deze bescherming is niet levenslang. De interactie tussen vaccinatie en het 
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versterken van de immuniteit door natuurlijke infectie met Bordetella pertussis aan de ene 
kant en de verdwijnende immuniteit na verloop van tijd aan de andere kant is van invloed op 
de epidemiologie en de dynamiek van kinkhoest in de bevolking. Het is daarom belangrijk 
de door ons verzamelde gegevens te gebruiken voor het bestuderen van de invloed van 
veranderingen in vaccinatieschema’s op de epidemiologie van kinkhoest.
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Dankwoord
Woorden schieten tekort om iedereen te bedanken die meegeholpen heeft de verschillende 
onderzoeken goed te kunnen doen, maar toch ga ik een poging wagen.
Toch nog gepromoveerd. Eindelijk maakt het drs. (voor niet latinisten “hij die (nog) doctor 
moet worden”) plaats voor Dr. Een mijlpaal waar ik niet meer op gerekend had. Dit proefschrift 
kon slechts een succes worden dankzij de hulp van heel veel mensen en instituten die ik enorm 
wil bedanken voor hun hulp. Een aantal wil ik in het bijzonder noemen, zonder anderen te 
kort te willen doen.
In de eerste plaats wil ik alle kinderen en ouders die meegedaan hebben aan de verschillende 
onderzoeken, bedanken voor hun bereidheid mee te doen en daarvoor soms vervelende 
onderzoeken te moeten ondergaan.
Prof.dr. J.J. Roord, beste John, op cruciale momenten in mijn carrière heb je een grote rol 
gespeeld. In 1989 gaf je mij het vertrouwen door me op te nemen in het team van de Algemene 
Pediatrie van het Wilhelmina Kinderziekenhuis, in 1999 gaf je me opnieuw het vertrouwen 
door je bereidheid uit te spreken mijn promotor te worden. In de vele jaren die je mij begeleid 
hebt op het pad naar dit proefschrift is het voortdurende vertrouwen dat je uitsprak dat het 
wel goed zou komen, een enorme steun geweest. Je “kwaliteit gaat voor snelheid” zal een 
leidraad blijven in mijn verdere carrière. Heel veel dank voor alles.
Dr. J.F.P. Schellekens, beste Joop, met enorm enthousiasme en tomeloze energie heb jij het 
afgelopen decennium geholpen bij het verzamelen van gegevens, het concipiëren van ideeën 
en het telkens blijven zoeken naar de best mogelijke oplossing en conclusie. Elk overleg was 
telkens weer een nieuw college kinkhoestkunde waar ik veel van geleerd heb. Je voortdurende 
steun heeft me geholpen ook de moeilijke momenten te overwinnen. Ik hoop dat dit 
proefschrift niet het einde is van onze samenwerking op kinkhoestterrein.
Dr. P.F.M. Teunis, beste Peter, heel veel dank voor je geduld mij als medicus-practicus te 
begeleiden op het moeilijke terrein van de biostatistiek. Hoe vaak moest iets niet over of 
anders en telkens lukte dat weer, ondanks je drukke andere werkzaamheden. We hebben nog 
wat losse eindjes liggen, ik kijk er naar uit die, samen met jou, ook nog aan elkaar te kunnen 
knopen.
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Dr. E.A.N.M. Mooi-Kokenberg, lieve Esther, zonder jouw jarenlange trouwe steun bij het 
verzamelen en verwerken van alle monsters was het tot een goed einde brengen van alle 
onderzoeken onmogelijk geweest. Heel veel dank.
Dr. G.J. Weverling, beste Gerrit Jan, vooral bij de laatste twee onderzoeken was jouw steun 
onmisbaar. Heel veel dank voor je vele vrije avonden die je uittrok om mijn brij aan gegevens 
te ordenen tot bruikbare getallen en het daarna ook nog duidelijk op papier te krijgen. 
De leden van de beoordelingscommissie, Prof.dr. W.M.C. van Aalderen, Prof.dr. E.J. 
Duiverman, Dr. A. Fleer, Prof.dr. R.J.B.J. Gemke, Dr. M.F. Peeters, Dr. P.F.M. Teunis wil ik 
hartelijk bedanken voor hun steun en kritische analyse van het manuscript.
Dr. M.F. Peeters en Dr. B. Wilbrink, beste Marcel, beste Berry, heel veel dank voor jullie 
belangenloze medewerking aan het prospectieve onderzoek en jullie enthousiaste hulp bij het 
verwerken van de gegevens.
Mw M.T.M. Veentra - van Schie, Mw J.M. van Leeuwen - Gerritsen, lieve Monique, lieve Ria, 
zonder jullie steun was het verzamelen van de gegevens en het includeren van de patiënten bij 
het prospectieve onderzoek nooit zo’n succes geworden als het geworden is.
Beste paranimfen, beste Marco, beste Jan, onze lange vriendschap maakt dat ik het geweldig 
vind dat jullie mij deze dag willen helpen goed door te komen.
Mijn co-auteurs Guy Berbers, Marina Conyn-van Spaendonck, Bert Elvers, Odette van der 
Heijden, Hans van Huisseling, Mirjam Kretzschmar, Hester de Melker, Paul Mertens, Barbara 
Muller, Ad Nagelkerke, en Anneke van der Zee wil ik bedanken voor het beschikbaar stellen 
van gegevens en jullie enthousiasme en inzet om de verschillende artikelen tot een goed eind 
te brengen.
B.R.S. McClements, beste Brian, je wist zelfs van mijn Engels nog zoiets moois te maken dat 
de redacties ervan overtuigd werden het artikel te plaatsen.
Prof.dr. F.R. Mooi, drs.  S.C. de Greeff, beste Frits, lieve Sabine, altijd weer de goede referentie 
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Dr. J. Buitenwerf en Mw. M. Woudenberg wil ik hartelijk bedanken voor hun hulp bij het 
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bedanken voor hun hulp bij het verzamelen van historische data.
Mijn collegae kinderartsen, J.C.M. Hoekx, Dr. E.H.G. van Leer, Dr. J.S. Starreveld, C.V. Tjon 
Pian Gi, beste Jurriaan, beste Cecil, de eerste jaren van onze samenwerking waren niet de 
makkelijkste. Ondanks onze aanvankelijke meningsverschillen hebben we altijd schouder aan 
schouder gestaan om de Kindergeneeskunde in Gouda op een hoog niveau te brengen en 
te houden en ik denk dat wij daarin behoorlijk geslaagd zijn. Heel veel dank voor heel veel 
collegialiteit en vriendschap.
Beste Ed, beste Sander, hoewel jullie pas korter deel uitmaken van onze vakgroep, is ook jullie 
steun onontbeerlijk geweest. Zeker Sanders hulp bij het opzoeken van literatuur heb ik erg op 
prijs gesteld. 
Ik ben blij dat ik in dit team mag werken en hoop dat de goede sfeer die onze samenwerking 
al zo lang kenmerkt, ook de komende jaren de basis zal zijn voor nog heel veel mooie 
ontwikkelingen in onze praktijk.
Prof.dr. H.K.A. Visser, beste Henk, hartelijk wil ik je danken voor de opleiding die ik van je 
mocht genieten, waarmee de basis is gelegd die geleid heeft tot dit proefschrift.
Het secretariaat van de afdeling Kindergeneeskunde, de verpleging van de Kinderafdeling, alle 
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van het Klinisch Chemisch Laboratorium en alle medewerkers van Medisch-microbiologisch 
Laboratorium wil ik bedanken voor hun hulp bij het verzamelen en verwerken van de gegevens 
en voor de vele jaren van goede samenwerking.
Mijn lieve schoonouders, Ik wil jullie bedanken voor jullie dochter, jullie interesse en steun.
Lieve ouders, heel veel dank voor alles wat jullie in mij geïnvesteerd hebben. Deze mijlpaal is 
ook voor jullie.
Tot slot, lieve Machelien, jij weet dat ik weet dat jij weet wat jij voor mij betekent, en daar heeft 
verder niemand iets mee te maken. Dank voor je steun, jij had er soms meer vertrouwen in 
dat het zou lukken dan ik. En nu ga ik echt mijn kamer opruimen.
Lieve Frédérique, Jan en Hendt, de computer zal vanaf nu vaker vrij zijn. Dank voor jullie 
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Curriculum Vitae
De auteur van dit proefschrift werd geboren op 13 oktober 1951 in Utrecht. 
Na het behalen van het eindexamen Gymnasium ß op de R.K.Scholengemeenschap “de Breul” 
in Zeist in 1971, ging hij geneeskunde studeren aan de Rijksuniversiteit Groningen. Tijdens 
zijn studie was hij onder andere bestuurslid van de Groninger Studenten Roeivereniging 
“Aegir”.
In 1979 haalde hij zijn doctoraal examen. Vervolgens vervulde hij zijn co-assistentschappen 
in het St. Elisabeth Hospitaal in Willemstad, Curaçao. Al vroeg bleek zijn voorliefde voor de 
kindergeneeskunde: hij deed, aansluitend aan zijn co-schappen, keuzestages neonatologie in 
het Rainbow Babies & Childrens Hospital, Case Western Reserve University in Cleveland 
(Prof. dr. A.A. Fanaroff, Prof. dr. R.J. Martin, Dr. W.A. Carlo) en kindercardiologie in het 
Childrens Hospital Medical Centre, Harvard Medical School in Boston (Prof. dr. A.S. Nadas, 
Dr. T.S. Hougen). In maart 1981 behaalde hij het artsexamen. Na terugkeer in Nederland 
werd hij van 1981 tot 1985 opgeleid tot kinderarts onder leiding van Prof. dr. H.K.A. Visser in 
het Sophia Kinderziekenhuis in Rotterdam.
Na zijn opleiding werkte hij tussen 1985 en 1991 in verschillende ziekenhuizen, onder andere 
het Academisch Medisch Centrum in Amsterdam en het Wilhelmina Kinderziekenhuis in 
Utrecht.
In 1991 ging hij werken in het St. Jozef Ziekenhuis in Gouda, dat na een fusie met het Bleuland 
Ziekenhuis opging in het Groene Hart Ziekenhuis. Daar werd vanaf 1993 in samenwerking 
met Dr. J.F.P. Schellekens (RIVM) en Prof. dr. J.J. Roord (VUmc) gewerkt aan de onderzoeken 
die geleid hebben tot dit proefschrift. 
In de afgelopen jaren was hij in het ziekenhuis betrokken bij het opzetten van het Kinder 
Diabetes Team en de Transmurale AStmaverpleegkundigen voor Kinderen (TASK). Ook nam 
hij deel aan de totstandkoming van het Kinderastma Netwerk Midden Holland, en het Down 
Team Midden Holland. Daarnaast is hij sinds 1998 lid van de Medisch Ethische Commissie, 
vanaf 2002 als voorzitter. 
De auteur is getrouwd met Machelien Bazuin. Zij hebben drie kinderen, Frédérique, Jan en 
Hendt.

